Development and validation of cellular models for studying amyloid precursor protein isoforms. by Potiwat, Natruedee.
Development and validation of cellular models for studying 
amyloid precursor protein isoforms.
POTIWAT, Natruedee.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/20244/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
POTIWAT, Natruedee. (2015). Development and validation of cellular models for 
studying amyloid precursor protein isoforms. Doctoral, Sheffield Hallam University 
(United Kingdom).. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
SHEFFIELD HALLAM UNIVERSITY 
ADSETTS LEARNING CENTRE 
CITY CAMPUS SHEFFIELD 
S1 1WB
Sheffield Hallam University 
Learning and Information Services 
Adsetis Centre, City Campus 
Sheffield S1 1WD
REFERENCE
ProQuest Number: 10700889
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10700889
Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Development and validation of cellular models for studying amyloid
precursor protein isoforms
Natruedee Potiwat
A thesis submitted in partial fulfilment of the requirements of 
Sheffield Hallam University 
for the degree of Doctor of Philosophy
September 2015
Abstract
The development and validation of cellular model for studying amyloid precursor 
protein isoforms
Amyloid 3 peptide (A(3) is the major constituent of neuritic plaques in the brains of 
patients with Alzheimer's disease (AD). A(3 is a small insoluble 39-43 amino acid 
peptide derived from the Amyloid Precursor Protein (APP) by proteolytic cleavage. 
Different gene splicing produces variant isoforms ranging from 365 to 770 amino acids 
in length. The main three isoforms are: APP695, APP751 and APP770 and all are 
potentially sources of A(3.
The project aimed to investigate the hypothesis that one of these APP isoforms 
(APP695, APP751 and APP770) is more likely to be the source of A3 in Alzheimer's 
disease under normal and stress-induced conditions. The clones of HEK293 cells stably 
expressing human APP695, APP751 and APP770 at comparable levels were put under 
stress inducing conditions: Serum alteration and energy deprivation.
By altering FBS concentration in culture medium, more APP751 was secreted than 
APP695 and APP770 at all concentrations of FBS. The serum alteration in culture 
medium had no significant effect on cell number, secreted APP and APP gene 
expression. Energy deprivation was achieved using 2-deoxy-D-glucose (2DG). There 
was a significant reduction in cell number to a similar level for all three clones while 
the level of secreted APP and APP gene expression increased significantly. Also, the 
trend of APP secretion from each clone under the same concentration of 2DG was the 
same: more APP751 was secreted than APP695 and APP770.
In summary, this project has suggested that serum in culture medium has no effect on 
cell number, APP secretion and APP gene expression between isoforms while energy 
deprivation using 2DG affected cell number, APP gene expression and APP production 
significantly. Not only does this confirm the importance of glucose as a source of 
energy but has also revealed the potential relationship between glucose metabolism 
and pathogenesis of AD. Ultimately, glucose metabolism could be the predominant 
factor in relation to A3 peptide production.
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Chapter 1: Introduction
1.1 Alzheimer's disease
Alzheimer's disease (AD) is a major neurodegenerative disease of the elderly. AD 
accounts for at least 60% of dementia cases which makes AD the most common form 
of dementia (Causevic et al. 2011; Xu, Ferrari and Wang 2013). AD was fully described 
in 1906 by German psychiatrist and pathologist, Alois Alzheimer. However, Alzheimer 
published his finding which became public knowledge in 1907. In his publication, he 
mentioned the case of a 51 years old female patient, Auguste Deter whom at the time 
experienced memory loss and disorientation to places and time. Her condition 
deteriorated rapidly, she became bed-bound and passed away four and a half years 
after the onset of her condition. At post-mortem examination of Auguste Deter's brain, 
Alzheimer discovered two major pathological hallmarks of AD: neurofibrillary tangles 
and amyloid plaques (Small, Klaver and Foa 2010).
1.1.1 Epidemiology
According to a consensus study in 2005 on the prevalence and incidence of dementia, 
there were 24.3 million people in the world who have dementia and there were 4.5 
million new cases per year (Ferri et al. 2005). However, the estimation of the number 
of people with dementia around the globe was changed to 44.4 million in 2013 and 
this number was predicted to double every 20 years. It was estimated that there will 
be 75.6 million people living with dementia in 2030 and 135.5 million in 2050. Among 
these numbers more than two thirds are associated with AD and almost 62% of the 
cases live in developing countries such as China and India (Alzheimer's disease 
international 2014). In addition, there are more than 850,000 people in the UK 
currently living with dementia (Alzheimer's Society 2015).
The prevalence of AD correlates with age which means the prevalence doubles every 5 
years after the age of 65 and the prevalence increases from 3% in 65-74 year old the 
elderly to 50% in the elderly older than 85. Due to prevalence rates of AD consistently 
increasing until the age of 85, it has been implied that AD results from the ageing
process (Castellani, Rolston and Smith 2010; Xu, Ferrari and Wang 2013). Moreover, 
the world population age structure has been undergoing significant changes from high 
birth and mortality rates to low birth and mortality rates coupled with advances in 
health care which increases life expectancy. As a consequence, while the total number 
of population has stopped growing, the ageing population is increasing markedly and 
there has been sharp increase in the incidence of chronic diseases (Prince, Prina and 
Guerchet 2013).
As a result of rapid growth of the ageing population, the demand in healthcare and 
social services has also increased, which has caused significant impacts on national 
economies. The total worldwide estimated cost of dementia in 2010 was 604 billion US 
Dollars and 23 billion pounds in the UK alone in 2012 (Alzheimer's Society 2015; Wimo 
and Prince 2010). It is claimed that the changes in demography and its impact on 
economies have turned dementia into one of many great challenges for the world 
(Alzheimer's disease international 2014).
1.1.2 Clinical features
AD affects each individual in different ways however there are some common 
patterns. The clinical manifestation of AD typically begins with short-term memory 
loss, disorientation to places and time, cognitive decline including not able to judge or 
reason, having language difficulties, long-term memory loss and, finally, patients 
become bed-bound due to motor function activities impairment. At the same time, 
patients might develop behavioral symptoms such as depression, anti-social behavior, 
delusions or hallucinations (Forstl and Kurz 1999; Yiannopoulou and Papageorgiou 
2013).
There are many possible causes of dementia such as Alzheimer's disease, vascular
disease or Parkinson's disease therefore the National Institute of Neurological and
Communicative Disorders and Stroke (NINCDS) and the Alzheimer' Disease and Related
Disorder Association (ADRDA) has established the criteria for staging the clinical
diagnosis of AD to distinguish AD causing dementia from others. These criteria were
described in 1984 and it has been known as NINCDS-ADRDA criteria until 2011. In
2011, the NINCDS and ADRDA revised and updated the criteria to take into account
and in keeping with advance records and better understanding in clinical manifestation
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of AD. The latest criteria can not only be used as criteria for dementia caused by AD 
but also all possible causes of dementia. Also it includes brain imaging, genetic and 
biochemical understanding of AD and neuropsychological assessment (Mayeux and 
Stern 2012; McKhann et al. 2011).
According to the criteria from NINDCA-ADRDA in 2011, the AD dementia is classified 
into one of three categories: (1) Probable AD dementia, (2) Possible AD dementia and 
(3) Probable or possible AD with pathological evidence. There are two sub-categories 
in main criteria for probable AD dementia:
(1) "Probable AD dementia" is used when a patient meets main dementia 
criteria and has one of the following scenarios: long-onset symptoms, 
pronounced signs of cognitive function deterioration, demonstration of 
cognitive deficiency by either amnestic or non-amnestic presentations and 
absence of medical history containing diseases which might possibly involve 
dementia AD.
(2) Probable AD dementia couples with document represented reduction in 
cognitive functions or a causative genetic mutation of AD.
The "possible AD dementia" is classified into either atypical course or etiologically 
mixed presentations. In order to be diagnosed as atypical course possible AD 
dementia, a patient has to meet the main criteria set for probable AD dementia but 
instead of long-onset of cognitive impairment, the patient has fast-onset of 
impairment. If the patient has a medical history containing causative disease of AD, the 
patient is classified as etiologically mixed presentation of possible AD dementia. 
Finally, the probable or possible AD dementia with pathological evidence is currently 
reserved for research purposes (McKhann et al. 2011).
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1.2 Neuropathological hallmarks
The outstanding neuropathological changes in the brain of AD patients are amyloid 
plaques and neurofibrillary tangles (see Figure 1.2.1) as first described by Alois 
Alzheimer (Small and Cappai 2006). Also, there are other changes in the brain which 
are considered to be minor lesions namely cerebral amyloid angiopathy, synaptic 
deficit and neuronal loss.
Amyloid plaque Neurofibrillary Tangle
Figure 1.2.1 The main classical pathological hallmarks of Alzheimer's disease; 
amyloid plaque and neurofibrillary tangle (adapted from Colorado's Dementia News 
and Resource Center 2014).
1.2.1 Amyloid plaques
Amyloid means a starch-like protein which is deposited in the liver, kidneys, spleen, or 
other tissues in certain diseases and Plaque means a small, distinct, typically raised 
patch or region on or within the body resulting from local damage or deposition of 
material. Therefore amyloid plaque means a deposition of amyloid protein in the 
organs and tissues in the body. Also, amyloid plaque, which is also known as senile 
plaque, is one of the major pathological hallmarks of AD (Ng and Chan 1993; Perl
2010). As shown in Figure 1.2.1, amyloid plaques are globular-like complex 
extracellular structures which vary from 10- 200 pm in diameter. The plaque core 
consists of 4 kDa protein which is known as Ap peptide. The amyloid plaques are 
classified practically into diffuse plaques, neuritic plaques and burnt-out plaques 
(Castellani, Rolston and Smith 2010; Perl 2010). The types of amyloid plaque are shown 
in Figure 1.2.2.
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Figure 1.2.2 Different types of amyloid plaque; diffuse plaque, burnt-out plaque and 
neuritic plaque (Murray et al. 2011).
The diffuse plaques are commonly found in the cerebral cortex region of the brain 
w ithout the presence of dystrophic neurites and it is usually found in the brains of 
normal aged individuals. It was reported that the number of diffuse plaques 
corresponded to the severity of cognitive impairment (Perl 2010). Also, diffuse plaques 
are believed to occur early on in the progression of AD before turning into neuritic 
plaques and this type of plaque exhibits no correlation to inflammation. The diffuse 
plaques are highly varied in size with the inversion to the distribution. For example, the 
smaller diffuse plaques tended to have higher distribution areas. The silver based 
staining method is routinely used to identify the diffuse plaques (Castellani, Rolston 
and Smith 2010).
The classical compact form of amyloid plaques is commonly known as a neuritic 
plaque. The neuritic plaques vary from 10-50 pm in diameter (Castellani, Rolston and 
Smith 2010). Similarly to other amyloid plaques, the core of neuritic plaques is 
composed of A(3 peptide. The A(3 peptide in the core of neuritic plaques are arranged 
in a spiral form and surrounded by dystrophic neurites. Structurally, the neuritic 
plaques exhibit a dense core, alteration of membrane and paired helical filaments. Also 
neuritic plaques are positively stained by silver stain procedure (Perl 2010). Unlike 
diffuse plaques, neuritic plaques showed a great relation to inflammatory process due 
to the presence of active microglia and astrocyte (Castellani, Rolston and Smith 2010).
The other type of amyloid plaque is called burnt-out plaques. The outstanding feature 
of this type of plaques is a solely dense core with an absence of dystrophic neurites. It 
was suggested that the burn-out plaques are the end-stage neuritic plaques.
5
1.2.2 Neurofibrillary tangles
Apart from amyloid plaques in the brains of patients with Alzheimer's disease, another 
crucial neuropathological hallmark of AD is neurofibrillary tangles (NFTs) which are 
often found mainly in the cerebral cortex and large pyramidal neurons of Ammon's 
horn in the hippocampus (Castellani, Rolston and Smith 2010; Causevic et al. 2011). 
The NFT is an intracellular aggregation of hyperphosphorylated microtubule-related 
protein (MAP) tau. NFTs start to develop inside neurons which slowly and eventually 
fill the intracellular space causing neuronal cell death. However, these dead neuronal 
cells still maintain their external and internal morphology and they are called ghost 
tangles (Bhatia and Hall 2013; Yates and McLoughlin 2007). The main component of 
NFTs is several 80 nm diameter paired helical filament. Although tau protein is the 
main component of NFTs, there are several other proteins involved in NTFs formation 
including Ap peptide and ubiquitin (Yen et al. 1995). Under normal conditions tau plays 
roles in microtubule structural stabilization and functional maintenance. As 
microtubules are responsible for neuronal and axonal transportation, therefore tau is 
indirectly responsible for those functions (Brunden et al. 2010). The proline directed 
serine-threonine protein kinase and non-proline directed protein kinase are the two 
main kinases involved in tau phosphorylation. The glycogen synthase kinase (GSK3) 
and cyclin dependent kinase 5 (cdk5) are the most frequently mentioned proline 
directed serine-threonine protein kinase and the protein kinase A, B and C are the 
most common non-proline directed protein kinases. The balance between the 
phosphorylation and dephosphorylation of tau designates the normal physiological 
functions of tau. Therefore, the aberrant and unusual phosphorylation of tau results in 
increased paired helical filaments formation and self-aggregation, indirect disruption 
of microtubule functions and biological activity impairment including an ability to  bind 
to microtubules, as shown in Figure 1.2.3 (Iqbal et al. 2010; Obulesu, Venu and 
Somashekhar 2011). Also, it was reported that phosphorylated tau showed higher 
potential for fibril formation (Brunden et al. 2010). In addition, NFTs can be visualized 
using silver-based staining procedure (Castellani, Rolston and Smith 2010).
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Figure 1.2.3 The relationship between microtubule and tau protein. Under the 
normal conditions, tau protein stabilises microtubule which facilitates axonal 
transportation. Once tau protein is phosphorylated, the microtubule is destabilised. 
The phosphorylated tau proteins start to aggregate and form Paired Helical Filament 
(PHF) which is the main component of neurofibrillary tangle (NTF) (adapted from de 
Paula et al. 2009).
The longest form of tau protein could potentially carry up to 80 phosphorylation sites 
(Kolarova et al. 2012). It was observed that the NFTs in the brain of AD patient 
contained almost nine phosphates per molecule of protein which is approximately 
three times higher than the healthy brains of the control subjects (Wang et al. 2013). 
Also, it was reported that cdk5 and GSK3 phosphorylated of Thr231 and Ser235 were 
the starting point in paired helical filament formation in AD (Obulesu, Venu and 
Somashekhar 2011). The work by Eva Braak and co-workers has pioneered the 
relationship between tau and AD pathogenesis by showing the strong correlation 
between the clinical manifestation of AD and NFTs lesions (Bhatia and Hall 2013).
Although the development of NFTs found strictly correlated to the severity of cognitive 
impairment, it is not limited only to AD as it was also found in other 
neurodegenerative disease including Parkinson's disease, Down's syndrome and Pick's 
Disease (Castellani, Rolston and Smith 2010; Iqbal et al. 2005).
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1.2.3 Cerebral amyloid angiopathy
The Cerebral Amyloid Angiopathy (CAA) was first described by Gustav Oppenheim in 
1909. At the time he discovered necrosis in the brain parenchyma and capillary walls at 
the post-mortem examination of AD patients with clinical manifestations which later 
established CAA: the complex diversity of biochemical and genetic disorders in the 
central nervous system (Biffi and Greenberg 2011). The term CAA is also used to 
describe amyloid deposition in the walls of small and medium sized cerebral blood 
vessels, especially arteries and arterioles (Ghiso et al. 2010; Resink et al. 2003). 
Practically, CAA is characterized by a positive staining with Congo-red dye which gave 
rise to an alternative name of CAA; Congophilic Angiopathy. Like neurofibrillary 
tangles, the CAA is common among aged-individuals. It is found in both familial and 
sporadic cases and it is not specific to AD (Attems et al. 2011). However, the 
researchers paid little to no attention to CAA in the pathogenesis of AD. More recently, 
CAA is considered to be one of the main contributors to AD pathogenesis (Arvanitakis 
et al. 2011).
In general, the main component of CAA is the short form of Ap peptide; A(340 and the
Ap40/ Ap42 ratio obtained from CAA is greater than the one obtained from amyloid
plaques (Attems et al. 2011). Although CAA is found in both cerebral blood vessels and
brain parenchyma, they can be distinguished by the distribution pattern and the A(3
peptide form. For example, the deposition in the brain parenchyma composes mainly
of A(342 and the cerebrovascular deposition consists of A(340 as the main component
(Ghiso et al. 2010). Pathologically, the CAA begins with the small amount o f Ap peptide
deposition on the wall of blood vessels in the brain and at this stage the deposition
neither blocks vessels lumen nor interferes with its biological functions (Perl 2010).
Once the degree of deposition increases to moderate or severe, the blood vessel walls
are thickening or thinning and the lumen of the vessels are either bigger or smaller,
depending on severity of deposition. For instance, the moderate deposition, the blood
vessel wall was thickened and the lumen appears smaller due to the blockage, while
the wall was thinned and the lumen appeared bigger in severe deposition (Attems et
al. 2011). In brief, the beginning of Ap deposition causes the thickening of vessel walls
which causes the size reduction of vessel lumen, whereas the continuous deposition of
AP degenerates smooth muscles hence the thinning vessel wall and dilated vessel
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lumen (Attems et al. 2011). The histochemistry procedure using Congo-red or 
Thioflavin S, or the immunhistochemistry procedure using Ap peptide antibody are 
required to visualize the CAA (Attems et al. 2011; Perl 2010). In addition, it was 
reported that around 30% of individuals age over 60 years old have CAA while up to 
90% of diagnosed AD patients exhibited CAA.
1.2.4 Synaptic deficits and neuron loss
Neuronal cell death and synaptic loss were found throughout the area where the 
deposition of amyloid p peptide (AP) and neurofibrillary tangles were observed (Yates 
and McLoughlin 2007). It has been reported that patients with AD showed an 
exaggeration of Ap related to intricate neuronal dysfunction. For example, amyloid 
plaque reduced the strength and plasticity of glutamatergic synaptic transmission 
(Palop and Mucke 2010). Moreover, the previous study on APP transgenic mice 
showed that the magnitude of neuronal loss is correlated to the number of amyloid 
plaques in the brain. (Bayer and Wirths 2010).
Learning and memorising functions require long-term potentiation of transmission 
(LTP) at synapses which mainly takes place in hippocampal area. In mouse model-A(3- 
induced Alzheimer's disease showed an impairment of hippocampal long-term 
potentiation transmission. The recent study revealed that NMDA receptor is 
responsible for the loss of an essential protein which is involved in the synaptic 
process. Under normal conditions, NMDA receptor is responsible for inducing LTP and 
memory development. Also an increased A(3 level suggested intercellular synaptic loss 
which corresponded to the severity of cognitive impairment in humans (Malenka and 
Manilow 2011).
1.3 Amyloid precursor protein
1.3.1 Amyloid precursor protein
The amyloid precursor protein (APP) is a type 1 transmembrane protein comprised of a 
large extracellular N-terminal domain, a hydrophobic transmembrane domain and a 
small intracellular C-terminal domain. APP is transported from the endoplasmic
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reticulum to the cell surface to be modified either by glycosylations or 
phosphorylations before being proteolysed by secretase or re-internalised into the 
endosomal compartment (O'Brien and Wong 2011).
Amyloid precursor protein (APP) expresses in several organs and tissues (Nalivaeva and 
Turner 2013). Several isoforms of APP ranging from 365 to 770 amino acid remnants 
result from the alternative splicing within 18 exons of amyloid precursor protein (APP) 
by secretases, three of which are the most common in Alzheimer's disease; APP695, 
APP751 and APP770, as shown in Figure 1.3.1. The APP isoforms are distinguished by 
both expression and structure (Zheng and Koo 2011).
Although the expression level of APP in the brain varies between regions, the 
expression level of APP695 is significantly higher in comparison to APP751 and APP770. 
The mRNA ratio between different isoforms of APP is APP695: APP751: APP770 = 20: 
10: 1 (Nalivaeva and Turner 2013). Also, the APP695 is mainly expressed in the CNS 
while the APP751 and APP770 are mainly expressed in non-neuronal tissues. (Cappai 
2014; Nalivaeva and Turner 2013; O'Brien and Wong 2011; de Silva et al. 1997).
All three main isoforms of APP contain A|3 domain at exon 16 and 17. Structurally, they 
are distinguished by the presence and/or the absence of exon encoding a 56-amino 
acid Kunitz protease inhibitor (KPI domain) and/or exon 8 encoding a 19-amino acid 
OX2 domain, which shares the similar sequence to thymus-derived lymphoid cells 
(Belyaev et al. 2010; Preece et al. 2004; de Silva et al. 1997). The APP770 contains both 
KPI and OX2 domains while the APP751 contains only KPI domain. Both KPI and OX2 
domains are absence in APP695 (Zhang et al. 2012). The KPI domain has been 
suggested to play role in blood coagulation and wound repair based on the highly 
expressed of APP751 and APP770 in platelets (Dawkins and Small 2014). Also, the KPI 
domain has been suggested to play role in dimerization and processing of APP (Khalifa 
et al. 2012). The 0X2 domain has been suggested to play role in cell-surface binding 
and recognition since it contains immunoglobulin loops which are commonly found in 
cell surface receptor (Dawkins and Small 2014).
APP is a member of a family of related proteins including amyloid precursor-like 
proteins 1 and 2 (APLP1 and APLP2) in mammals and amyloid precursor protein-like 
(APPL) in Drosophilia. Also members of this protein family share the same conserved
10
domains among them such as El and E2 which are located in extracellular N-terminal 
part of APP. The El domain is believed to be involved in the dimerisation of APP and 
APLPs but there has been no solid evidence to suggest the function of E2 domain. 
However, APP is the only member of this protein family that contains the 
amyloidogenic A(3 sequence (O'Brien and Wong 2011; Zheng and Koo 2011; Zhang et 
al. 2012).
APP770
KPI 0x2
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Figure 1.3.1 The three main isoforms of amyloid precursor protein; APP696, APP751 
and APP770. The APP770 contains two additional domains which are Kunitz-type 
serine protease inhibitor (KPI) and 0X2 domains while APP751 only contains one 
additional domain; the KPI domain and there is no additional domain found in APP695.
1.3.2 Proteolytic processing of APP
Neurons do not only have a large capacity when it comes to producing APP but have
the ability to metabolize APP promptly as well (Lee et al. 2008). Once APP is produced,
it is categorized in the endoplasmic reticulum and Golgi before being packed and
distributed to axon and synaptic terminal via fast axonal transport. The two main vital
steps in APP processing take place at the cell surface and in the trans-Golgi network
(TGN). In brief, APP on the cell surface is either cleaved by a-secretase then y-
secretase, which does not result in A3 fragment formation, or reinternalised into an
endosomal compartment which contains 3“ and y-secretase, which generates the A3
fragment. The A3 fragment is then transported to the extracellular space. On the other
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hand, APP processing which occurs at the TGN is simpler than the process at the cell 
surface. APP from TGN is either transported directly to the cell surface or to an 
endosomal compartment; the latter is mediated by retromers (O'Brien and Wong
2011).
Amyloid 3 peptide (Ap) is the major constituent of amyloid plaques in the brains of AD 
patients. Ap consists of 39-43 amino acids and the most common form is Ap40 but 
Ap42 is considered to play a crucial role in plaque development. Also there are a 
number of studies which suggested that Ap42 is the most abundant in plaques and it 
also has greater potential to aggregate, oligomerise and form fibrils in comparison to 
A|340. These accumulations may cause deleterious effects to neurons (Vetrivel and 
Thinakaran 2010; Zheng and Koo 2011).
As already mentioned, APP is metabolically processed by different secretases, mainly 
a-, p- and y-secreatase (see Figure 1.3.2), at different subcellular sites via either 
amyloidogenic or non-amyloidogenic pathways as shown in Figure 1.3.3.
The non-amyloidogenic pathway mainly occurs at the cell surface due to the 
availability of the secretases. In this pathway, APP is initially cleaved by a-secretase at 
Ap sequence (between lysine 16 and leucine 17) resulting in the release of the soluble 
APPa (sAPPa) fragment into the extracellular matrix (Anderson et al. 1991; Sisodia et 
al. 1990). Cleavage of APP by a-secretase is the main and universal pathway of APP 
metabolism in most cells (Ling, Morgan and Kalsheker 2003). The a-secretase is a 
membrane bound enzyme and mainly works at the cell surface (Sisodia 1992). Also it 
has been reported that several zinc metalloproteinases share similar functions to  a- 
secretase. In other words, the enzymatic activity of a-secretase is being shared by a 
group of the disintegrin and metalloproteinase (ADAM) family such as ADAM 9, ADAM 
10 and ADAM 17 (Allinson et al. 2003; Haass et al. 2012). The remaining membrane- 
associated C-terminal fragment, which contains 83 amino acids (so called C83), is then 
cleaved by y-secretase in the transmembrane region of APP resulting in 3 kDa p3 
fragment and APP intracellular domain (AICD). Moreover, 3 kDa p3 fragment does not 
play role in pathogenesis of AD (Cao and Sudhof 2001; Haass et al. 1993; Hartmann 
1999).
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In the amyloidogenic pathway, APP is initially cleaved at the extracellular domain of 
the N-terminal of the A(3 sequence, at amino acid +1 or +11 sites, by p-secretase 
resulting in the release of soluble APPp into the extracellular matrix (Vassar et al. 
1999). The remaining membrane-associated C-terminal fragment, which contains 99 
amino acids (so called C99), is then cleaved by y-secretase generating Ap fragment and 
AICD (Annaert and De Strooper 2002).
Unlike the non-amyloidogenic pathway that mainly occurs at the cell surface, the 
amyloidogenic pathway involves trafficking APP through endosomal compartment 
which contains p- and y- secretase (Thinakaran and Koo 2008). Even though the 
majority of APP is believed to go to the cell surface, there is only a limited number of 
APP molecules detected on the cell surface despite its very fast processing (O'Brien 
and Wong 2011). Also, increased a-secretase activity significantly reduces Ap fragment 
generation hence plaque formation both in vivo and in vitro, which suggests that APP 
processing is a competitive process (Nitsch et al. 1992; Postina et al. 2004). After all, 
the balancing of APP processing might play an important role in the development and 
progression of AD.
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Figure 1.3.2 The organisation of secretases including a-secretase, p-secretase and 
part of y-secretase; Presenilin and Nicastrin (adapted from Ling, Morgan and 
Kalsheker 2003).
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Figure 1.3.3 The processing pathway of amyloid precursor protein (APP). (A) Non- 
amyloidogenic pathway, the APP is cleaved by a- and y-secretase, respectively which 
generates soluble APPa and a small non-toxic fragment; p3. (B) Amyloidogenic 
pathway, the APP is cleaved by (3- and y-secretase, respectively which generates 
soluble APP3 and A3 peptides (Portelius et al. 2008).
1.3.2.1 a-secretase
Several proteins have been identified to have a-secretase-like activity and they belong 
to a disintegrin and metalloproteinase (ADAM) family including ADAM9, ADAM10 and 
ADAM17 (Zhang et al. 2012). Also, the ADAMs family of integral membrane protein 
belongs to the zinc protease super family which means members of this family are 
characterized by a metalloproteinase domain, integrin receptor binding activity and a 
cytoplasmic domain. The ADAMs family has been suggested to play several roles such 
as control of cell migration, membrane fusion, growth factor and cytokine shedding 
(Seals and Courtneidge 2003). Fundamentally, as previously mentioned, the majority of 
a-secretase activity occurs at the cell surface whereas the regulated activity is mainly 
located inside the Golgi (Ling, Morgan and Kalsheker 2003). The activity of a-secretase 
in the Golgi is rather important since there is evidence suggesting a significant increase 
in a-cleavage after the activation of protein kinase C; including an increase in APP 
being transported to the cell surface, an increase in a-cleavage in TGN and an 
inhibition of re-uptake of cell surface APP into the endosomal compartment (O'Brien 
and Wong 2011).
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ADAM9 is universally expressed in human tissues. Evidently, COS cells co-expressed 
ADAM9 and APP then treated with phorbol ester have shown that ADAM9 cleaved 
APP, specifically at the a-secretase site. Also, overexpression of ADAM9 in COS cells 
increased sAPPa production which strongly suggested that ADAM9 has a-secretase 
activity (Ling, Morgan and Kalsheker 2003; Seals and Courtneidge 2003).
ADAM10 is mainly localised to Golgi and TGN. However it was first isolated during 
bovine myelin membrane preparation which later showed the ability to cleave APP at 
a-cleavage site (Ling, Morgan and Kalsheker 2003). Moreover, HEK293 cells 
overexpressed ADAM10 also showed a sharp increase in sAPPa production which 
suggested the role of ADAM10 in a-secretase processing of APP. Also, increasing the 
expression of SIRT1 (the ADAM10 gene expression regulator) in mice models has 
shown a significant reduction of Ap fragment deposition alongside reduced cognitive 
decline (O'Brien and Wong 2011).
ADAM17 is found in most tissues and is typically expressed in neurons, vascular cells 
and leukocytes (Schlondorff, Becherer and Blobel 2000). It was originally identified as 
the enzyme responsible for cleavage of the membrane-bound pro-protein of tumor 
necrosis factor a (TNF- a) hence it is also called tum or necrosis factor alpha converting 
enzyme (TACE) (Ling, Morgan and Kalsheker 2003). Also a mouse model with ADAM17 
deficit which showed signs of EGF signalling defect confirming the role of ADAM17 in 
cleavage of EGF family member (Peschon et al. 1998)
1.3.2.2 p- secretase
p-secretase is a 501 amino acid typ e l transmembrane aspartyl protease containing an 
extracellular membrane active site (Zhang et al. 2012). Currently, there are two 
enzymes which have been identified to act as p-secretase; p-site APP-cleavage 
enzymel and 2 (BACE1 and BACE2, respectively) (Ling, Morgan and Kalsheker 2003). 
Both BACEs require low pH conditions for its activity and are mainly expressed within 
endosome, TGN as well as on the cell surface (Vassar et al. 2009).
BACE1 cleaves APP at the aspartic acid 1 and glutamic acid 11 sites on the extracellular 
domain suggesting it is a site specific protease. However, cleaving APP by BACE1 is 
both general and specific. For example, human APP can be cleaved by murine BACE1 at
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position 1, or vice versa, but human APP cannot be cleaved by murine BACE1 at 
position 11 (Ling, Morgan and Kalsheker 2003). Moreover, the studies on BACE1 
knockout mice showed that BACE1 is a neuronal p-secretase since neurons obtained 
from mice do not produce Ap fragment but glia cells do. Although BACE1 is able to 
cleave various substrates, its preferential substrate site would be acidic or contain 
polar residues. It was suggested that BACE1 is a membrane bound protease and only 
cleaves APP that is bound to membrane (Venugopal et al. 2008).
BACE2 is another enzyme which has been identified as a P-secretase. As a counterpart 
enzyme of BACE1, BACE2 share 71% homology and 45% identity with BACE1, but 
BACE2 has much lower expression levels in the brain and it is mainly expressed in glia 
cells (Zhang et al. 2012). Interestingly, instead of cleaving APP at amino acid position 1 
or 11, BACE2 cleaves APP at amino acid position 19 or 20 which is in the middle of the 
A(3 sequence, resulting in a 79 amino acids C-terminal fragment, which does not 
contribute to Ap generation (Venugopal et al. 2008).
1.3.2.3 y-secretase
y-secretase is a multiple-protein complex consisting of several units of transmembrane 
protein (see Figure 1.3.4); presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin (Net), 
anterior pharynx defective 1 (Aph-1) and presenilin enhancer protein 2 (Pen-2). 
Essentially, in order to enable y-secretase activity, all four compartments are required 
to act together (Small, Klaver and Foa 2010).
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Figure 1.3.4 The y-secretase complex; presenilin 1 & 2, anterior pharynx defective 1, 
presenilin enhancer 2 and nicastrin (Kopan and Hagan 2004).
PS1 and PS2, which consist of 463 and 448 amino acids respectively, are comprised of 
nine transmembrane units and intracellular N- and C- terminal (De Strooper, Iwatsubo 
and Wolfe 2012; Ling, Morgan and Kalsheker 2003). Not only do PS1 and PS2 share 
76% homology but they both also have a big cytoplasmic loop between 
transmembrane unit 6 and 7, which is cleaved during the post-translational process to 
generate the N- and C-terminal fragments. Each of these fragments contain aspartyl 
residues required to activate the y-secretase activity (Small, Klaver and Foa 2010; 
Zhang et al. 2012). Also both PSs are mainly detected in ER and Golgi.
Nicastrin (Net) is described as a type 1 transmembrane glycoprotein with a large 
extracellular domain. After glycosylation, which is a part of maturation of Net 
recognises and binds to the C-terminal fragment of APP after either a- or (3- cleavage 
(O'Brien and Wong 2011).
Anterior pharynx defective. 1 (Aph-1) consists of seven transmembrane units with 
cytoplasmic C-terminal. The main function of Aph-1 is to assemble preliminary 
structure y-secretase multiple-protein complex by interacting with immature nicastrin 
and PSs. The complex is then transported from the ER to the TGN (O'Brien and Wong 
2011; Zhang eta l. 2012).
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Presenilin enhancer protein 2 (Pen-2) consists of 2 transmembrane units and it has a 
hairpin-like shape with both N- and C- termini in the extracellular space. The function 
of Pen-2 in the complex is to facilitate the cleavage of PSs which generate essential isl­
and C-terminal fragments required to initiate y-secretase activity activation process 
(Zhang et al. 2012).
1.3.3 Function of APP and its derivatives
To date, the exact function of APP is still unclear but as its structure is significantly 
similar to Notch, therefore one of its proposed functions is as a cell surface receptor. 
Besides, it has been reported that APP has effects on both health and growth in 
transgenic mice, overexpressed wild-type APP and transient transfected cell lines. 
According to the structure of APP, the extracellular part contains two heparin-binding 
domains which were suggested to be responsible for its bioactivity. Several proteins, 
such as A(3 fragment or F-spondin, bind to extracellular part of APP resulting in APP 
processing and downstream signalling modulation (O'Brien and Wong 2011; Zhang et 
al. 2012). In 2004, Wang and Ha suggested that APP plays role in cell adhesion by 
forming parallel dimers facilitated neurite outgrowth and synaptogenesis. Also it was 
shown that the expression of APP is not only different during the neuronal maturation 
and differentiation but also during traumatic brain injury (Corrigan et al. 2010; Wang 
and Ha 2004).
It has been suggested that the soluble APPa (sAPPa) fragment, a product from non- 
amyloidogenic processing pathway, has neuroprotective and neurotrophic properties 
as well as the ability to regulate cell excitability and synaptoplasticity (Zhang et al. 
2012). In 2007, the study showed that abnormalities occurred with mice caused by APP 
deficiency were rescued using sAPPa alone, which suggested that nearly all o f APP 
functions are initiated by its extracellular part (Ring et al. 2007). Not only are there 17 
amino acid differences between sAPP(3 and sAPPa but they also function 
contradictorily. Generally,. sAPPP seems to lack the neuroprotective property. 
Furthermore, it can act as a precursor of an N-terminal fragment which is able to bind 
to Death Receptor 6 and activate caspase 6, causing axonal pruning and neuronal cell 
death (O'Brien and Wong 2011; Zhang et al. 2012).
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Since the discovery of relationship between A(3 and AD, AP has been the centre of 
attention in pathological study of AD. So far, it has been reported that excessive 
amount of Ap promotes cause neurotoxicity, neuronal tangle formation, synaptic 
damage and neuronal death (Zhang et al. 2012). Indeed, the combination o f low levels 
of APP fragments and the accumulation of Ap may be an explanation for cognitive 
decline in early onset AD (Turner et al. 2003). On the other hand, the recent studies 
reported that by applying low concentrations of Ap fragments showed positive effects 
on synaptic plasticity and memory.
As APP intracellular domain (AICD) degrades rapidly, it is virtually impossible to 
conduct a physiological investigation in vivo, hence the majority of information on 
AICD obtained from experiments based on exogenous system. AICD is a consequence 
of y-cleavage and its size could vary from 50 to 59 amino acids. It has two proposed 
functions; transcriptional regulator and self-intracellular sorting regulator. There are 
three conserved domains on AICD; YTSI, VTPEER and YENPTY. Each domain is 
responsible in binding to different binding partners. For example, to become the 
binding partner of YENPTY requires the existence of phosphotyrosine interacting 
domain (PID): the two best candidate binding partners of YENPTY are Fe65 and X l l  
(O'Brien and Wong 2011; Zhang et al. 2012). On its own, Fe65 induces transportation 
of APP to cell surface but together with AICD and Tip60, it facilitates the formation of 
transcriptional active complex (Slomnicki and Lesniak 2008). The X l l  binding partner is 
found to reduce AP production by interacting with AICD. Also both Fe65 and X l l  are 
strongly expressed in the brain.
1.4 Other pathologies associated in AD
Besides amyloid plaques and neurofibrillary tangles formation, cerebral amyloid 
angiopathy, synaptic and neuronal loss, neuronal inflammation, oxidative stress and 
metallobiology are suggested to have significant contribution for AD pathogenesis.
1.4.1 Inflammation and AD
Inflammation is a biological process responding to self and non-self antigens. The aim
of an inflammatory process is to eliminate the antigen and the damage it has caused to
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cells and tissues. The unsuccessful attempt to get rid of the antigen and restore 
healthy cells and tissues could turn the inflammation into a chronic condition which 
results in further deterioration of the surrounding area (Rubio-Perez and Morillas-Ruiz 
2012). The inflammatory process occurs in two phases; (1) acute inflammation where 
the response to an antigen is short and aggressive, and (2) chronic inflammation where 
there is a mild and continuous response to an antigen (Zotova et al. 2010). Moreover, 
the acute phase clinically manifests with pain, swelling, redness and heat where 
monocytes, macrophages in PNS or glia cells and astrocytes in CNS are the 
inflammatory features of chronic phase.
Evidently, the immune response involved in AD pathogenesis was observed since the 
1980s when immune related molecules were found surrounding amyloid plaques in 
the brains of AD patients. Ten years later, the view on inflammation in CNS or 
neuroinflammation was prompted by the additional findings about the molecules 
involved in the inflammatory process. These molecules include compliment factors, 
chemokine and cytokines (Zotova et al. 2010). As a result, the inflammation within the 
brain is classified as one of the pathological hall mark of AD. However, the clinical sign 
of acute inflammation phase is absent therefore the neuroinflammation is usually 
referred to as chronic inflammation (Rubio-Perez and Morillas-Ruiz 2012).
It was believed that inflammation alone is more likely to contribute to the progression 
of AD rather than being the cause of AD itself. The inflammation is a response to the 
insults, including infection which causes cell injury and necrosis (Rubio-Perez and 
Morillas-Ruiz 2012). It was proposed that the inflammation participates in the 
progression of the AD by (1) immediately acting in response to the changes and (2) 
later persisting in response to the low-level of inflammatory stimuli, such as A(3 
plaques and NFTs, in the brain (Zotova et al. 2010). This concept is supported by 
several studies. For example short-term infection initiated inflammation as a response 
which in the AD patients, resulted in a rapid decline in cognitive functions which hardly 
recovered to the point before infection had occurred, even after the infection was 
treated (Perry, Cunningham and Holmes 2007). It was also reported that the level of 
inflammatory proteins increased prior to the onset of clinical manifestation o f AD; or 
inflammatory features were mainly found in the AD affected area of the brain 
(Overmyer et al. 1999). Also microglia, astrocytes and neurons are accountable for the
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inflammatory process in the brain and by activating these cells the pro-inflammatory 
molecules are produced (Rubio-Perez and Morillas-Ruiz 2012).
Microglia contribute approximately 10% of the total cell number in the nervous system 
(Rubio-Perez and Morillas-Ruiz 2012; Wyss-Coray and Rogers 2012). One of the crucial 
roles of microglia is removing debris and dead neurons which results in brain 
remodelling. The recent studies have shown that microglia repeat the housekeeping 
routine every few hours. Also, microglia act as the first port of call towards the 
pathogens, cellular and tissue injury in order to maintain healthy brain condition. As 
the activated microglia are able to remove detritus, it is often referred to as brain's 
macrophage (Wyss-Coray and Rogers 2012). A reduction in microglia activation was 
observed when the APP gene and APP processing were interfered with and the binding 
of A(3 peptide to microglia promotes chemokine and cytokine production (Rubio-Perez 
and Morillas-Ruiz 2012). The microglia are able to produce several inflammatory 
factors including; cytokines, chemokines, reactive oxygen species, growth factors and 
complement factors and an increased level of these factors usually results in 
neurodegeneration in cellular and animal models. It was reported, in the cell culture of 
microglia and histochemistry of sections of the AD brain, that microglia were attracted 
to A3 peptide as well as attempting to remove it. The study of the relationship o f A3 
peptide and microglia using two-photon microscope suggested that microglia reached 
neurons at the same time as the damage was done to adjacent neurons. Despite the 
observation, it is still not conclusive whether microglia are responsible for neuronal 
damage during their recruitment to the plaques (Wyss-Coray and Rogers 2012).
In the nervous system, the number of astrocytes is five times higher than the neuron. 
The astrocytes are also often known as neuroprotective cells in the brain. Not only do 
astrocytes play numerous roles in the brain including; providing optimal condition for 
the neurons in the brain, supporting neuronal structure, regulating metabolism and 
modulating neuronal development but also act primarily in the synaptic transmission 
process; recycling neurotran'smitters, remodelling synapses, maintaining the balance of 
ion and regulating oxidative stress levels (Molofsky et al. 2012; Wyss-Coray and Rogers 
2012). It was reported that an exposure of A3 peptide to the astrocytes evidently 
interfered astrocytes' homeostasis which eventually resulted in neuronal degradation. 
Also, the astrocytes play role in the defensive system similar to microglia. For example,
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it was reported that one of the functions of astrocytes was to attack and remove A(B 
peptide deposition as well as providing defensive construct between Ap peptide 
deposition and healthy neurons. This example was further supported by the 
observation in the brains of AD patients and animal models showing that astrocytes 
migrated around the Ap peptide deposition to provide a protective barrier in the 
damage control manner (Rubio-Perez and Morillas-Ruiz 2012; Wyss-Coray and Rogers 
2012 ).
It was believed that neurons only acted as witnesses while the changes in the brain 
occurred. However, recently it was reported that neurons are capable of producing 
inflammatory factors such as fractalkine and complement protein CD59. It was 
observed in the AD animal model that there was a reduction of fractalkine level in the 
hippocampus and cortex. Also, the expression level of CD59 in brains of AD patients 
partially decreased in the affected areas (Beech et al. 2007; Singhrao et al. 1999).
1.4.2 Oxidative stress and AD
The term oxidative stress has been used to describe the condition resulting from an 
alteration of oxidative homeostasis. In other words, oxidative stress is an imbalanced 
condition between free radicals and antioxidants. The major form of free radicals 
derived from oxygen is called reactive oxygen species (ROS) which includes superoxide 
radical anion (02—), hydrogen peroxide (H20 2) and hydroxyl radical (-OH). These ROS 
are generated under normal conditions and are kept in a minimal state by various 
antioxidants. However the excess amount of free radicals from both self-produced and 
environmental sources are able to overwhelm the elimination process provided by 
antioxidants, which results in molecular damage. There are several ways to address the 
molecular damage caused by ROS, depending on the targets. For example, protein or 
DNA/RNA oxidation describes the condition where protein or DNA/RNA is damaged by 
ROS. The condition where the ROS caused damage to lipids is addressed as lipid 
peroxidation. In the brains of AD patients, the damage caused by ROS during the 
development of the disease is exhibited (Pratico 2008; Swomley et al. 2013). 
Moreover, overexpression of A(3 peptide in animal models and cell cultures exhibit an 
increase in oxidative stress biomarkers (Axelsen, Komatsu and Murray 2011).
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The oxidation of protein occurs at both the backbone and the side chain of the amino 
acid within the protein. Also, protein oxidation commonly refers to the oxidation of the 
protein at its side chain. The breakage of the polypeptide chain and protein-protein 
crosslinking is ultimately the most common results of protein oxidation (Pratico 2008). 
Chemically, the oxidation of protein by ROS via the carbonylation process occurs both 
directly and indirectly. The direct carbonylation of protein occurs where carbonyl 
groups are directly introduced to amino acid residues such as lysine, arginine, proline 
and threonine, whereas indirect carbonylation is where the hydroxyl group at the side 
chain of the amino acid is oxidized and turned into either ketone or aldehyde 
derivatives. However, there are several other oxidative pathways which cause protein 
carbonylation including the oxidation of glutamyl and the a-amidation pathway (Gella 
and Durany 2009). Evidently, there was an increase in carbonylized protein in the 
frontal and parietal lobe in the brains of AD patients in comparison to same age 
controls (Pratico 2008). Other studies also supported the fact that there was an 
increase in protein carbonylation in the hippocampus and parietal cortex; the common 
brain regions which are usually affected by the progression of AD (Axelsen, Komatsu 
and Murray 2011; Sultana and Butterfield 2010).
Lipid peroxidation is the process where the hydrogen atom at the side chain of the 
methylene carbon is removed as a consequence of ROS action. Also, the susceptibility 
to lipid peroxidation depends on the number of double bonds in the lipid molecule. For 
example, the poly-unsaturated fatty acids (PUFAs) are more prone to lipid peroxidation 
by ROS in comparison to saturated fatty acids. As the brain has high oxygen demands 
and contains a vast quantity of peroxidizable fatty acids, the brain is highly susceptible 
to lipid peroxidation. In addition, arachidonic acid and docosahexaenoic acid are the 
main component of lipid bilayers in the brain and the oxidation of these lipids results 
in aldehyde productions (Pratico 2008). Besides an observation that Ap peptide 
promoted peroxidation of lipid, it was also reported that the products gained from the 
lipid peroxidation process, including 4-hydroxynonenal (HNE), acrolein, 
melondialdehyde and F2-isoprostanes, increased in comparison to controls at the 
same age. The HNE is a product resulting from lipid peroxidation of arachidonic acid 
and is able to bind to protein causing several dysfunctions including inhibition of 
glucose and glutamate transporters in neurons, inhibition of Na-K ATPases, disruption
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of intracellular calcium signalling and eventually initiating apoptosis. Furthermore, one 
of the AD neuropathological hallmarks; NFTs was found to be enriched with HNE and 
melondialdehyde which indicated lipid peroxidation process (Gella and Durany 2009). 
It was reported that A(3 peptide continued to promote peroxidation of lipid 
compounds such as cholesterol and phospholipids as long as the methionine side chain 
is not damaged (Axelsen, Komatsu and Murray 2011). Although these are only a few 
examples of HNE involved in oxidative stress, it is enough to conclude that HNE is toxic 
and one of the causes of AD pathogenesis via oxidative stress. Besides HNE, F2- 
isoprostane is able to induce the oxidation of arachidonic acid and it can be used as a 
marker due to its high accuracy against lipid peroxidation (Milne, Musiek and Morrow 
2005). F2-isopropanes belong to a prostaglandin-like compound family and it is formed 
as a consequence of ROS-mediated lipid peroxidation in the absence of enzymatic 
reactions. The increasing level of F2-isopropanes was found in the brain regions which 
are usually affected by AD pathogenesis such as the frontal lobe and hippocampus, as 
well as in CSF (Pratico 2008).
The ROS induced oxidation of DNA results in DNA-protein crosslinking, fragmentation 
of DNA strands and, ultimately, DNA mutations due to direct modification at purine 
and pyrimidine bases. The DNA fragmentation also generates free carbonyl groups 
within neurons and glia cells (Pratico 2008). The 8-hydroxy-2-deoxyguanosine 
(80HdG), 8-hydroxyguanine (80HG) and 8-hydroxyadenine (80HA) were typical 
markers against DNA damage. It was reported that the level of 80HdG, 80HG and 
80HA were increased in the AD patient at the affected brain regions such as temporal, 
parietal and frontal lobes. Also, 80HdG and 80HG were found to restrict to amyloid 
plaque and NFT (Pratico 2008; Sultana and Butterfield 2010). The elevation o f 80HdG 
was increased in CSF of the AD patient as well as in the brain. Due to the lack of 
protection by histones or hydrogen bonds and being a single strand nucleic acid, it 
makes RNA more prone to oxidation by ROS in comparison to  DNA (Sultana and 
Butterfield 2010). Also, the number of RNA molecules is greater than DNA and RNA 
tends to locate in the proximity of mitochondria which is the main origin of ROS 
production. The susceptibility to oxidative damage of RNA was supported by studies in 
both cell culture and human tissues including human leukocytes and skin fibroblasts as 
well as in the brains of AD patients (Nunomura et al. 2009). The 8-hydroxyguanine (8-
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OHG) and 8-hydroxyuracil (8-OHU) are accounted as RNA oxidation markers. Both 8- 
OHG and 8-OHU were increased in the brains of AD patients; particularly frontal, 
temporal and parietal lobes (Sultana and Butterfield 2010). Whereas the increased 
level of 8-OHG was decreased inversely to the development of amyloid plaque and NFT 
formations (Pratico 2008).
It was found that both DNA and RNA markers could be detected prior to plaque 
formation.
Another substrate which is related to oxidative stress is sugar. The oxidation process of 
sugar requires either protein or lipid molecules. The oxidation of protein or lipid 
related sugar can be addressed with different terminology; non-enzymatic 
glycosylation, glycation or the Maillard reaction (Srikanth et al. 2011). The Advance 
Glycation end products (AGEs) are believed to  be involved in pathogenesis of many 
diseases including diabetes, vascular disease, renal failure and Alzheimer's disease 
(Goldin et al. 2006; Singh et al. 2001; Srikanth et al. 2011). The mechanism of AGEs is 
induced by the reaction between the carbonyl group obtained from oxidized sugar and 
lipids or protein molecules which produced Schiff bases and Amadori products. The 
denatured protein forms an aggregation which yellow-brown is the common result 
from the reaction (Goldin et al. 2006; Srikanth et al. 2011). It was suggested that the 
presence of either high turnover rates of suitable proteins for glycation or the 
considerate level of oxidative stress are the main controlling factors of AGEs.
1.4.3 Metallobiology in AD
Metal ions play a crucial part and are responsible for several biological functions and
cellular processes in living organisms, both prokaryotes and eukaryotes (Jomova and
Valko 2011; Jomova, Baros and Valko 2012). The levels of metal ions are regulated by
the system called "ion homeostasis" based on the balance between the absorption
and elimination or excretion of metal ions of the cells. As metal ions are essential for
normal enzymatic and catalytic functions, stability of cellular structure, oxygen
transportation and cellular signaling, and by disrupting the balance of the metal ions
can become toxic causing oxidative deterioration to the target molecules. The most
common transition metal ions found in eukaryotic cells are iron (Fe), zinc (Zn) and
copper (Cu) (Robert et al. 2012). In addition, it was found that the level of Fe, Zn and
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Cu were higher in the brains of mammals in comparison to other tissues which 
corresponded to the fact that there are several ion-dependent enzymes and metabolic 
pathways within the brain. The levels of these metals in the brain are strictly controlled 
by the blood brain barrier (BBB). It was reported that the total concentrations of each 
of these metals were greater in AD patients in comparison to the same age controls. In 
the post-mortem examination of the brains of AD patients, it was found that the 
centre of amyloid plaques contained excessive amounts of Fe, Zn and Cu (Tabner, 
Mayes and Allsop 2011). As well as an increased total concentration of each metal, 
these metals were found localized strictly within the same location of amyloid plaques 
in both AD patients and animal models (Greenough, Camakaris and Bush 2013). Also, 
Fe, Zn and Cu are able to cause A(3 peptide precipitation (Robert et al. 2012).
Iron (Fe) is essential for many biological processes including oxygen transportation, 
electron transfer and the production of both neurotransmitters and myelin (Robert et 
al. 2012). Although Fe is important for maintaining normal biological activity, the 
excessive amount of Fe in the system can become toxic. The toxicity of Fe is due to its 
catalytic ability in the Fenton reaction which produces free radicals causing damage to 
the affected organ. Fe has two major oxidation states; Fe (II) and Fe (III) in the 
biological system (Jomova, Baros and Valko 2012). It was shown that Fe was involved 
in downstream processes after NMDA (N-methyl-D-aspartate) receptor activation such 
as ryanodine-mediated calcium release. The NMDA receptor involves in cholinergic 
hypothesis of AD. It was believed that the level of Fe in the brain increases according 
to age. The mild acidity condition is the preferred condition for Fe binding to A(3. It was 
also suggested that the mild acidic condition facilitated Fe entry into neurons, which 
was the cause for toxicity of A(3 peptide in animal models of AD (Robert et al. 2012).
Zinc (Zn) plays roles in cell metabolic processes o f protein, lipid and carbohydrate 
molecules as it is involved in more than 70 metabolic enzymes. Zn also plays a role in 
maintaining insulin, blood glucose levels, and immune system (Jomova and Valko
2011). A high concentration of Zn is found in the nerve terminals of glutamatergic 
neurons. Once it is released from synaptic clefts, Zn binds to receptors including the 
NMDA receptor. The overall concentration of Zn does not change despite aging 
condition. It has been a well-known fact that the core amyloid plaques from AD 
patients contain high concentrations of Zn compared to the same age controls.
26
Therefore it was suggested that the accumulation of Zn in amyloid plaques may 
potentially cause dysfunction of Zn in the brain (Robert et al. 2012).
Copper (Cu) acts as a co-factor of several redox-related enzymes including cytochrome 
C oxidase, ascorbate oxidase and superoxide dismutase. Also, azurin and plastocyanin 
are examples of copper proteins which play roles in electron transportation. Cu is 
normally obtained from food and stored in the liver. The serum albumin and histidine 
facilitate the transportation of Cu either to the target organ or to be removed from the 
system (Jomova and Valko 2011). The Cu level in the brain is varying depending on 
brain region. Also, the level of Cu in the brain was found increasing up until adulthood 
then the level started to decline (Robert et al. 2012). The most common oxidation 
state of copper in biological system are Cu (I) and Cu (II) (Jomova and Valko 2011; 
Jomova, Baros and Valko 2012). One of several ways to facilitate amyloid plaque 
formation is by reactive oxygen species which requires the presence of a transition 
metal; especially Cu. It was reported that Cu was able to bind strongly to A(3 peptide as 
long as histidine and tyrosine were present (Jomova, Baros and Valko 2012). In the 
brains of AD patients, the level of Cu was decreased in the brain tissue while the high 
concentration of Cu was found within the amyloid plaques. As a consequence, it was 
suggested that Cu was drawn toward the plaques and accumulated there which left 
the rest of the brain with low concentration of Cu (Robert et al. 2012).
1.5 Genetics aspects of AD
Alzheimer's disease is an intricate and genetically different neurodegenerative disease.
The estimation of an inherited rate has been presumed to be less than 30% of all
patients with Alzheimer's disease. As a result, genetic mutations are considered as a
small factor which influenced the increasing risk of developing Alzheimer's disease.
Until now there are four mutated genes which have been clearly verified to be
involved in causing Alzheimer's disease. The mutations occur in amyloid precursor
protein gene (APP) located on chromosome 21, Presenilin 1 (PSEN1) located on
chromosome 14, Presenilin 2 (PSEN2) located on chromosome 1 and ApolipoproteinE
(APOE) located on chromosome 9 (Guerreiro, Gustafson and Hardy 2012). Moreover,
there are studies which have suggested that since the clinical manifestation of the
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disease are similar in both sporadic and familial types; most of patients with 
Alzheimer's disease must carry hidden genetic causes (Castellani, Rolston and Smith
2010). In 1996, Lautenschlager and co-workers did a study on the age-specific 
incidence of Alzheimer's disease; it was suggested that the first degree relative of a 
patient with Alzheimer's disease had developed a significant risk of the disease. Also, 
the offspring of Alzheimer's disease carrier couples had developed five times the risk of 
having Alzheimer's disease in comparison to offspring of non-carrier couples (Crentsil 
2004). The APP, PSEN1 and PSEN2 are believed to be involved in early-onset 
Alzheimer's disease (EOAD) which is mainly familial type Alzheimer's disease (FAD), 
while APOE and SORL1 are seen as risk factors of late-onset Alzheimer's disease (LOAD) 
which is mainly sporadic type Alzheimer's disease (SAD) (Guerreiro, Gustafson and 
Hardy 2012). Surprisingly, the three genes; APP, PSEN1 and PSEN2 which have 
incomparable mutations, give the same outcome after the mutation process which is 
an increase in amyloid p peptide (Ap) production. In addition, APOE decreases Ap 
production but increases its aggregation resulting in an increase in plaque formation 
(Crentsil 2004).
1.5.1 Amyloid Precursor Protein (APP) mutations
The APP gene is located on chromosome 21, more accurately on the long arm of
chromosome 21 at position 21 (21q21) (Guerreiro, Gustafson and Hardy 2012). The
identification of a mutation in APP, the so called autosomal dominant mutation, was
the first contribution to initiate a study of the genetic aspects of AD. So far there are
24 single nucleotide mutations on APP. All mutations occur either around or inside the
Ap sequences specifically within 54 amino acids (Brouwers, Sleegers and Van
Broeckhoven 2008; Schellenberg and Montine 2012). The mutation in APP associated
AD has affected more than 80 families with age-at-onset ranging between 30 and 65
years (Cruts, Theuns and Van Broeckhoven 2012). The first example of APP mutation is
the Swedish mutation. Swedish mutation involves two amino acid replacements close
to the beginning of AP sequence; lysine to asparagine and methionine to leucine at
positions 670 and 671, respectively. As Swedish mutation does not occur within the Ap
sequence and the consequence of mutation is a double or triple increase in AP
production in comparison to non-mutated APP, this suggested that the mutation
affects p-secretase activity. In addition, it is believed that an excessive production of
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Ap is enough to cause AD which was supported by the observation made on Down 
syndrome (DS) patients (trisomy 21) who have developed neuropathological hallmarks 
since an early age (Goate and Hardy 2012; Schellenberg and Montine 2012). It was 
proposed that the location of APP gene possibly provides the pathological aspects 
correlating between Down syndrome (DS) and Alzheimer's disease (AD) based on 
reports showing that the lack of APP coding sequence on the third chromosome in DS 
patients resulted in AD pathological hallmarks abolishment (Castellani, Rolston and 
Smith 2010). Another common example of APP mutation is the mutation that occurs 
after Ap sequence; substitution of valine with isoleucine at amino acid position 717 
(Val717lle). Under normal conditions, the C-terminal fragment is cleaved by y- 
secretase and mainly generates AP40 resulting in low ratios of Ap42/AP40. However, 
after mutation, y-cleavage tends to generate more of Ap42 and higher Ap42/Ap40 
ratios, but it does not necessarily suggest that the process generates smaller amounts 
of AP40 (Schellenberg and Montine 2012). Most studies on neuropathological effects 
of APP mutations have been carried out in a small sample group hence the data might 
not be appropriate to be used to represent global population. Nonetheless one of 
many interesting aspects of APP mutation on neuropathological hallmarks is the 
variety of Ap aggregation structures. For instance, the substitution of alanine with 
glycine at amino acid position 692, the so called Flemish mutation, results in 
compressed plaques (Kumar-Singh et al. 2002) whereas replacing glutamic acid with 
glycine at position 693, the so called Arctic mutation, results in circular shaped plaques 
(Basun et al. 2008).
1.5.2 Presenilin mutations
Presenilin 1 (PS1) and presenilin 2 (PS2) are located on chromosomes 14 and 1,
respectively, and they encode proteins which are the major components of y-secretase
(Guerreiro, Gustafson and Hardy 2012; Small, Klaver and Foa 2010). Up to date, there
are approximately 185 mutations in the PS1 gene and 13 mutations on the PS2 gene
(Cruts, Theuns and Van Broeckhoven 2012). These mutations predominantly occur
within the transmembrane domain of PSs (Li and Greenwald 1998). Normally, a
consequence of y-secretase activity is the generation AICD and p3 or AP fragment,
mainly Ap40. However mutated PSs genes seemed to produce more Ap42 than Ap40
(Schellenberg and Montine 2012). Even though, the final outcome of both PSs
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mutation are the same but mutations in PS1 and PS2 affect A(342/ A(340 in a different 
way. PS1 mutations result in an increased amount of A(342 while A(340 remains the 
same (Jankowsky et al. 2004). In contrast, mutations in PS2 resulted in the same 
amount of A(342 with decreased amount of A[340 (Walker et al. 2005).
Furthermore, a single amino acid replacement is a consequence of the majority of 
mutations in PS1; missense mutations. Although there are other kinds of mutation 
occurring in PS1, the most serious one has to be a double amino acids replacement 
with in-frame deletion of exon 9; donor-acceptor splice mutation (De Strooper 2007). 
Also, PS1 mutations affect the Ap aggregation structure by generating a cotton wool 
shape plaque which, again, consisted more of A(342 (Schellenberg and Montine 2012).
According to brain autopsy reports of EOAD patients caused by PS1 or PS2 mutations, 
not only did the number of amyloid plaques increase but also the A|342/ A(340. Despite 
PSs mutation effects on neurofibrillary tangles, there is no significance different in 
term of numbers of NFT presented in FAD and SAD. Another neuropathological 
hallmark associated with PSs mutation, the less common one, is Lewy's body 
(Schellenberg and Montine 2012).
1.5.3 Apolipoprotein E (ApoE) allelles
Originally, ApoE was discovered to be involved in lipid metabolism but, with more
advanced technologies, it has been suggested that ApoE also plays roles in lipid
transport, synaptic function, intracellular signalling, immune regulation and, very
importantly, Ap trafficking (Schellenberg and Montine 2012). ApoE is also responsible
for glycoprotein synthesis in the brain and liver. ApoE is located on chromosome 19
and it encodes Apolipoprotein E. ApoE acts as a binding component of lipoprotein to
cell surface receptors and it is the majority of apolipoprotein in HDL complexes,
especially in the brain. As the majority of Alzheimer's disease cases are SAD and the
high susceptibility of ApoE as a genetic risk factor for SAD have made ApoE a centre of
attention in the genetic contribution of Alzheimer's disease. Unlike other mammals,
humans have three main alleles of ApoE; e2, e3 and e4. These alleles are encoded by
one genetic locus and are distinguished by two amino acid differences; at positions 112
and 158. For example, e2 encodes cysteine at both position 112 and 158, e3 encodes
cysteine at position 112 and arginine at position 158, and e4 encodes arginine at both
30
positions. In addition, e3 is a dominant allele found and e2 is a minor allele among all 
alleles. Each allele of ApoE has played a different role in AD. e2 has a neuroprotective 
property against AD development and e3 has a neutral effect against AD while e4 has a 
great ability to increase the risks of AD development (Guerreiro, Gustafson and Hardy
2012). In other words, the onset age of AD associated with the ApoE allele is e4> e3> 
e2 to early> middle> late, respectively. Homozygous allele such as e4/ e4 tends to have 
higher risk than heterozygous e4/ e3 or e4/ e2. Also e4/ e4 is more aggressive than e2/ 
e2. Interestingly, an individual carrying a single copy of e4 has three times higher 
chance to develop AD than carrying zero copies, but if an individual was carrying two 
copies of e4, homozygous, a chance of developing AD increased up to  15 times 
(O'Brien and Wong 2011). Nevertheless, ApoE only acts as an additive to AD 
development as a risk or disposable factor but not a causative factor on its own 
(Schellenberg and Montine 2012), and there is a possibility that ApoE contributes to 
AD development through its cellular ability on the uptake and clearance of Ap (O'Brien 
and Wong 2011).
1.5.4 SORLA
SORLA or sorting protein-related receptor is a type 1 membrane protein which is 
mainly expressed in the brain. It belongs to a low density lipoprotein superfamily and 
its function as a shuttle transporting vesicles to the cell surface, endosome, Golgi and 
ER. It has been suggested to play an important part in APP processing and producing 
Ap fragment as a result. SORLA operates vesicle transportation by using its N-terminal 
to bind to APP and its vacuolar protein-sorting region to bind to the retromer complex; 
the retromer complex mediates the connection between endosomal compartments 
and TGN (Anderson et al. 2005; O'Brien and Wong 2011). The function of SORLA as an 
APP shuttle is supported by studies which have shown that SORLA is able to deliver 
APP for y-cleavage. It was also discovered that the expression of SORLA in the brain of 
AD patient has declined and suppression of SORLA gene expression in animal models 
induced Ap aggregation. Apart from binding to APP, SORLA also plays role as an ApoE 
receptor (Schellenberg and Montine 2012).
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1.6 Hypotheses proposed to account for AD
1.6.1 Cholinergic hypothesis
The cholinergic neurons are responsible for several brain functions including neuronal 
plasticity sleep regulation, depression, delirium, learning ability and cognitive function. 
The cholinergic neurons are categorised into; (1) projection neurons which are mainly 
located in the upper brain stem and prosencephalon and (2) interneurons which are 
found in the spinal cord, cortex, cerebellum and striatum. The principal function of 
cholinergic neuron is to produce neurotransmitters; acetylcholine and its enzyme; 
choline acetyltransferase (ChAT). Since acetylcholine was identified and characterised 
by Henry Dale and Otto Loewi in 1936, many researchers have been influenced to 
investigate its properties in detail. One of several findings of acetylcholine, and indeed 
the most well-known one, is the cholinergic hypothesis in relation to cognitive 
imparment and dementia; the so called "cholinergic hypothesis in AD" (Contestabile
2011).
The cholinergic hypothesis was originally proposed in the 1970s (Francis et al. 1999) 
based on the post-mortem examination that a loss of cholinergic neurons was often 
observed in the brains of AD patients (Craig, Hong and McDonald 2011). As a 
consequence of losing cholinergic neurons, a significant reduction in choline 
acetyltransferase was also observed. During the development of the cholinergic 
hypothesis, it was observed that the loss of cholinergic neurons mainly appeared in the 
brain areas associated with cognitive and memory functions such as the hippocampus 
and frontal lobe area. Also, pyruvate dehydrogenase which is a crucial enzyme in 
acetylcholine synthesis was found to be significantly decreased in the brains of AD 
patients. However, it was reported that cholinergic neuronal loss was more likely to be 
a consequence of the ageing process and it was not specified to AD, but other 
neurodegenerative disease as well (Contestabile 2011). It has been suggested that a 
single factor theory of the cholinergic hypothesis was not sufficient to be used solely as 
an explanation of clinical and pathological manifestations of AD. Consequently the 
multiple co-factor theory has been proposed whereby cholinergic depletion, for 
example, when enhanced by an episode of stroke becomes sufficient to  be used as an 
explanation for AD related manifestations (Craig, Hong and McDonald 2011; Parent et
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al. 2013). It was shown that the damage done to the brains with pre-acquired 
cholinergic depletion by a stroke attack was worse than the damage done to the 
healthy brains (Craig, Hong and McDonald 2011).
Regardless of the diversity of evidence, cholinergic drugs which were based on the 
cholinergic hypothesis still remain the most effective available symptomatic treatment 
drugs for AD.
1.6.2 Tau hypothesis
The principal of tau hypothesis is based on the fact that aberrant phosphorylation of 
tau protein leads to pair helical filament (PHF) formation which eventually turns into 
neurofibrillary tangles (NFTs) (Mohandas, Rajmohan and Raghunath 2009). Under the 
normal conditions, the binding ability of tau protein to microtubule or tubulin 
assembly promotion is regulated by the phosphorylation process. However the 
hyperphosphorylation condition compromises tau protein biological activity, causing 
the conformational changes and structural misfolding which leads to excessive 
aggregation within neurons (Kolarova et al. 2012). Also, it was suggested that neuronal 
cell death as a consequence of continuous modification of tau protein initiated neuro- 
inflammatory process by releasing oligomerised and filament forms of tau into 
extracellular spaces which led to neurodegeneration (Maccioni et al. 2010).
Tau protein belongs to the microtubule-associate protein (MAP) family and it is the 
main component of MAP in mature neurons. The size of tau protein ranges from 352- 
441 amino acids. The alternative splicing of tau protein generates six different isoforms 
which are mainly distinguished by the repetition of tubulin binding domain at the C- 
terminal and the number of inserts at the N-terminal (Maccioni et al. 2010). For 
example, the longest tau protein containing 441 amino acid residues has four repeats 
of tubulin binding protein and two 29-amino acid residue inserts while the shortest 
isoform of tau protein has three repeats of tubulin binding protein with an absence of 
29-amino acid residue inserts (Mohandas, Rajmohan and Raghunath 2009). Tau 
protein does not only play a crucial role in microtubule stabilisation but is also able to 
promote tubulin assembly (Maccioni et al. 2010).
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There are several reasons which have suggested the accuracy of the tau hypothesis 
and clinical manifestation including; (1) an increase of NFT in the brain corresponds to 
stage of AD, (2) there is a strong connection between hyperphosphorylated tau in CSF 
and severity of cognitive impairment and (3) using drugs to reduce tau oligomerisation 
results in improvement of cognitive functions.
1.6.3 Amyloid hypothesis
The amyloid hypothesis was established in 1992 by Hardy and Higgins, based on a 
study in the biochemical effects of the amyloid precursor protein processing and the 
discovery of an amino acid sequence called amyloid p peptide (Ap). A3 is a 4 kilo 
Dalton peptide which is the major element of amyloid plaques. The amyloid hypothesis 
has been postulated as a main influence in the causation of Alzheimer's disease which 
was determined by the imbalance in production and elimination of A3 in the brain 
(Glenner and Wong 1984; Hardy and Higgins 1992). In 2002, Chechler and Vincent 
described that the neurodegenerative process in the brains of patients o f Alzheimer's 
disease pathology was induced by an abnormal process of the amyloid precursor 
protein resulting in over production, aggregation and deposition (Checler and Vincent 
2002). The order of events occurring in amyloid hypothesis was shown in Figure 1.6.1. 
Also, the principal of amyloid hypothesis has been modified over time due to the 
better understanding of the pathogenic nature of Ap (Pimplikar 2008).
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Figure 1.6.1 The order of events occurring in amyloid hypothesis (Hardy and Selkoe 
2002).
Later, the amyloid hypothesis was partially questioned mainly due to  the discrepancy 
of the severity of cognitive impairment and the number of plaques, including the 
presence of high numbers of plaques in cognitively healthy people (Pimplikar 2008). 
Also, there were four crucial debatable aspects which contributed to the amyloid 
hypothesis. Firstly, Alzheimer's disease pathogenesis was a result of the generation 
and elimination of Ap peptide. Although this was supported by the confirmation of the 
direct correlation between presenilins and amyloid production which resulted in an 
increase in production of Ap42 in cell culture, transgenic mice models of AD and AD 
patients, however, the same could not be said for the apolipoprotein E4 since there 
has been no evidence suggesting the mechanism of this relationship. Secondly, Ap 
peptide is toxic. Although the Ap oligomers were proved to have an effect at the 
synapses, it was not a toxic effect and it only created minimal synaptic changes. It was 
reported that the behavioural improvement in APP transgenic mice was a 
consequence of Ap immunisation. Thirdly, Ap triggered neurofibrillary tangle 
dysfunction. This aspect presents a large area which required further investigation
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since there has been no convincing evidence available. Finally, neuronal cell death is 
more likely to be caused by neurofibrillary tangle formation rather than amyloid 
deposition (Hardy 2009).
The most recent idea of amyloid hypothesis is the aggregation of soluble A(3 oligomers. 
This idea was supported by the fact that Ap peptide is amphiphilic and the first 28 
amino acid residues of Ap are polar, while the latter 12-14 amino acid residues are 
non-polar. At neutral pH, the polarity of both termini of Ap is enhanced resulting in Ap 
aggregation and formation (Pimplikar 2008). Also, there were studies suggesting that 
there is a strong relationship between soluble Ap, including soluble AP oligomers, and 
the severity of cognitive impairment (Yates and McLoughlin 2007).
Nevertheless, the post-mortem examination of the brains of AD patients unveiled 
great neuronal damage including dead neuronal cells and synaptic loss which has been 
postulated as a result of Ap peptide (Yates and McLoughlin 2007). On the other hand, 
the neuronal cell death and synaptic loss could be the results of reactive oxygen 
species and nitric oxide production, decreased membrane fluidity, redox-active iron, 
inflammatory process and intracellular calcium accumulation (Kayed et al. 2003; 
Salminen et al. 2009; Vetrivel and Thinakaran 2010).
1.7 Current treatments
It was previously mentioned in Section 1.1.1 Epidemiology of AD, that global 
demography has changed because of low birth rates and longer life expectancies. As a 
consequence of the changes the total world population has been maintained, if not 
declined, and there has been a significant increase in the proportion of the ageing 
population; consequently the mean number of population having AD is higher. Also, 
the higher number of AD patients results in higher demand for health care and social 
services. These consequences have a huge impact on the global economy (Prince, Prina 
and Guerchet 2013).
At the present, there are four drugs; donepezil, rivastigmine, galantamine and
memantine which were approved by the Food and Drug Administration (FDA) to be
used as a symptomatic treatment of AD. These four drugs are classified into two
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different groups according to mechanism of action; (1) acetylcholinesterase inhibitor 
(AChEI); donepezil, rivastigmine and galantamine and (2) N-methyl-D-aspartate 
(NMDA) receptor antagonist; memantine. Cholinesterase inhibitors are commonly 
used in AD patients with mild and moderate symptoms while the NMDA receptor 
antagonist is used in AD patients with moderate to severe symptoms (Salomone et al. 
2011; Yiannopoulou and Papageorgiou 2013).
1.7.1.1 Acetylcholinesterase Inhibitors (AChEIs)
The usage of acetylcholinesterase inhibitor (AChEI) is mainly based on the cholinergic 
hypothesis of AD (see Section 1.6.1). The mechanism of action of AChEI is to inhibit 
acetylcholinesterase activity resulting in prolonged half-life of acetylcholine. In other 
words, by using AChEI the level of acetylcholine is increased. It was proposed in the 
cholinergic hypothesis that there was impairment in the cholinergic system during the 
early stage of AD. The impairment included a deficit in cholinergic activities due to  a 
loss of cholinergic neurons which caused memory loss and cognitive functions 
declined. The AChEIs are often referred as an empirical treatment of AD. Interestingly, 
it was reported that there was no significant difference among each cholinesterase 
inhibitor and adverse reactions of these drugs is dose-dependent. Moreover, there 
was another drug which belonged to this group and it was the first of AChEI which was 
approved by the FDA; tacrine. However, tacrine was withdrawn from the market by 
the FDA due to acute hepatotoxicity (Lukiw 2012; Yiannopoulou and Papageorgiou
2013).
1.7.1.2 N-methyl-D-aspartate (NMDA) receptor antagonist
The neuronal excitotoxicity caused by excess glutamate has often been linked to  the
pathogenesis of AD (Yiannopoulou and Papageorgiou 2013) and it was supported by
observations made in the brains of AD patients; the majority of dead neurons were
glutamatergic neurons (Hynd, Scott and Dodd 2004). Under normal conditions,
glutamate acts as a mediator in fast excitatory synaptic responses and involves in
learning ability and memory function (Butterfield and Pocernich 2003). The excess
glutamate is believed to cause continuous stimulation of NMDA receptors which
eventually resulted in cell death. The mechanism of action of memantine is to bind to
NMDA receptor and inhibit usual physiological activities of the receptor (Johnson and
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Kotermanski 2006). Once memantine binds to NMDA receptors, it is able to inhibit 
continuous Ca2+ influx into neurons, hence preventing neuronal excitotoxicity (Parson, 
Stoffler and Danysz 2007). Therefore, memantine which is a NMDA receptor 
antagonist has been used in order to prevent the effect of excess glutamate and as a 
consequence the neurons regain normal functions (Lukiw 2012).
1.7.1.3 Other treatments
Despite the fact that at the present there is no effective treatment for AD which would 
be able to treat AD at its causes, prevent symptoms from worsening and restore the 
lost cognitive functions, the existing drugs are able to improve the quality of life of the 
AD patients, mostly up to 12 months (Alzheimer's Society 2014; Lukiw 2012). Besides 
symptomatic treatment drugs for AD, most patients usually require additional drugs; 
such as antidepressants to treat depression and apathy, and antipsychotics to treat 
hallucinations and delusions. The commonly prescribed antidepressants are selective 
serotonin reuptake inhibitors (SSRIs) such as fluoxatine, sertraline and citalopram; 
serotonin-norepinephrine reuptake inhibitors (SNRIs) such as mirtazapine and 
duloxatine; and non-tricyclic antidepressants (non-TCA) such as bupropion. The 
antipsychotics of choice are second generation antipsychotics (so called atypical 
antipsychotics) such as olanzapine and risperidone because of the weaker 
parkinsonian effect. Benzodiazepine acts on gamma-aminobutyric acid A (GABAa) 
receptors and is often used in anxiety and agitation management. However, it was 
reported that benzodiazepines increased cognitive impairment (Alzheimer's Society 
2014; Yiannopoulou and Papageorgiou 2013).
1.8 Background of the project
It has been over two decades since the amyloid cascade hypothesis was established 
(Hardy and Higgins 1992). The amyloid cascade hypothesis has provided the 
fundamental concept for understanding the pathogenesis of the Alzheimer's disease; 
the deposition of A(3 peptide, derived from APP, is the cause of Alzheimer's disease 
(Hardy and Higgins 1992; Nalivaeva and Turner 2013; Preece et al. 2004). Although 
several aspects related to APP: regulation of the expression, trafficking, post-
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translational modification and proteolytic process are intensively studied and well 
understood (Dawkins and Small 2014), yet there are many questions remaining to be 
answered including the normal function of APP, the functional differences between 
different isoforms of APP and the physiological role of the APP metabolites (Belyaev et 
al. 2010; Nalivaeva and Turner 2013).
Moreover, effort has been made in order to gain a better understanding of the 
differences between the three main isoforms of APP; APP695, APP751 and APP770 
using both animal and cellular models. Despite clear structural differences between 
the three APP isoforms; the presence and the absence of KPI and 0X2 domains, few 
studies studied and directly compared these three isoforms of APP:
• Belyaev et al. (2010) reported that the APP695 was a preferred isoform, in 
comparison to APP751 and APP770, for proteolytic processing via the 
amyloidogenic pathway in neuronal cells. The experiment was carried out using 
neuronal cells transfected with expression vectors containing human APP 
isoforms (Belyaev et al. 2010). However, this proposal needs to be accepted 
with caution since there are some concerns regarding the experimental 
protocols such as the two different types of expression systems: pIREShyg 
containing human APP770 and plREShyg2 containing human APP751 and 
APP695 used to generate stable clones, the absence of the standardisation of 
the clones and the changes in culture condition prior to the actual experiments.
• Qiao Qui et al. (1995) reported that the A(3 peptide produced from APP751 and 
APP770 strongly promoted neurite outgrowth of hippocampal neurons, in 
comparison to Ap peptide produced from APP695. The experiment was carried 
out by co-culturing hippocampal neurons and CHO cells transfected with 
expression vectors containing human APP isoforms (Qiao Qiu et al. 1995).
Some studies categorised the experimental subjects into KPI+ APP or KPI containing 
APP isoform (APP751 and APP770) and KPI' APP or non-KPI containing APP isoform 
(APP695):
• Chua, Lim and Wong (2013) reported that the KPI+ APP (i.e. APP751) lowered 
the expression of major mitochondrial enzymes significantly in comparison to 
KPI APP (i.e. APP695). The mitochondrial dysfunction associated with the
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abnormal expression and function of mitochondrial enzymes along with an 
increase in KPI+ APP are important features in the AD brain. This observation 
has confirmed the importance of KPI+ APP isoform as a potential 
pharmacological target for the treatment of AD. The experiment was carried 
out using APP knock-out cell line transfected with expression vectors containing 
human APP695 representing KPT APP and APP751 representing KPI+ APP (Chua, 
Lim and Wong 2013).
Khalifa et al. (2012) reported that the KPI domain of APP751 facilitated APP 
dimerization. The native fold of the KPI domain is involved in the trafficking and 
processing of the APP to favour the non-amyloidogenic pathway. These 
observations have provided information regarding the functional differences 
between the isoforms of APP. The experiments were carried out using cell lines 
transfected with expression vectors containing APP isoforms where APP695 
represented the KPI'APP and APP751 represented KPI+APP (Khalifa et al. 2012). 
Matsui et al. (2007) reported an increased expression of KPI+ APP mRNA in the 
temporal neocortex which correlated to the protein level of KPI+ APP. The study 
was carried out by examining temporal cortex tissue of the AD patients and the 
measurement values were reported as a total APP, KPI+APP and KPI+APP ratio 
(KPI+APP divided by total APP) (Matsui et al. 2007).
Preece et al. (2004) reported that the increased ratio of KPI+ APP mRNA to KPI' 
APP mRNA was the result of change in the cell population. These observations 
have further confirmed that KPI+ APP isoforms are non-neuronal isoforms and 
suggested that a small change in the relative level of KPI+ APP mRNA could 
significantly contribute to pathogenesis of AD. The experiment was carried out 
by examining the APP mRNA level in the brain tissue of AD patients and 
reported as an individual isoform such as APP695 and a combination of several 
isoforms such as APP C (695/714/751/770) (Preece et al. 2004).
Panegyres, Zafiris-Toufexis and Kakulas (2000) reported an increase ratio of 
APP751 to APP695 in frontal and temporal regions. Since the KPI+APP isoforms 
were reported to be more amyloidogenic in vitro, this observation suggested 
the possibility that the progression of AD could be initiated as a consequence. 
The study was carried out by examining the brain tissue of AD patients to
determine the relationship of the APP695 (KPI' APP) and APP751 (KPI+ APP).
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Since the number of samples used in this study was small, the results obtained 
might not represent the general population (Panegyres, Zafiris-Toufexis and 
Kakulas 2000).
• M oir et al. (1998) reported the relative increase of the soluble form cerebral A(3 
as APP695 and APP751 representing KPT APP and KPI+ APP, respectively. The 
study was carried out by examining the brain tissue of the AD patients (Moir et 
al. 1998).
• Brugg et al. (1995) reported that the experimentally-induced inflammation 
causes a shift in APP isoforms, from APP695 to KPI+APP. This observation has 
suggested that inflammatory processes play a role in APP processing in relation 
to AD pathogenesis. The experiment was carried out using transgenic mice and 
reported the measurement values as APP695 and KPI+ APP isoform (APP751 
and APP770) (Brugg et al. 1995).
Some studies either studied one isoform of APP or made comparisons between wild- 
type APP and mutated APP:
• Chasseigneaux et al. (2011) reported that sAPPa was more efficient in 
enhancing the elongation of axons in comparison to sAPP(3 and the elongation 
of axons related to a decrease in cell adhesion. The experiment was carried out 
using primary cortical neurons growing in the culture medium containing either 
sAPPp or sAPPa generating from APP695 (Chasseigneaux et al. 2011).
• De Strooper et al. (1995) reported that the Swedish and Flemish mutation 
caused an increase in all APP metabolites while there was a significant 
reduction of APP metabolites produce from mouse APP. The experiment was 
carried out using rat hippocampal neuron transfected with mouse APP, human 
APP and human APP with mutations; Swedish and Flemish (De Strooper et al. 
1995).
• Haass et al. (1993) reported that the APP which matures in the late Golgi 
and/or cell surface was predetermined to produce A(3 peptide w ithout being 
processed in the lysosome. The experiment was carried out using HEK293 cells 
transfected with APP695 (Haass et al. 1993).
• Liu et al. (2003) reported that APP expression and secretion were enhanced by
hepatocyte growth factor leading to an increase in Ap peptide secretion in both
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normal and Swedish mutation. The experiment was carried out using HEK293 
cells transfected with wild-type human APP751 and human APP751 containing 
Swedish mutation. (Liu et al. 2003).
So far, there have been numerous animal and cellular models which have been created 
and used in AD studies. However they do have some limitations including an inability 
to completely reflect the AD pathology. For example, the A(3 peptide-obtained from 
rodents is less prone to the aggregation due to three amino acid differences within the 
A(3 domain (Fraser et al. 1992; Nalivaeva and Turner 2013). Despite the 
overexpression of human APP in transgenic mice, it was reported that the human APP 
is proteolytically cleaved differently in mice due to the lack of secretases specifically 
for human APP and the mouse models do not reflect the advanced stage of disease 
when a patient is diagnosed (Chow et al. 2010). Also, the treatments which are 
available for Alzheimer's disease either treat the symptoms or slow down the 
progression of the disease for a period of time. The treatments could not reverse the 
damage that has been done to the brain. Therefore, it is necessary to establish a 
suitable model to allow researchers to attain a better understanding of pathogenesis 
of the Alzheimer's disease in order to prevent or prolong the onset of the disease. 
Also, the model could also be used to develop the effective treatment or, even, a cure.
1.9 Aim and objectives
The aim of this project is to develop and validate the cellular model for studying 
amyloid precursor protein (APP) isoforms.
The objectives of the project are as follows:
• Develop an appropriate cell model of Alzheimer's disease using genetic 
manipulation of existing cell lines to secrete APP695, APP751 and APP770
• Investigate the effects of nutritional stress, using altered FBS concentration 
on APP isoforms expression and secretion
• Investigate the effects of energy deprivation, using 2DG on APP isoforms 
expression and secretion
42
Chapter 2: Materials and methods
2.1 Bacterial culture
Bacteria were grown two ways: agar-based cultures and liquid cultures performed 
according to different experimental requirements. The agar-based bacterial cultures 
were performed with the purpose of single colony identification and selection, carried 
out in petri dishes containing 25 ml of sterile LB broth agar and selective antibiotic. The 
LB agar plates were incubated overnight at 37 °C.
The liquid bacterial cultures were performed with the purpose of increasing the 
bacterial biomass to prepare for the further experiments such as plasmid DNA 
extraction (minipreparation). The liquid bacterial cultures were carried out in sterile 50 
ml plastic tubes containing 10 ml of liquid LB broth and selective antibiotic. Once 
bacteria were suspended in the prepared liquid mixture, the tube was incubated 
overnight at 37 °C in a shaker at 200 rpm.
Negative control plates and tubes were always carried out alongside each of the 
bacterial culture procedures.
The amplicillin was used as the selective antibiotic in the bacterial culture and the 
concentration was 50-150 pg/ml. The bacteria used in this project were NEB 5-a 
competent E.coli.
2.2 Cryopreservation and recovery of bacteria
In order to cryopreserve bacteria, bacteria containing the expression vector were 
cultured at 37°C overnight in liquid culture and shaken at 200 rpm. 850 pi of the 
culture was transferred to a sterile tube before addition of 300 pi o f 50% v/v sterile 
glycerol, which acted as cryopreservative agent. The culture was dispersed evenly by 
vortexting and stored as aliquots at -80°C.
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In order to recover bacteria from cryopreservation, a sterile plastic loop was used to 
scrape the surface of frozen bacteria then immediately streaked onto LB agar plates 
containing selective antibiotic. LB agar plates were incubated overnight at 37°C and 
the cryopreserved bacteria tube was returned to be stored at -80°C.
2.3 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) was developed during the 1980s for the purpose 
of DNA or RNA amplification. There are 3 main steps in the PCR process: (1) 
denaturation where double-strand DNA is separated, (2) annealing where primers bind 
to single-stranded DNA and (3) extension where the new complementary strand of 
DNA is synthesized by polymerase enzyme. However, in case of amplification o f RNA, 
RNA is required to be transcribed into cDNA before the three-step PCR can begin 
(Schochetman, Ou and Jones 1988).
Polymerase chain reaction was generally performed as 50 pi reactions composed of 1 
unit of Phusion* DNA polymerase (NEB), sterile water, 5x Phusion* HF buffer (NEB), 10 
mM dNTPs mixture (NEB), 10 pM forward primer (Invitrogen), 10 pM reverse primer 
(Invitrogen) and 2 pi of template DNA. The primers are listed in Figure 3.2.1 in Chapter 
3. Reaction was carried out using a Primus 96 plus PCR machine (MWG-Biotech). The 
standard amplification was performed with an initial denaturation at 98 °C for 2 
minutes following by 30 cycles of denaturation at 98°C for 45 seconds, annealing at 
54°C for 45 seconds and extension at 72°C for 2 minutes and 30 seconds, then final 
extension at 72°C for 5 minutes.
The other forms of PCR were also performed: Touchdown PCR (TD-PCR), Overlap 
Extension PCR (OE-PCR), Reverse Transcriptase PCR (RT-PCT) and quantitative Real- 
Time PCR. The last two types of PCR; Reverse Transcriptase PCR (RT-PCT) and 
quantitative Real-Time PCR are explained in Section 2.22.
TD-PCR is a well-known solution to reduce non-specific amplification and to avoid the
need for extensive optimization of PCR reactions. The main concept of TD-PCR is to
start the reaction with a high annealing temperature, usually higher than melting
temperature (Tm) of the primers, and over 10-15 cycle period the annealing
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temperature is decreased gradually; 0.5°C per cycle until the Tm of the primers is 
reached. Then the reaction continues with 20-25 cycles using the final touchdown 
temperature (Korbie and Mattick 2008). In other words, decreasing an annealing 
temperature over 10-15 cycles allows primers to bind to the template DNA at various 
temperatures which generates both correct and incorrect PCR products. Then over the 
last 20-25 cycles allows the correct product to be amplified. In this project TD-PCR 
reaction started with an initial denaturation at 95°C for 3 minutes following by 10 and 
25 cycles step. The first 10 cycles began with denaturation at 95°C for 1 minute, 
annealing at 54°C for 45 seconds (temperature decreased by 0.5°C every cycle) and 
extension at 72°C for 2 minutes. The next 25 cycles started with a denaturation at 95°C 
for 1 minute, annealing at 50°C for 45 seconds and extension at 72°C for 2 minutes. 
The final step of this reaction was the final extension which was carried out at 72°C for 
10 minutes.
OE-PCR was proposed as an alternative way to create mutations at a specific site 
within a DNA fragment and it has usually been the method of choice for genetic 
engineering (An et al. 2005; Bryksin and Matsumura 2010; Urban, Neukirchen and 
Jaeger 1997). The principal of OE-PCR is that two separated typical PCR reactions 
generated two DNA fragments which contained mutated overlapping regions 
introduced by the primers. When the two fragments are combined and extended by 
DNA polymerase, the strand serves as a template DNA for further amplification 
(Higuchi, Krummel and Saiki 1988). In this project, the two DNA fragments were 
generated by TD-PCR. The two fragments were assembled by preparation of 50 pi of 
reaction containing sterile water, 5x Phusion® HF buffer (NEB), 10 mM dNTPs mixture 
(NEB) and approximately 10 ng of each fragment. The assembled reaction was carried 
out in a Primus 96 plus PCR machine (MWG-Biotech). The OE-PCR reaction began at 97 
°C for 4 minutes followed by 75 cycles at 95 °C for 15 seconds with 0.5 °C decrease in 
temperature every cycle. The reaction was then placed on ice before an addition of 1 
unit of Phusion* DNA polymerase (NEB) and heated at 72 °C for 3 minutes and placed 
on ice. The 10 pM of forward and reverse primer from 5' end and 3' end o f the full 
length PCR product were added to the reaction following by the standard PCR steps.
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2.4 Restriction enzyme digestion
Restriction enzyme digestion is the method used to obtain the DNA fragments which 
suitable for further analysis or experiments. This method allows the enzyme to cleave 
DNA at specific sites to produce DNA fragments of interest (Goodsell 2002; Hartl and 
Jones 2005). In this project, both single and double restriction digestions were carried 
out as 50 pi reactions containing 10 units of each restriction enzyme, 1 pg of plasmid 
DNA, 5 pi of lOx NEBuffer 4, 5 pi of 1 mg/ml BSA, with the volume adjusted to 50 pi 
with deionized water. Single restriction digestion was incubated at 37 °C for 2 hours 
then inactivated at 80 °C for 20 minutes. Whereas double restriction digestion was 
performed using two restriction enzymes; Aflll and BstBI that have different working 
temperature, so the first enzyme was added to the reaction and incubated at 37 °C for 
2 hours then the second enzyme was added. Once the second enzyme was added, the 
reaction was incubated at 65 °C for 2 hours before 20 minutes of inactivation of the 
restriction enzymes at 80 °C. The vector map containing restriction sites can be found 
in Figure 3.5.1.
2.5 Ligation
The selected method for joining DNA fragments and linearised plasmids together was 
ligation using T4 DNA Ligase (NEB). The 20 pi ligation reaction contained 1 pi T4 DNA 
Ligase, 2 pi of lOx ligase buffer, 0.02 pmol of linearised vector, 0.06 pmol of DNA 
fragment and the final volume was adjusted to 20 pi with deionized water. The 
amount of DNA fragment was usually three times of the amount of linearized DNA (in 
molar terms) and the T4 DNA Ligase was added last. Ligation reaction was carried out 
at 16 °C for 4 hours (adapted from Sambrook and Russell 2001).
2.6 Agarose gel electrophoresis
Agarose gel electrophoresis is used to separate DNA fragments using a property of 
DNA: the negative charge. DNA has a negative charge due to the presence of
46
phosphate groups on its backbone therefore the DNA migrates toward the anode 
during electrophoresis when an electric field is applied across an agarose gel. The 
agarose has pores which allow the DNA to be separated according to its size and shape 
as well as its charge. The smaller molecules of DNA have higher mobility rate hence 
migrating through the porous matrix faster in comparison to the larger molecules, thus 
using agarose gel also allows approximate size measurement for DNA.
In order to detect the DNA on agarose gel, ethidium bromide (EtBr) was used. Also 
EtBr does not require a de-staining step and can be added to the gel prior to setting. 
Ethidium bromide intercalates itself between the base pairs of DNA to enable 
fluorescence visualization.
Throughout the project 1% agarose gels were used. The Tris acetate EDTA (TAE) buffer 
was prepared as lOx stock solution by dissolving 48.4 g Trizma base in 750 ml de­
ionized water, adding 11.42 ml glacial acetic acid and 20 ml of 0.5 M EDTA (pH 8.0) 
solution, and brought the final volume up to 1 L with de-ionized water. The final pH of 
TAE buffer was adjusted to 8.3 and the buffer was stored at room temperature. 
Preparation of a 1% agarose gel was carried out by dissolving 0.5 g agarose powder 
(Bio-Rad) in 50 ml of lx  TAE buffer; 5 ml of lOx TAE buffer diluted in 45 ml de-ionized 
water. Before pouring the gel, 2 pi of 10 mg/ml ethidium bromide was added and 
mixed thoroughly. Once the gel was poured the plastic comb was placed in order to 
create loading wells. The agarose gel was allowed to set for at least 15 minutes at 
room temperature. DNA loading buffer (6x) was prepared by dissolving 25 mg 
bromophenol blue in 1 ml de-ionized water, adding 3 ml glycerol and making up the 
final volume to 10 ml using de-ionized water.
Prior to running the agarose gel, 1 pi of 6x DNA loading buffer was added to 5pl of 
each DNA sample and mixed thoroughly by pipetting before loading onto each well of 
the gel. A 1,000 base-pair (bp) DNA ladder (Sigma-Aldrich and NEB) was prepared by 
adding 1 pi of 6x DNA loading buffer to 5 pi DNA ladder and mix thoroughly by 
pipetting. The agarose gel was run at 100 volt for 60 minutes before being visualized 
using a UV light box at 302 nm and captured on UVP camera with LabWorks software.
47
2.7 Gel extraction
Gel extraction procedure was used to isolate the DNA fragments of interest from 
agarose gels after electrophoresis. The procedure was carried out using a spin column 
of Qiaquick gel extraction kits (Qiagen). The 500 pi of QG buffer was added to the gel 
piece in microcentrifuge tubes and heated at 60 °C for at least 10 minutes or until the 
gel piece was completely melted. The QG buffer facilitated the binding of DNA 
fragments to the silica membrane of the spin column at high salt conditions. Also, the 
QG buffer contained a pH indicator which allowed the optimal pH < 7.5 to be 
maintained to maximise DNA binding. After an additional of 100 pi of isopropanol, the 
melted gel was transferred to the Qiaquick spin column where DNA fragments were 
then absorbed to silica membrane by centrifugation at 13,000 rpm for 1 minute. The 
flow-through was discarded before another 500 pi of QG buffer was added to the spin 
column in order to remove the trace of agarose gel on the silica membrane. The flow ­
through from 1 minute centrifugation at 13,000 rpm was discarded. The remained high 
salt on the silica membrane was removed by adding 750 pi of PE buffer (10 mM Tris- 
HCI, pH7.5 and 80% v/v ethanol). The PE buffer and existing ethanol in the PE buffer 
were removed by centrifugation twice for 1 minute each time at 13,000 rpm. In short, 
the impurities, including agarose gel, ethidium bromide and ethanol, did not bind to 
silica membrane of spin column therefore impurities flowed through the membrane 
after centrifugation step. The DNA fragment was eluted into 1.5 ml Eppendorf tubes 
from the spin column by adding 50 pi o f EB buffer (Tris-CI, pH 8.5) following by 
centrifugation at 13,000 for 1 minute.
2.8 Plasmid preparation
The purpose of plasmid preparations is to prepare plasmid DNA for further 
experiments. In this project the plasmid preparation was carried out at small scales 
which will be referred to as minipreparation. Minipreparation was carried out using 
QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer's standard protocol. 
The principle of this method is to extract plasmid DNA from bacteria by using alkaline 
lysis with SDS. In details, 24 hours before starting the minipreparation procedure, a
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selected colony was inoculated into 2 ml LB broth containing 50 pg/ml ampicillin and 
inoculated overnight at 37 °C in a shaker at 200 rpm. Minipreparation was carried out 
at room temperature. The next day, bacterial cells pellet were harvested by 
centrifuged 1.5 ml of overnight culture at 13,000 rpm for 2 minutes. Then the pelleted 
bacteria were resuspended completely with 250 pi of PI buffer by vortexing. Then the 
250 pi P2 of buffer was added to suspended bacterial to lyse the cells and mixed by 
inverting tube four times. The bacterial cell lysate was then neutralized and adjusted 
to high-salt by adding 350 pi of N3 buffer, the high salt aiding DNA-column binding. At 
this point, protein, chromosomal DNA and cellular debris were degraded and 
precipitated while small plasmid DNA was still intact and retained in solution. The 
solution after adding N3 buffer was transferred onto Qiaprep spin column and 
centrifuged at 13,000 rpm for 1 minute and the flow through was discarded. The silica 
membrane of spin column was washed by adding 500 pi and 750 pi of PB and PE buffer 
respectively before centrifugation at 13,000 rpm for 1 minute. The flow  through 
obtained from each centrifugation step was discarded. Although, both, PB and PE 
buffers are wash buffers, the PB buffer was used to inhibit the activity of nuclease 
from host strain and PE was used to precipitate any leftover acid residue from the 
membrane. Finally, the plasmid DNA was eluted from the silica membrane by adding 
50 pi of EB buffer (Tris-CI, pH 8.5) before centrifugation at 13,000 rpm for 1 minute 
(Qiagen).
2.9 Transformation of NEB 5-a competent E.coli
The transformation method for NEB 5-a competent E.coli recommended by the 
manufacturer (NEB) was the heat shock method. In short, a tube of competent cells 
was thawed on ice for 10 minutes then 100 ng of plasmid DNA was added. The tube 
was agitated four times to mix plasmid DNA and competent cells. The tube was placed 
on ice for 10 minutes and heat shocked at 42 °C for exactly 30 second before placing 
the tube back on ice for 5 minutes. Next, 950 pi of SOC (2% Vegetable Peptone 
0.5% Yeast Extract, 10 mM NaCI, 2.5 mM KCI, 10 mM MgCI2, 10 mM MgS04 
20 mM Glucose) medium at room temperature was added to  the transformation 
reaction tube. The SOC medium allowed NEB 5-a competent E.coli to recover from the
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heat shock procedure. The transformation reaction tube was incubated for 60 minutes 
at 37 °C in a vigorous shaker at 200 rpm. Finally, 100 pi of transformed cells was 
transferred onto warm LB agar plate containing 50 pg/ml ampicillin and incubated 
overnight at 37 °C.
2.10 Sequencing
DNA sequencing was performed by Eurofins MWG Operon. The plasmid DNA samples 
were sent at 50-100 ng/pl. Purified PCR products were sent at 100 ng/pl due to its size 
being greater than 1,000 bp. Along with samples, primers were sent at 15 pmol per 
primer. Generally, sequencing was carried out on strands of DNA that were no longer 
than 1,000 base pairs otherwise the sequencing result was not reliable. Therefore, 
throughout the study, sequencing was carried out as a two-step process. The first step, 
the DNA was sequenced from both ends of the PCR products. The results obtained 
from the first sequencing then were used to design another pair of primers. These pair 
of primers was then used in sequencing process in order to complete the full 
sequence.
2.11 Cell culture
Cell culture media, antibiotics and cell counting equipments were obtained from 
Gibco™ Invitrogen UK unless stated otherwise. All cell culture methods and procedures 
were carried out under sterile conditions in a class II lamina a irflow  cabinet.
2.11.1 Cell line stock
Chinese Hamster Ovary (CHO) cells and Human Embryonic Kidney (HEK293) cells were 
preserved in 1 ml of heat-inactivated fetal bovine serum (HI-FBS) (Biosera) containing 
10% (v/v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Cells were stored in cryovials in a 
liquid nitrogen Dewar until required for use.
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2.11.2 CHO culture
The CHO cell stock in a cryovial was thawed quickly at 32 °C and grown in a cell culture 
incubator at 37°C and 5% C02 in a 25 cm2 flask containing 6 ml complete media. The 
complete medium consisted of Dulbecco's Modified Eagle's medium (DMEM) 
Glutamax II which contained 10% (v/v) HI-FBS, 1% penicillin-streptomycin (100 
units/ml and 0.1 mg/ml, respectively). Once cells were determined to be more than 
80% confluence, cells were passaged into new 25 cm2 flasks by removing culture media 
and washing cells using 5 ml of lx  Dulbecco's Phosphate Buffer Saline (PBS) solution. 
The cells were incubated in 3 ml of Dulbecco's Trypsin-EDTA solution (containing 0.25% 
(v/v) trypsin and 0.38 g/l EDTA) at 37°C for 5 minutes. The flask was tapped gently if 
the ceils were not completely detached from the flask. The reaction of Trypsin-EDTA 
was stopped by adding 3 ml of complete medium and the cell suspensions were 
transferred to 50 ml Falcon tubes. Cell suspensions were centrifuged at 1,000 rpm for 
5 minutes and supernatant was discarded. The cell pellet was re-suspended in 10 ml of 
complete medium and 1 ml of cell suspension was dispensed into a new 25 cm2 flask 
to make up 1:10 passage ratio; adding 1 ml of cell suspension to 5 ml of complete 
medium. In order to allow cells to grow, flasks were incubated at 37 °C and 5% C02.
2.11.3 HEK293 culture
HEK293 cells were cultured in a similar procedure to that used to culture CHO cells.
2.11.4 Cell counting
Cells were counted by combining 10 pi of cell suspension to 10 pi of 0.4 % Trypan blue 
and mixed thoroughly. 10 pi of the cell's mixture was then transferred onto Countess® 
Cell Counting Chamber Slides. The cells were counted using the Countess® Automated 
Cell Counter which determined the number of cell in to ta l/m l, the number of live 
cells/ml, the number of dead cells/ml and the percentage of cell viability. The principle 
of Trypan blue stain is that the live (viable) cells with the intact cell membrane are able 
to prevent the dye entering the cells whereas dead cells with compromised cell 
membrane do not have that ability, therefore being stained by the dye.
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2.12 Cryopreservation and resurrection of mammalian cells
In order to cryopreserve mammalian cells, cells were cultured according to methods 
described in Section 2.11. After centrifugation, the cell pellet was re-suspended in 1 ml 
of cryopreservative solution; 90% HI-FBS and 10% DMSO before being transferred to 
cryo-vial. The vial was kept in -80 °C freezer for 24 hours before transferring to a liquid 
nitrogen Dewar for long-term storage purpose.
In order to resurrect mammalian cells from cryopreservation, the cryo-vial was 
removed from liquid nitrogen Dewar and thawed quickly. The vial was wiped using 
70% Ethanol. Cells were transferred to 15 ml tubes before adding 3 ml of warm 
complete medium drop wise. Cells were centrifuged at 1,000 rpm for 5 minutes and 
re-suspended with 6 ml of fresh complete medium.
2.13 Antibiotic k ill curve
The antibiotic kill curve procedure was used to determine the optimal concentration of 
a selective antibiotic for transfection. The optimal concentration of a selective 
antibiotic is just enough to kill all the host cells after 4-7 days and this optimal 
concentration is used in transfected colony selection after the transfection procedure. 
The general idea of antibiotic selection is that the host cells taking up the expression 
vector benefit from an antibiotic resistance gene carried in the vector therefore the 
host cells are able to survive in the presence of the antibiotic. The concentration o f the 
antibiotic for colony selection was twice the concentration used for maintenance.
The selection of stably transfected cell line was carried out using two antibiotic 
selectable markers on two different expression vectors; hygromycin resistant gene in 
plREShyg2 and neomycin resistant gene in pcDNA3.1. Throughout this project, 
hygromycin B (Sigma-Aldrich) and geneticin (G418) (Sigma-Aldrich) were used as 
selective antibiotics. The suggested concentration of Hygromycin B for CHO cells 
ranges from 50-600 pg/ml therefore the five chosen concentrations for selection were 
50, 100, 200, 400 and 600 pg/ml and the control concentration was 0 pg/ml. The 
suggested concentrations of G418 are 200-400 pg/ml for CHO cells and 400-1000
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(ig/ml for HEK293 cells, therefore the five chosen concentrations and a controlled 
concentration for CHO selection were 0, 100, 200, 300, 400 and 500 pg/ml. Whereas 
concentrations for HEK293 selection were 0, 200, 400, 600, 800, 1000 pg/ml. In brief,
2.5 x 105 cells/well were dispensed onto each well of six-well plate and allowed to 
adhere at least 6 hours before adding selective medium containing varied 
concentrations of the selective antibiotic. Cells were observed and photographed with 
camera attached to the microscope and the XLI cap program, every day for 7 days.
2.14 Transfection
Due to the properties of the phospholipid bilayer of cell membranes, water soluble 
molecules such as nucleic acid are prevented from entering mammalian cells. 
Therefore, a transfection agent is an ideal solution for gene delivery into mammalian 
cells. Transfection can be carried out in different ways such as particle bombardment 
(micro particle, such as gold is loaded with nucleic acid, was then directly injected into 
cell nucleus), electroporation (applying the short-term electric field to the cells 
resulting in an increased permeability of the cell membrane) or lipid formulation 
(liposome vesicle containing nucleic acid fuse to cell membranes and allowed nucleic 
acid to transfer) (Hahn and Scanlan 2010). In this project, plasmid DNA was introduced 
into nuclei of the host cells to allow the expression of recombinant genes by using 
Lipofectamine® LTX with Plus™ Reagent (Invitrogen).
Lipofectamine® LTX with Plus™ Reagent is a transfection agent which is classified as a 
lipid formulation forming cationic liposome vesicles. Plasmid DNA can be delivered by 
liposomes in two ways; plasmid DNA is carried within the enclosed vesicle of the 
liposome or plasmid DNA was integrated into the phospholipid bilayer of the liposome. 
The cationic lipid forming liposome is usually comprised of cationic and zwitterionic 
lipids which allowed liposomes to interact and fuse to cell membranes, respectively, in 
order to deliver plasmid DNA into host cells (Hahn and Scanlan 2010).
The transfection procedure was carried out in 24-well plates according to the 
manufacturer's standard protocol. The preparation of cells was done one day before 
starting the transfection procedure. For each well, CHO 4 x 104 cells and HEK293 1.25 x
53
105 cells were plated in 500 pi of complete medium and allowed to adhere overnight 
or grow up to 80% confluence. The DNA-Lipofectamine complex was prepared for each 
well by diluting 500 pg of plasmid DNA with 100 pi of DMEM-Glutamax I® w ithout FBS, 
then add 1 pi of PLUS™ Reagent and the mixture was then incubated for 5 minutes at 
room temperature. The 3 pi of Lipofectamine® LTX was added to the diluted DNA 
solution and DNA-Lipofectamine® LTX complexes to form by incubating the mixture for 
25 minutes at room temperature. The complete medium was removed from each well 
and replaced with 500 pi of fresh DMEM-Glutamax I® w ithout FBS and 100 pi of DNA- 
Lipofectamine® LTX complexes. The 24-well plate was incubated at 37 °C with 5% C02 
incubator for 24 hours before selection with antibiotic for 4-7 days and then 
processing limited dilution cloning.
2.15 Limited dilution cloning
Limited dilution cloning is a technique used in molecular cell biology experiments to 
obtain single cells which can then be expanded into a clone. The main principle of this 
technique is that a heterogeneous population is separated in order to generate a 
homogeneous population by carrying out a series of dilutions in a 96-well plate (Figure 
2.15.1). The limited dilution cloning was carried out twice before the selective culture 
medium was screened for protein expression.
Cells were cultured, trypsinised and resuspended according to cell culture procedure in 
Section 2.11. A 100 pi of selective medium was dispensed to every well o f 96-well 
plate, apart from A l well. The cell suspension was prepared at 2 x 104 cells/ml and 200 
pi of prepared cell suspension was dispensed to well A l. Then 100 pi of cell suspension 
in A l well was transferred vertically down the column; from B1 well to H I well. The 
final 100 pi was discarded. Also, during the transfer, the cell suspension was mixed 
thoroughly by pipetting gently to avoid creating bubbles. Another 100 pi of selective 
medium was added to the first column of the 96-well plate and mixed gently using 
multi-channel pipette. The 100 pi of cell suspension in the first column was then 
transferred horizontally across the plate; from column 1 to 12. Again, the final eight of 
100 pi from each row was discarded and during the transfer the cells suspension was
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mixed thoroughly but gently to avoid bubble formation. The final volume of each well 
was adjusted to 200 pi by adding 100 pi of selective culture medium. The plate was 
incubated at 37 °C with 5% C02 for at least a week until required, and at the same time 
the plate was observed under phase microscopy for wells containing single colonies. 
The plate set up diagram is shown in Figure 2.15.1. The chosen wells containing single 
colonies were then expanded into 12-well plates and then 6-well plates. The cells were 
allowed to grow to at least 50% confluency in 12-well plates before transfer to 6-well- 
plates. Once the cells in the 6-well plate grew at least to 50% confluence, they were 
proceeded with the repeat o f limited dilution cloning procedure. At the end of the 
second limited dilution cloning procedure, cells were grown in complete medium with 
additions of antibiotic at concentrations one half of that obtained from the kill curve, 
and cells were allowed to grow until 80% confluence before culture medium was 
collected for protein expression screening.
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Figure 2.15.1 A plate set up for limited dilution cloning procedure in a 96-well plate.
The plate was prepared as described in Section 2.15. The cells were transferred and 
mixed thoroughly but gently using pipette. The dilution of the cells was carried out 
from the well A l to H I first before it was carried out horizontally. The cell suspension 
from well H I and column 12 were discarded. The plate was then put back in the 
incubator.
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2.16 Im munoprecipitation
Immunoprecipitation is the method used to isolate proteins of interest from a complex 
solution by using a specific antibody. Cell culture medium was collected at various 
points of time throughout this project dependent on the nature of experiment. The 
immunoprecipitation procedure was carried out in 1.5 ml Eppendorf tubes. Each 
reaction contained 1 ml of cell culture medium, 250 pi of anti-Ap DE2 (mouse 
monoclonal supernatant), 100 pi of lOx Tris Buffer Saline (TBS; 0.2 M Tris, 1.5 M NaCI) 
pH 7.5 and 50 pi of 50% slurry anti-mouse IgG agarose beads (Sigma-Aldrich). Sample 
was mixed by rotating for 1 hour at room temperature then centrifuged at 13,000 rpm 
for 1 minute and the supernatant was discarded. For double immunoprecipitation; 
additional 1.0 ml of cell culture media and 100 pi of lOx TBS were added to the 
precipitated agarose beads and mixed by rotation for 1 hour at room temperature. The 
samples were centrifuged at 13,000 rpm for 1 minute and the supernatant was 
discarded. The beads were washed three times with 1.0 ml of lx  TBS, centrifuged at 
13,000 rpm and the supernatant was discarded. In order to dissociate samples from 
the beads, 100 pi of 2x SDS-PAGE sample buffer containing 30.8 mg/ml of DTT was 
added and heated at 60 °C for 10 minutes. The 2x sample buffer was prepared by 
dissolving 308 mg of DTT in 10 ml of 0.5 M Tris-HCI pH 6.8 following by addition o f 2 ml 
of 10% SDS, 3 ml of 60% glycerol and 0.5 ml of 2 mg/ml bromophenol blue.
2.17 Reduction and alkylation of disulphide bonds
In order to facilitate the binding of antibodies which were used in the project, 
especially 993 and 1151, the disulphide bonds within the target protein molecules 
must be broken. After the sample was dissociated from the beads with SDS-PAGE 
sample buffer, sample was allowed to cool down for 15 minutes at room temperature 
before adding fresh 5 pi of 400 mM iodoacetamide then the sample was mixed by 
rotation for 1 hour at room temperature. The sample was centrifuged at 13,000 rpm 
for 1 minute before loading onto SDS-PAGE gel.
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2.18 Sodium Dodecyl Sulfate polyacrylamide gel electrophoresis
The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method 
used to separate macromolecules such as protein based mainly on molecular weight. 
The typical gel electrophoresis procedure cannot be used to determine the molecular 
weight of biological molecules because the mobility of a molecule in the gel depends 
on both its charge and size. Therefore, it is necessary to treat the protein in order to 
obtain the uniform charge to mass ratio by using 2x SDS-PAGE sample buffer 
containing 30.8 mg/ml of DTT). At this point, the separation on the gel is primarily 
based on the polypeptide size.
The gel consists of 2 parts: stacking and resolving gels. The stacking gel is located at the 
upper part of the gel and usually contains a large pore size with low pH (pH 6.8) 
whereas the resolving gel is located at the bottom part of the gel and usually contains 
smaller pore size with higher pH (pH 8.8)
Throughout this project 5% stacking gel were used with 6% and 8% resolving gel. SDS- 
PAGE gels were prepared using the following stacking and resolving gel mixes:
Resolving gel
6% 8%
Deionised water 2.6 ml 2.3 ml
30% Acrylamide/Bis 1.0 ml 1.3 ml
1.5M Tris-HCI pH 8.6 1.3 ml 1.3 ml
10% (w/v) SDS 0.05 ml 0.05 ml
10% (w/v) ammonium persulphate 0.05 ml 0.05 ml
TEMED 0.004 ml 0.003 ml
Total solution volume (per gel) 5 ml 5 ml
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Stacking gel
5%
Deionised water 1.4 ml
Acrylamide/Bis 0.33 ml
0.5M Tris-HCI pH 6.6 0.25 ml
10% (w/v) SDS 0.05 ml
10% (w/v) ammonium persulphate 0.05 ml
TEMED 0.002 ml
Total solution volume (per gel) 2 ml
2.19 SDS-PAGE running conditions and immunoblotting
SDS-PAGE gels were run typically at room temperature at 0.4A for 1 hour and then 
transferred onto nitrocellulose membranes. SDS-PAGE running buffer was prepared as 
lOx stocking concentration consisted of 250mM Tris, 1.92 mM Glycine and 1% SDS. 
Prior to transfer, the nitrocellulose membrane was wetted in transfer buffer (25mM 
Tris, 192mM glycine and 10% methanol, pH 8.3). The transfer process was carried out 
at 0.4 A for 1 hour.
The immunoblotting procedure was carried out at room temperature on the rocking 
rack. To start the procedure, the nitrocellulose membrane was blocked in 5% W/V 
non-fat dry milk in TBST for 30 minutes (0.05% V/V Tween 20 (Sigma-Aldrich) in lx  
TBS). Then, the membrane was incubated in primary antibody solution for 90 minutes 
at room temperature followed by two washes with 25 ml TBST for 5 minutes on the 
rocking rack. The antibodies used in this project are listed and shown in Figure 2.19.1. 
The membrane was then incubated in secondary antibody solution for 45 minutes. The 
secondary antibody was selected according to origin of primary antibody; DE2 primary 
antibody paired with anti-mouse secondary antibody while 23/2, 993, 1151 primary 
antibody paired with anti-rabbit secondary antibody. The membrane was washed 
twice with 25 ml TBST for 5 minutes and once with 10 ml deionised water for 10 
minutes. Both washes were carried out on the rocking rack. If the secondary antibody 
solution was either IRDye 680RD Goat anti-Mouse IgG or IRDye 680RD Goat anti-
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Rabbit, the membrane was visualised using an infrared fluorescent imaging system (Li- 
Cor Odyssey, Li-Cor) whereas using AP conjugated secondary antibody, the membrane 
was developed in 10 ml reconstituted BCIP/NBT solution (Sigma-Aldrich) for 30 
minutes.
Antibody Description Dilution
Function Binding
DE2 (mouse) Immunoprecipitation A(3 domain on APP 1:5.6
Primary antibody solution A(3 domain on APP 1:10
23/2 (rabbit) Primary antibody solution 0X2 domain on APP 1:250
993 (rabbit) Primary antibody solution KPI domain on APP 1:250
1151 (rabbit) Primary antibody solution N-terminal of APP 1:250
Anti-mouse
AP-linked
Secondary antibody solution DE2 antibody 1:1000
Anti-rabbit
AP-linked
Secondary antibody solution 23/2, 993 and 1151 
antibody
1:1000
IRDye 680RD 
Goat anti- 
Mouse IgG
Secondary antibody solution DE2 antibody 1:20000
IRDye 680RD 
Goat anti- 
Rabbit IgG
Secondary antibody solution 23/2, 993 and 1151 
antibody
1:20000
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Figure 2.19.1 (top) antibodies used in immunoprecipitation and immmunoblotting 
procedure, (bottom) antibodies recognition of APP.
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2.20 RNA extraction
RNA extractions from cell culture were carried out using RNeasy Mini Kit (Qiagen) 
which uses spin technology to obtain total RNA from cultured cells. The RNA extraction 
from HEK293 cells was carried out according to the manufacturer's standard protocol. 
In brief, lx lO 6 HEK293 cells were harvested and prepared as cell pellets in 1.5 ml 
microcentrifuge tubes by centrifugation at 10,000 rpm for 1 minute. The lysis buffer 
(RLT; containing guanidinium salt), originally prepared by manufacturer, was added 10 
pi of p-mercaptoethanol (p -ME) per 1 ml of RLT buffer. 600 pi of P -ME/RLT buffer was 
added to each cell pellet and the pellets loosened by agitating the tube. The p-ME/RLT 
buffer inactivated RNases therefore providing intact RNA. The cell lysate was 
homogenised thoroughly by passing through a 20 gauge needle before adding 600 pi 
of 70% ethanol. The homogenised lysate including precipitates was transferred to an 
RNeasy spin column placed in a 2 ml collection tube and centrifuged at 13,000 rpm for 
15 seconds. The flow-through was discarded and the spin column contained bound 
total RNA was saved.
The bound total RNA on the membrane of spin column placed in collection tube was 
washed by adding 700 pi of washing buffer 1 (RW1) then centrifuged at 13,000 rpm for 
15 seconds. After the flow-through was discarded, the spin column was washed twice 
with 500 pi of washing buffer 2 (RPE) by centrifugation at 13,000 rpm firstly for 15 
seconds then 2 minutes. The purpose of the 2 minute centrifugation was to dry the 
spin column ensuring that the spin column was dry and ethanol free before eluting the 
total RNA, the spin column was placed on a new 2 ml collection tube and centrifuged 
at 13,000 rpm for 2 minute. The spin column was placed on a new 1.5 collection tube 
and 50 pi of RNase-free water was added directly to the spin column membrane 
followed by centrifugation at 13,000 rpm for 1 minute. The purified total RNA was 
stored at -80°C.
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2.21 Quantification of RNA samples using NanoDrop ND-1000 UV-VIS 
Spectrophotometer
The precise quantity of total RNA was quantified using a NanoDrop ND-1000 UV-VIS 
Spectrophotometer in the RNA nucleic function (RNA40) where the concentration was 
determined at 260 nm. RNase/DNase free water was used to initialise the 
spectrophotometer and was used as a blank. In order to obtain the total RNA 
concentration value, 1 pi of each total RNA sample was loaded onto machine. 
Moreover, the acceptable purity o f RNA was determined by OD 260/OD 280 ratios: 
1.8-2.0.
2.22 The principle of Reverse Transcriptase PCR (RT-PCR) and 
quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR is a procedure used to detect and quantify the 
expression of a gene of interest. In order to begin quantitative real-time RT-PCR, mRNA 
is converted to complementary DNA (cDNA) using reverse transcriptase enzyme. Next, 
the cDNA undergoes repetitive amplification steps or the thermal cycle of quantitative 
real-time RT-PCR resulting in the synthesis of numerous copies of DNA of interest 
exponentially. The amplified product was measured after every cycle via the use of 
fluorescence labelled molecules which accumulate after each amplification cycle. 
Figure 2.22.1 shows the mechanism of action of taqman probe. The fluorescence 
intensity was reported as a semi-log graph between the variations of log (ARn) with 
PCR cycle number; where ARn is the difference between the fluorescence signal from 
the reporter and the background fluorescence. The example of the semi-log graph 
obtained from quantitative real-time RT-PCR was shown in Figure 2.22.2.
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Figure 2.22.1 The mechanism of action of Taqman probe in real-time RT-PCR. The
TaqMan probe contains a fluorophore at the 51 end and a quencher on the 3’ end, 
rendering the molecule non-fluorescent. During the real-time RT-PCR amplification, 
the probe binds to the template. When the polymerase encounters the probe at the 5' 
end, it starts the cleaving process and releasing the fluorophore into solution (Applied 
Biosystems 2014).
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Figure 2.22.2 Quantitative real-time RT-PCR semi-log graph consisted of exponential 
phase and plateau phase. In the exponential phase, there were plenty amounts of 
reagents for the PCR reactions therefore the PCR products were doubled every cycle. 
These PCR reagents, however, decreased as the PCR reactions moving toward the end 
of exponential phase which slowing down the PCR products amplification. In the 
plateau phase, all the reagents were used up and eventually the PCR reactions 
stopped.
Key: Ct value; Cycle threshold value
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2.23 Complementary DNA synthesis from RNA sample for real-tim e RT- 
PCR
The complementary DNA synthesis was carried out using QuantiTect Reverse 
Transcription Kit (Qiagen). Total RNA (lpg) was transferred to 0.2ml microcentrifuge 
tube before adding 2 pi gDNA Wipeout buffer. The tube was incubated at 42 °C for 2 
minutes in Primus 96 plus PCR machine (MWG-Biotech). This step allowed 
contaminating genomic DNA to be removed which enhances the accuracy of real-time 
RT-PCR result. Then, RNA was reversed transcribed to cDNA by adding 6 pi of reverse- 
transcription master mix; 1 pi Quantiscript Reverse Transcriptase, 1 pi RT Primer mix 
and 4 pi of 5x Quantiscript RT Buffer. The final volume was adjusted to 20 pi using 
RNase/DNase free water. The tube was incubated at 42 °C for 15 minutes to activate 
the reverse transcriptase following with inactivation of the enzyme at 95 °C for 3 
minutes.
The negative controls for cDNA synthesis were carried out using the same protocol as 
mentioned above but w ithout RNA as one negative control and replacing 1 pi 
Quantiscript Reverse Transcriptase with lp l of RNase/DNase free water.
2.24 Reference gene assessment for use in real-tim e RT-PCR
A reference gene is also known as a housekeeping gene. Also, it is acknowledged that 
the expression of a reference gene does not change under various experimental 
conditions in order to maintain cellular functions. Determination of suitable reference 
genes for real-time RT-PCR is crucial since all of gene expression measurements are 
normalised against the value of reference genes. In this project, the geNorm™ PLUS 
Reference Gene Selection kit (PrimerDesign), which is a set of primers of twelve 
candidates reference genes, was used to obtain the reference gene expression value 
which was analysed using geNorm software. The details of twelve reference gene 
candidates are shown in Figure 2.24.1.
The twelve candidate reference genes were obtained in lyophilised form and the tubes 
were centrifuged briefly at 10,000 rpm for 15 second to avoid spillage when opening.
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Each primer was prepared by addition of 220 pi RNAse/DNAse free water before re- 
suspending completely by vortexing.
The reference genes assessment was carried out using MicroAmp® Optical 96-Well 
Reaction Plate (Applied Biosystem) and StepOnePlus™ Real-Time PCR Systems. Each 
real-time PCR reaction consisted of 1 pi of 5 ng/pl cDNA, 1 pi of re-suspended primer 
mix, 10 pi of PrimerDesign Precision™ 2x qPCR Mastermix and RNAse/DNAse free 
water. The negative control reactions were carried out using 1 pi of no reverse 
transcriptase enzyme cDNA, 1 pi of no RNA cDNA and replacing cDNA with 1 pi of 
RNAse/DNAse free water. The real-time PCR reaction began with enzyme activation at 
95 °C for 10 minutes followed by 50 cycles of 15 seconds denaturation at 95 °C and 1 
minute data collection at 60 °C. The thermocycle of real-time RT-PCR using SYBR 
green® is shown in Figure 2.24.2.
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Gene
symbol
Description and functions Anchor
nucleotide
Context 
length 
sequence(bp )
Amplicon  
length (bp)
ERCC6 Hom o sapiens excision repair cross-complem enting  
rodent repair deficiency, com plem entation group 6. 
Encoding DNA-binding protein fo r transition and 
excision repair.
2170 160 121
UBE2D2 Hom o sapiens ubiquitin-conjugating enzym e E2D 2. 
Regulated degradation o f m isfolded, dam aged or 
short-live protein.
952 168 127
UBE4A Hom o sapiens ubiquitination facto r E4A (UFD2 
hom olog, yeast). Encoded ubiquitin ligase fam ily  
involving in chrom osom e condensation and 
separation.
2764 94 88
EN0X2 Hom o sapiens ecto-NO X disulfide-thiol exchanger 2. 
Encoded cell surface NADH oxidase.
879 148 114
PRDM 4 Hom o sapiens PR dom ain containing 4. 
Transcription factor o f the  PR-domain protein  
fam ily.
2346 174 128
SCLY Hom o sapiens selenocysteine lyase. Catalyzed the  
pyridoxal 5-prim e phosphate-dependent conversion 
o f L-selenocysteine to  L-alanine and elem ental 
selenium.
928 138 111
TYW 1 Hom o sapiens tRN A-yW  synthesizing protein 1 
hom olog (S. cerevisiae). Stabilized codon-anticodon  
interaction in the  ribosome.
1186 163 126
RNF20 Hom o sapiens ring finger protein 20. Regulated 
chrom osom e structure.
2735 175 129
C H 0140R F Hom o sapiens chrom osom e 14 open reading fram e  
133. Involved in th e  sorting o f lysosomal proteins.
448 166 122
ACTB Hom o sapiens actin, beta. Encoded actin proteins. 1195 106 92
GAPDH Hom o sapiens gIyceraldehyde-3-phosphate  
dehydrogenase. Encoded glyceraldehyde-3- 
phosphate dehydrogenase protein fam ily.
1087 142 110
18S Hom o sapiens 18S rRNA gene. 235 99 93
Figure 2.24.1 Table reference genes analyzed for expression stability in gene 
expression experiments. Twelve human reference genes in geNorm™ PLUS Reference 
Gene Selection kit were assessed for expression stability between non-transfected 
HEK293 and selected clone of HEK293 transfected APP isoforms, also the stability of 
reference genes in experimental conditions.
66
Activation of DNA 
Polymerase 
(1 cycle)
Cycling stage 
(50 cycles)
Melt curve 
(lcycles)
95 °C 95 °C
15 min 15 sec 30 sec
1 min 30 sec
Figure 2.24.2 SYBR green® real-time RT-PCR thermocycler protocol. The reference 
genes stability assessment was carried out using real-time RT-PCR mastermix 
containing SYBR green and subjected to  the thermocycle shown above. The 
thermocycler protocol for SYBR green composed of 3 main steps: (1) a cycle of DNA 
polymerase activation at 95 °C for 15 minutes. (2) 40 cycles of amplification of target 
gene and (3) melt curve. The melt curve was carried out due to the possible non­
specific binding which may occur. The melt curve was used to distinguish specific PCR 
product from non-specific one. Also, the melt curve initially started at 60 °C w ith an 
increase of 0.5 °C per cycle until the final temperature reached 95 °C.
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2.25 Reference gene stability assessment
The reference gene transcript stability of non-transfected and transfected HEK293 was 
determined using the following method. Each 15 pi SYBR Green real-time RT-PCR 
reaction (Section 2.24) was prepared in triplicate for each of the individual 12 
reference genes (Figure 2.24.1) in order to compare between non-transfected HEK293 
and selected clone of HEK293 transfected APP isoforms, and the stability of reference 
genes under experimental conditions; variation in FCS and an additional of 2-Deoxy-D- 
glucose. The three negative control reactions were carried out using 1 pi of no reverse 
transcriptase enzyme cDNA, 1 pi of no RNA cDNA and replacing cDNA with 1 pi of 
RNAse/DNAse free water. The samples were assessed by carrying out real-time RT-PCR 
reaction in the StepOnePlus™ Real-Time PCR Systems according to standard thermal 
protocol showed in Figure 2.24.2.
The result of the real-time RT-PCR performance was obtained as the cycle threshold 
(Ct) value of each sample. These values were later exported from the PCR system and 
analysed using GeNorm software (Biogazelle). The software processed Ct values and 
analysed the stability of the reference genes by sequential removal of these gene after 
calculation of the pair-wise correlations of all probabilities which eventually left a pair 
o f the most stable reference genes represented with expression stability values (M) 
(Pfaffl et al. 2004; Vandesompele et al. 2002). The most stably expressed reference 
genes were then used as gene transcript quantification references to quantify the 
relative expression of the genes of interest throughout the gene expression 
experiments.
The GeNorm software (Biogazelle) not only analyzed the stability of reference genes 
(M-value) but it also generated a pair-wise variation value (V). The V-value was used as 
a guideline to determine the minimum number of reference gene required for 
normalization in gene expression experiments and the V-value at 0.15 was used as a 
cut-off point. The V-value was given as Vn/n+i and If Vn has V-value less than 0.15, then 
it was not necessary to introduce an additional reference gene in that gene expression 
experiment.
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2.26 Conditions and components of TaqMan® real-tim e RT-PCR 
reaction
The TaqMan® real-time RT-PCR master mix consisted of 5 pi of TaqMan® Fast Universal 
Master Mix (Applied Biosystems), 0.5 pi of TaqMan® assay probe (Applied Biosystems) 
and 3.5 pi of RNAse/DNAse free water. Master Mix was prepared for the total number 
of reactions plus 10 % for potential pipetting errors. Each individual reaction contained 
1 pi of cDNA sample and 9 pi of master mix. 1 pi of cDNA sample obtained from 
reaction in the absence of reverse transcriptase, no RNA reaction and RNAse/DNAse 
free water were used as negative controls. The MicroAmp® Optical 96-Well Reaction 
Plate (Applied Biosystems) was set up according to the nature of each experiment and 
then sealed with MicroAmp® Optical Adhesive Film (Applied Biosystems). The reaction 
plate was placed in the StepOnePlus™ Real-Time PCR Systems and subjected to  the 
amplification.
The amplification condition consisted of two main steps which started with enzyme 
activation, at 95 °C for 10 minutes followed by 40 cycles of denaturation and data 
collection. The denaturation was carried out at 95 °C for 15 seconds and data 
collection was carried out at 60 °C for 1 minute. The thermocycle of real-time RT-PCR 
using TaqMan is shown in Figure 2.26.1.
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Holding stage Cycling stage 
(40 cycles)
10 min 15 sec
1 min 
(Data collection)
Figure 2.26.1 The thermocycle used for TaqMan® real-time RT-PCR. The thermocycle 
of TaqMan® real-time RT-PCR began with a cycle of holding stage at 95 °C for 10 
minutes following by 40 cycles of the cycling stage where cDNA of interest was 
amplified. Each cycle of the cycling stage consisted of an amplification step at 95 °C for 
15 second and data collection step at 60 °C for 1 minute where the cycle threshold (Ct) 
value was obtained.
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2.27 Prim er efficiency assessment
The efficiency of primers used in real-time RT-PCR experiments was determined to 
ensure that they were effective and reliable. The cDNA obtained from a conversion of 
total extracted RNA from cell pellets was diluted into four dilutions: 1:5,1:10, 1:50 and 
1:100 by adding appropriated volume of RNAse/DNAse free water. Each dilution was 
prepared in triplicate in the MicroAmp® Optical 96-Well Reaction Plate by adding 1 pi 
of each diluted cDNA sample and 9 pi of TaqMan® real-time RT-PCR master mix of each 
set of primers. The reaction plate was placed in the StepOnePlus™ Real-Time PCR 
Systems and amplified according to standard procedure stated in Section 2.26.
According to the method described in "A new mathematical model fo r  relative 
quantification in real-time RT-PCR" by Michael W. Pfaffl in 2001, the Ct values gained 
from each sample and each set of primers were plotted into an individual semi-log 
graph between dilution of cDNA and Ct values (X-axis and Y-axis, respectively). The 
slope was generated using linear regression analysis. Then the slope o f each graph was 
used in the followed formula to determine efficiency of each primer: Efficiency = 10 
( i / s io p e )  (pfaff| 2001). In addition, efficiency (E) is obtained as a number such that value 
of 1 means there is no PCR product in each cycle or a value of 2 which means PCR 
product was amplified doubly in every cycle. In addition to the slope of the graph the 
function also generated the linear correlation coefficient (R2). The R2 value generally 
represents the strength of relationship between two values or how close the data is to 
the trend line and normally ranges from -1 to +1, and an R2 value of higher than 0.99 
was considered as acceptable.
2.28 Real-time RT-PCR data analysis
There are two ways to analyse data obtained from real-time RT-PCR experiments: (1) 
absolute quantification which determines definite copy numbers of gene of interest 
based on an absolute standard curve and (2) relative quantification which determines 
approximate amount of fold difference of gene of interest either based on differences 
between Ct value of gene of interest and control and reference genes or a standard 
curve. The first quantification method is normally used for viral copy number
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determination. The second quantification method is typically used in gene expression 
studies (Applied Biosystems 2014).
The reference gene in relative quantification was used as a normalizer in order to 
monitor changes of other genes during transcription. Although, this method of 
analysing real-time RT-PCR data does not require highly precise standard curves due to 
the use of normalizer and controls but it is essential that the expression of the 
reference genes is highly stable across samples. Also, results obtained from this 
method are easily interpreted. For example, value of 1 is given when an expression of 
gene of interest is equal to the expression of the reference gene; a value of less than 1 
is given when the expression of the gene of interest is less than the expression of 
reference gene and a value of more than 1 is given if the expression of the gene of 
interest is higher than the expression of the reference gene.
To date, there are two available and commonly used relative quantification models. 
The first model is:
Fold difference = 2‘AACt
Where A A C t =  A C t sampie - A Q controi; A C t sample is the difference of mean of Ct between the 
gene of interest and the reference gene of the sample; A C t control is the difference of 
mean of Ct between control and reference gene of control. The fold difference in gene 
expression can be determined using this model assuming that primer efficiency of the 
sample (gene of interest) and the reference genes are 2: Esampie = Ereference = 2. 
Therefore, this model was used only for general assessment of relative expressions of 
the gene of interest. Also, this model is used when percentage of primer efficiency (E) 
is within the acceptable range of 90-110%.
The second model takes the actual primer efficiency into account which makes this 
model more complicated than the first model:
Fold difference = Esample4Ct samp7  EreferenCe4Ctre,ere" ce
Where Esampie is the primer efficiency of gene of interest; Ereference is the primer 
efficiency of a reference gene; ACt sampie is the difference of the mean of Ct between the
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control and the gene of interest; ACt reference is the difference of the mean of Ct between 
the reference gene of control and the reference gene of the sample.
2.29 Statistics
Statistical analysis was performed using the program Prism (GraphPad Software Inc.). 
Two-way A N O V A  and the Bonferroni's multiple comparison test were performed in 
order to determine the possible effects of independent factors; isoforms of APP and 
concentration of foetal calf serum (FCS) or 2-deoxy-D-glucose (2DG) in the culture 
media.
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Chapter 3: Confirmation of APP770 
construct and generation of APP751 
and APP695 constructs (pIREShyg2)
3.1 Introduction
As stated in the introduction Chapter (Chapterl, Section 1.3.1), there are three main 
isoforms of APP: APP695, APP751 and APP770, which may be involved in the 
pathogenesis of Alzheimer's disease (AD). In order to determine which isoform of APP 
might be more likely to be involved in AD pathogenesis, the first objective was to 
obtain separate expression vectors containing each of the three isoforms of APP. Once 
the expression vectors containing three human APP isoforms were generated, the next 
objective was to stably express the expression vectors in mammalian cells using a 
transfection procedure, and selecting the clone from each APP isoform which 
expressed each APP isoform at a similar level.
3.2 Method for confirmation of APP770 construct
An expression vector, plREShyg2 encoding APP770 (shown in Figure 3.5.1), was kindly 
provided by Professor Nigel Hooper (University of Leeds) as an E.coli stab culture. 
However, to confirm the presence of APP770 and its location in the multiple cloning 
sites of the vector, the multiple cloning site of plREShyg2 required sequencing as the 
expression plasmid was to be used as a basis to generate APP751 and APP695 
constructs.
3.2.1 Primer design
The sequence of plREShyg2 was obtained as well as sequences of Aflll and BstBI 
restriction sites via Addgene online database (http://www.addgene.org/browse/ 
sequence vdb/3180/) and the plREShyg2 vector information provided by Clontech 
Laboratories. Every pair of primers used in this experiment was designed using online
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software; Primer3 Input v.0.4.0 (http://b ioinfo.ut.ee/prim er3-0.4.0/prim er3/). The first 
pair of primers was designed to bind to the multiple cloning site of plREShyg2 outside 
Aflll and BstBI restriction sites for the purposes of amplification and then sequencing 
APP770. The pair of primers consisted of a forward primer APP770_Lf and a reverse 
primer APP770_Rt. The detail of these primers is shown in Figure 3.2.1.
In order to obtain a significant amount of plREShyg2 expressing APP770, E.coli from 
the stab culture was streaked onto LB-agar plates containing 50 pg/ml amplicillin to 
obtain single colonies which were then used as an inoculum for an overnight growth in 
5 ml liquid medium. Subsequently, plasmid DNA was extracted using the QIAprep Spin 
Miniprep Kit and its presence was confirmed by agarose gel electrophoresis (as shown 
in Figure 3.2.2). Once purified and confirmed, the integrity of the plasmid was 
primarily verified by double restriction enzyme digestion analysis; at the Aflll and BstBI 
restriction sites in the plasmid DNA and gel electrophoresis before sequencing. The 
result obtained from double restriction enzyme digestion is shown in Figure 3.2.3. Each 
sequencing process was only able to generate a limited number of sequences. 
Therefore, after obtaining the sequencing results, another pair of primers was 
designed in order to complete the APP770 sequence.
3.2.2 Sequence alignment
Each sequencing result was aligned against the human APP770 (huAPP770) sequence 
obtained from the online database of European Molecular Biology Laboratory (EMBL) 
using online software; BLAST 2 Sequences (BI2seq) via National Centre for 
Biotechnology Information (NCBI) webpage which allowed the obtained nucleotide 
sequence alignments to be compared to known reference sequences w ithout 
searching the whole online database. The alignment results are shown in Figure 3.2.4
(a) to (d) and Figure 3.2.4 (e) represents the alignment to the complete APP770 
sequence.
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No. Primer
Name Sequence (5'-3') Purposes
1. APP770_Lt TCACTATAGGGAGACCCAAG
C
Amplifying and 
sequencing APP770
2. APP770_Rt GAGGGAGTACTCACCCCAAC Amplifying and 
sequencing APP770
3. APP770A_Lt AATTCTTACACCAGGAGAGG
AT
Sequencing APP770
4. APP770A_Rt CCAAGACGTCATCTGAATAG
TT
Sequencing APP770
5. APP751_Rt_Front TGTTGTAGGAATGGCGCTGC
CACACACG
Amplifying and 
sequencing APP751
6. APP751_Lt_Back CC ATT CCTAC A ACAG C AG CC 
AGT
Amplifying and 
sequencing APP751
7. APP695_Rt_Front TGCTGTTGTAGGAACGAACC 
ACCT CTT CCAC AG
Amplifying and 
sequencing APP695
8. APP695_Rt_Back AAGAGGTGGTTCGTTCCTAC 
AACAG CAG CCAGT
Amplifying and 
sequencing APP695
Figure 3.2.1 Table stating primer names, sequences and purposes.
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4.5-1
-0.2038X+3.8853 
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Figure 3.2.2 The purified plasmid using QIAprep Spin Miniprep Kit® on 1% agarose 
gel. Lane 1, 1 kb DNA Ladder; lane 2, negative control (without plasmid); lanes 3 to 6, 
purified plasmid obtained from minipreparation procedure, its size was approximately 
6.0 kb. (b) The graph illustrated the distance of the bands and the number o f base pair 
of DNA ladder and as average distance of the plasmid DNA was 0.7 cm which was 
predicted to be 5.8 kb.
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4.5-1
y = -0.2718x+ 3.8435 
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Figure 3.2.3 The restriction enzyme digestion of plasmid DNA containing APP770 
sequence, (a) Plasmid DNA digested with restriction enzymes, Aflll and BstBI, and 
analysed on a 1% agarose gel. Lane 1, GeneRuler™ 1 kb DNA Ladder used as a size 
marker; lane 2 and 4 are negative controls (without plasmid DNA); lane 3, plasmid DNA 
digest with Aflll and BstBI - upper band is approximately 6.0 kb and lower band is 
approximately 2.5 kb; lane 5, lkb  DNA Ladder. The upper band was linearized 
plREShyg2 and the lower band was APP770 sequence as an insertion, (b) The graph 
illustrates the migration distance of the bands and the number of base pairs of DNA 
ladder and as the migration distance of the digested product was 1.75 cm which was 
predicted to be 2.5 kb.
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Figure 3.2.4 The alignments of the reference human APP770 obtained from EMBL
online database and the results obtained from sequencing, (a) and (b) were the
alignments of sequences obtained from the first reading using APP770_Lt and
APP770_Rt; base 1-881 and 1518-2378, respectively, (c) and (d) were the alignments of
sequences obtained from the second reading using APP770A_Lt and APP770A_Rt; base
521- 1129 and 870-1694, respectively, (e) the alignment of complete sequence of
APP770 obtained from sequencing process against reference human APP770.
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3.3 Expression vector expressing APP751 construct
The complete sequence of APP770 was used as a basis to generate APP751 using 
molecular biology techniques; namely touchdown and overlap extension PCR (TD-PCR 
and OE-PCR, respectively). APP770 contains two domains; KPI and 0X2 domains while 
APP751 only contains the KPI domain which means the 0X2 domain needs to be 
deleted. Once the complete APP751 cDNA fragment was obtained, it was then ligated 
into plREShyg2 and transformed into competent cells. The plasmid DNA was extracted 
from transformed competent cells and sent for sequencing. The APP751 was 
confirmed by aligning against reference human APP751 sequence from EMBL.
3.3.1 Primer Design
According to the alignment between the reference human APP770 sequence and the 
human APP751 sequence obtained from EMBL online database using ClustalW 
software, it revealed the sequence and location of the missing additional domain; 0X2 
domain on APP751. The online software called Primer3 Input v.0.4.0 
(http://b ioinfo.ut.ee/primer3-0.4.0/primer3/) was used in order to design a pair of 
internal primers; APP751_Rt_Front and APP751_Lt_Back in order to  amplify the 
sequence outward from the 0X2 domain of APP770. The sequences and functions of 
the primers are listed in Figure 3.2.1.
3.3.2 Generation of APP751 cDNA and expression vector
As a result of the TD-PCR procedure, two DNA fragments on each side of the 0X2 
domain were generated as shown in Figure 3.3.1 (a). By using the standard curve in 
Figure 3.3.1 (b), the size of fragments A and B were approximately 1.05 kb and 1.25 kb, 
respectively. These fragments were extracted using Qiaquick gel extraction kits (see 
Section 2.7 for the complete procedure) before assembly into a single DNA fragment 
containing the complete sequence APP751 using the OE-PCR procedure. The complete 
APP751 cDNA was initially analysed by agarose gel electrophoresis (Figure 3.3.2 (a)). 
The standard curve showed that the size of APP751 cDNA was 2.5 kb. The complete 
descriptions of TD-PCR and OE-PCR are described in Section 2.3.
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The complete APP751 DNA fragment was then ligated into the multiple cloning sites of 
empty plREShyg2 vector; at Aflll and BstBI restriction sites, generating the expression 
vector expressing human APP751. The ligation procedure was carried out using the T4 
DNA Ligase standard protocol obtained from New England Biolabs (NEB) which is 
described in Section 2.5. The transformation of expression vectors into competent 
cells; NEB 5-a was carried out according to the standard high efficiency transformation 
protocol from New England Biolabs (NEB) which is described in Section 2.9. The 
transformed competent cells were inoculated overnight in the LB containing ampicillin 
followed by plasmid preparation before dispatch to MWG Eurofinsfor sequencing.
3.3.3 Sequence alignment
As a limitation of the sequencing process is the limited number of bases per read, the 
complete APP751 sequence was obtained in two steps (see Section 2.10). Each 
sequencing result was aligned against the human APP751 (huAPP751) sequence 
obtained from the online database of European Molecular Biology Laboratory (EMBL) 
using online software; BLAST 2 Sequences (BI2seq) via National Centre for 
Biotechnology Information (NCBI) webpage which allowed the obtained nucleotide 
sequence to be aligned to known reference sequences w ithout searching the whole 
online database. The alignment results are shown in Figure 3.3.3 (a) to (d) and Figure
3.3.3 (e) represented the alignment to the complete APP751 sequence.
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Figure 3.3.1 APP751 fragments generated by Touchdown PCR. (a) Fragments obtained 
from touchdown PCR were analysed on a 1% agarose gel. Lane 1 and 6, DNA 1 kb 
Ladder; Lane 2, fragment A is approximately 1.1 kb; lane 3, fragment A negative 
control (without template DNA); lane 4, fragment B is approximately 1.3 kb and lane 5, 
fragment B negative control (without DNA template), (b) The graph illustrates the 
distance of the bands and the number of base pair of DNA ladder. The size of 
fragments A and B were approximately 3.35 and 3.2 cm which were 1.05 and 1.25 kb, 
respectively.
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Figure 3.3.2 The assembly of two APP751 fragments by Overlap Extension PCR. (a)
Assembling fragment A and B using Overlap Extension PCR analysed on 1% agarose gel. 
Lane 1, GeneRuler™ 1 kb DNA Ladder; lane 2, fragments A and B assembly negative 
control (without fragment A and B); lane 3, APP770 is approximately 2.5 kb and lane 4 
and 5,assembled fragment A and B (APP751) is approximately 2.4 kb. (b) The graph 
illustrates the migration distance of the bands and the number of base pair of DNA 
ladder. The migrating distance of APP770 was 3.4 cm which was approximately 2.6 kb 
and distance of APP751 was 3.41 cm which was approximately 2.5 kb.
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Figure 3.3.3 The alignments of the reference human APP751 obtained from the EMBL 
online database and the sequencing results, (a) and (b) were the alignments of 
sequences obtained from the first read using APP770_Lt and APP770_Rt; bases 1-886 
and 1485-2256, respectively, (c) and (d) were the alignments of sequences obtained 
from the second reading using APP751_Rt_Front and APP751_Lt_Back; bases 448-1037 
and 1020-1624, respectively, (e) the alignment of combined sequence of APP751 
obtained from sequencing process against reference human APP751.
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3.4 Expression vector expressing APP695 construct
In a similar method to the construction of the expression vector expressing APP751, 
the complete sequence of APP770 was used as a basis to generate an expression 
vector containing APP695 using touchdown PCR (TD-PCR) and overlap-extension PCR 
(OE-PCR). The APP695 does not contain either the KPI or the 0X2 domains. Therefore, 
both additional domains need to be deleted. Once the complete APP695 cDNA 
fragment was generated, it was ligated into plREShyg2 and generated an expression 
vector expressing APP695. The expression vector was confirmed by sequencing and 
alignment of the obtained sequence against the human APP695 sequence obtained 
from the EMBL database.
3.4.1 Primer design
The ClustalW software was used as an alignment tool between the reference human 
APP770 sequence and APP695 sequence obtained from the EMBL online database 
which showed the locations and sequences of the KPI and 0X2 domains on APP770. As 
these two domains need to be deleted, the pair of internal primers; APP695_Rt_Front 
and APP695_Lt_Back were designed using online software called Primer3 Input v.0.4.0 
(http://b ioinfo.ut.ee/primer3-0.4.0/primer3/). As the KPI and 0X2 domains are located 
next to each other, these primers were designed to amplify the sequence outward 
from the KPI and 0X2 domains of APP770. The sequences and purposes o f the primers 
are listed in Figure 3.2.1.
3.4.2 Generation of APP695 cDNA and expression vector
The two DNA fragments on each side of the KPI and 0X2 domains generated through 
TD-PCR procedure are shown on the Figure 3.4.1 (a) The agarose gel electrophoresis 
showed that the estimated size of fragment A was 0.63 kb and the size of fragment B 
was 1.58 kb. These fragments were extracted using Qiaquick gel extraction kits (see 
Section 2.7 for the complete procedure) before assembly into a DNA fragment 
containing the complete APP695 sequence using the OE-PCR procedure. The complete 
APP695 cDNA was initially analysed by agarose gel electrophoresis (Figure 3.4.2 (a)). 
The size of APP695 cDNA was 2 kb. The complete descriptions of TD-PCR and OE-PCR 
are described in Section 2.3.
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The complete APP695 DNA fragment was then ligated into the multiple cloning sites of 
empty plREShyg2 vector at Aflll and BstBI restriction sites generating the expression 
vector containing human APP695. The ligation procedure was carried out using the T4 
DNA Ligase standard protocol obtained from New England Biolabs (NEB) which is 
described in Section 2.5. The transformation of expression vectors into competent 
cells; NEB 5-a was carried out according to the standard high efficiency transformation 
protocol from New England Biolabs (NEB) which is described in Section 2.9. The 
transformed competent cells were inoculated in the LB containing ampicillin overnight 
followed by plasmid preparation before dispatch to MWG Eurofins for sequencing.
3.4.3 Sequence alignment
As a limitation of the sequencing process is the limited number of bases per read, the 
complete APP695 sequence was obtained in two steps (see Section 2.10). Each 
sequencing result was aligned against the human APP695 (huAPP695) sequence 
obtained from the online database of European Molecular Biology Laboratory (EMBL) 
using online software; BLAST 2 Sequences (BI2seq) via National Centre for 
Biotechnology Information (NCBI) webpage which allowed the obtained nucleotide 
sequence to be aligned to known reference sequences w ithout searching the whole 
online database. The alignment results are shown in Figure 3.4.3 (a) to (d) and Figure
3.4.3 (e) represented the alignment of the complete APP695 sequence.
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Figure 3.4.1 APP695 fragments generated by Touchdown PCR. (a) Fragment A and B 
of APP695 obtained from touchdown PCR procedure analysed on a 1% agarose gel. 
Lane 1 and 4, DNA 1 kb Ladder; Lane 2, fragment A negative control (w ithout template 
DNA); lane 3, fragment A is approximately 0.55 kb; lane 5, fragment B negative control 
(without template DNA) and lane 6, fragment B is approximately 1.5 kb. (b) The graph 
illustrates the migration distance of the bands and the number of base pairs o f DNA 
ladder, migration distance of fragments A and B are 2.8 and 3.2 cm which were 
predicted to be 0.63 and 1.58 kb in size, respectively.
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Figure 3.4.2 The assembly of two of APP695 fragments by Overlap Extension PCR. (a)
Assembled fragments A and B of APP695 using Overlap Extension PCR analysed on a 
1% agarose gel. Lanes 1 and 5 are 1 kb DNA ladder; lanes 2, 3 and 4 are the product of 
the assembled fragments A and B of APP695 approximately 2 kb in size, (b) The graph 
illustrates the migration distance of the bands and the number of base pairs of DNA 
ladder, APP695 has travelled 2.4 cm which is approximately 2 kb in size.
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Figure 3.4.3 The alignments between the reference human APP695 obtained from 
EMBL online database and the sequencing results obtained from sequencing, (a) and
(b) were the alignments of sequences obtained from the first read using APP770_Lt 
and APP770_Rt; bases 1-789 and 1310-2088, respectively, (c) and (d) were the 
alignments of sequences obtained from the second read using APP695_Rt_Front and 
APP695_Lt_Back; bases 476-1385 and 552-1501, respectively, (e) the alignment of 
combined sequence of APP695 obtained from sequencing process against reference 
human APP695.
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3.5 Expression of pIREShyg2 containing APP695, APP751 and APP770 
by Chinese Hamster Ovary cells
After completion of the human APP770 expression vector validation and generation of 
expression vectors encoding human APP695 and APP751, the second objective of the 
project was to stably express all three isoforms of APP in Chinese Hamster Ovary (CHO) 
cells by transfection at comparable levels.
3.5.1 Introduction
The CHO cells were originally established in 1956 by Dr. Puck (Wurm and Hacker 2011). 
Due to their flexibility in in vitro cultivation and high reproduction rate, CHO cells have 
been selected for several different studies such as studying the cell cycle, cancer 
biology and treatment studies because of their ease to synchronise and anchorage- 
independent characteristics, respectively (Jayapal et al. 2007; Wurm and Hacker 2011). 
Also, CHO cells are commonly selected to be used in APP processing study (Khalifa et 
al. 2012). In this project, the CHO cells were the mammalian cell line of choice due to 
its low maintenance requirement and ease of transfection and cloning which have 
made them easy to work with. In the other words, CHO cells were chosen for the initial 
step because they are relatively easy to transfect and clone.
Transfection is a process to introduce nucleic acids into mammalian cells in order to 
express proteins of interest in mammalian cells. Also, for stable transfection it is 
important that prior to the transfection the optimal concentration of a selective 
antibiotic is determined by kill curve. The optimal concentration is used after 
transfection in order to select cells that have taken up the expression vector and are 
capable of expressing the vectoral gene. The general idea of the antibiotic selection is 
that the host cells taken up expression vector benefit from an antibiotic resistance 
gene expressed by the vector itself therefore these host cells are able to survive in the 
presence of antibiotic. In this Chapter the expression vectors encoding APP695, 
APP751 and APP770 contained hygromycin B resistance gene, therefore the optimal 
concentration of hygromycin B was determined.
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3.5.2 Hygromycin B kill curve
The plREShyg2 vector contains two antibiotic resistance genes; ampicillin and 
hygromycin B. The ampicillin resistance gene was used as a selectable marker during 
transformation procedure in bacterial culture while hygromycin B resistance gene was 
used as a selective agent in mammalian cell culture. The hygromycin B antibiotic 
resistance gene encodes Hygromycin B phosphotransferase (Hph), as shown in Figure 
3.5.1. Hygromycin B is an aminocyclitol which is a major component of aminoglycoside 
antibiotic family, and is produced by Streptomyces hygroscopicus. The proposed 
mechanisms of actions are that hygromycin B inhibits transport of mRNA and tRNA on 
the ribosome, and interrupts the binding affinity of aminoacyl-tRNA (Blochlinger and 
Diggelmann 1984; Borovinskaya et al. 2008). The recommended concentration of 
hygromycin B as a selective agent is between 50-1,000 pg/ml which depends on the 
cell line. The recommended concentration of hygromycin B for CHO cell culture 
selection ranges between 50 pg/ml to 600 pg/ml.
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Figure 3.5.1 The plREShyg2 vector map with restriction sites, (a) The plREShy2 vector. 
This is a 5.8 kb vector which contains two antibiotic resistance genes; ampicillin and 
hygromycin B. Ampicillin is used as a selectable marker in transformation whereas 
hygromycin B is used transfection, (b) the multiple cloning site (MCS). The DNA of each 
APP isoform was inserted in the MCS, bases 912 to 1003, of the vector using Aflll and 
BstBI.
Five hygromycin B concentrations were tested and compared to growth in the absence 
of hygromycin B: 0, 50, 100, 200, 400 and 600 pg/ml. The hygromycin B kill curve 
experiment was carried out in 6-well plates over a 7-day period. The CHO cells were 
allowed to adhere in the 6-well plates for at least six hours before adding various 
concentrations of hygromycin B. The CHO cells were alive and healthy at every 
concentration up until day 3. On day 4, which was the time CHO cells normally took to 
become confluence (as seen in the absence of hygromycin B), cells seemed to  either 
stop growing or slowed their growth rate at 200 and 400 pg/ml and there were 
significant numbers of dead cells at 600 pg/ml, as shown (Figure 3.5.2 (a)). As also 
shown in Figure 3.5.2, (b) on day 7 that cells were 80% confluence at 200 pg/ml and 
there were only few cells left at 400 pg/ml while cells were all dead at 600 pg/ml,
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which at this point cells were very confluence at controlled concentration (0 pg/ml), 50 
and 100 pg/ml.
As a result of the hygromycin B kill curve experiment, the optimal concentration for 
CHO cells culture selection, after the transfection procedure, was 400 pg/ml and this 
concentration was used during the first and second limited dilution cloning 
procedures. The concentration of hygromycin B was reduced to 200 pg/ml in order to 
maintain the expression vector in the transfected CHO clones.
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Figure 3.5.2 CHO cell viability during hygromycin B kill curve. CHO cells were plated 
at 2.5 x 105 cells/well in 6-well plates and allowed to adhere over night before adding 
hygromycin B at various concentrations, (a) Day 4 of hygromycin B kill curve 
experiment. At 200 and 400 pg/ml, cells were growing albeit slowly, in comparison to 
control (0 pg/ml) whereas there were significant numbers of dead cells at 600pg/ml.
(b) Day 7 of hygromycin B kill curve experiment. At 200 pg/ml, cells became 80% 
confluence while at 400pg/ml showed significant numbers of dead cells and at 600 
pg/ml all cells were dead. It appeared that the optimal concentration of hygromycin B 
for CHO cell culture selection was 400 pg/ml. (magnification x200)
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3.5.3 Generation of CHO cells stably expressing APP695, APP751 and 
APP770 using pIREShyg2 expression vector
After determining the optimal concentration of antibiotic from the kill curve, the next 
step was to introduce the expression vector containing human APP constructs into 
host cells by transfection.
Methods in brief
Prior to the transfection procedure, CHO cells were plated at 4 x 104 cells per well in 
24-well plates and cells were allowed to adhere overnight or allowed to grow up to 
80% confluence before proceeding with the transfection procedure. The transfection 
reagent used was Lipofectamine® LTX plus Reagent. The preparation and procedure of 
transfection were described in Section 2.14.
Cells were incubated in transfection reagent at 37 °C with 5% C02 for 24 hours before 
the beginning of limited dilution cloning procedure described in Section 2.15. Four 
days after the first limited dilution cloning, four wells of a 96-well plate which 
appeared to have a colony of cell originated from single cells were selected and 
expanded into 12- and 6-well plates in the selective culture medium containing 400 
pg/ml of hygromycin B. Cells were cultured until 50% confluence before proceeding 
with the second limited dilution cloning. On day 4 of the second limited dilution 
cloning, four wells of each 96-well plate were selected, trypsinised and transferred to a 
12-well plate. Once cell growth had grown to at least 50% confluence, cells were 
transferred to 6-well plates. Then cells were cultured until 80% confluence in selective 
culture medium containing 200 pg/ml o f hygromycin B. At this stage the selective 
culture medium was collected for APP secretion analysis.
The conditioned culture medium was immunoprecipitated using DE2 antibody 
according to procedure described in Section 2.16, followed by reduction and alkylation 
of disulphide bonds (Section 2.17). Samples were initially run on 8% SDS-PAGE before 
changing to 6% SDS-PAGE, which was freshly prepared (Section 2.18) followed by 
protein transfer and immunoblotting (Section 2.19). There were three primary 
antibodies used in immunoblotting; DE2, 993 and 23/2 (listed in Figure 2.19.1 (top)). 
Each of the primary antibodies recognizes different epitopes on APP sequence. The
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DE2 antibody recognizes A(3 domain which is found in all three isoforms of APP. The 
993 antibody recognizes KPI domain which is found in APP751 and APP770 and 23/2 
recognizes 0X2 domain which only existed on APP770. The DE2 and 993 antibodies not 
only recognize human APP but also recognize bovine APP present in culture medium 
while 23/2 antibodies does not. The AP-linked anti-mouse IgG and anti-rabbit IgG were 
used as secondary antibodies. The estimated concentration and size of protein of the 
secreted APP was evaluated by a colorimetric detection method using reconstituted of 
BCIP/NBT solution which converted alkaline phosphatase existing in the secondary 
antibody to give the intensity of purple band which indicated the approximate size and 
concentration of APP.
Results
The preliminary transfection data was obtained using the pooled selective culture 
medium from transfected clones according to the isoform of APP at the end o f the first 
limited dilution cloning stage where CHO cells were allowed to grow in 6-well plates to 
at least 50% confluence. The medium was immunoprecipitated before proceeding with 
the immunoblotting procedure where the membrane was incubated in primary 
antibody solution containing DE2 antibody and secondary antibody solution containing 
anti-mouse IgG AP-linked before purple bands of protein were developed. The 
preliminary result of transfection is shown in Figure 3.5.3. The band of protein (arrow) 
on the membrane suggested that the transfected CHO cells secreted APP into selective 
culture medium as the band of protein (arrow) was approximately 120 kDa 
corresponded to molecular weight of secreted APP770.
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Figure 3.5.3 Protein analysis using DE2 antibody against processed pooled selective 
media of secreted APP by plREShyg2 transfected CHO cells over 96-hour incubation 
period in 6-well plates. Cells were allowed to proliferate for four days in a 6-well plate 
in 2 ml selective medium containing 400 pg/ml of hygromycin B before the medium 
was collected. The secreted APP was immuoprecipitated from pooled selective 
medium before reduction and alkylation of disulphide bonds, and running on 8% SDS- 
PAGE gel. Protein on SDS-PAGE gel was transferred to nitrocellulose membrane 
following by immunobloting procedure using DE2 as primary antibody and anti-mouse 
IgG AP-linked as secondary antibody. The protein bands were detected using 
reconstituted BCIP/NBT solution. The arrow indicates the protein band produced by 
transfected CHO. The protein band (arrow) is located above 116 kDa mark and at the 
same location as CHOF5 (APP positive control, star) which is estimated to be 120 kDa 
which corresponded to the expected molecular weight of APP.
Key: CM; complete medium, NTFX; non-transfected
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As the preliminary data suggested that APP was secreted by transfected clones, the 
selective culture medium collected at the end of the second limited dilution cloning 
from each clone APP isoforms was processed individually by immunoprecipitation 
followed by immunoblotting in order to determine the relative amount of secreted 
APP from each clone. The DE2 antibody was used as the primary antibody and anti­
mouse IgG AP-linked was the secondary antibody. The membrane was developed using 
colorimetric detection. As it appeared on the membranes shown in Figure 3.5.4, there 
were two clones which secreted APP; one clone from CHO cells transfected with 
APP751 (APP751H4) and another from CHO cells transfected with APP770 (APP770H6) 
as the protein band was located above the 116 kDa mark of protein marker. The 
estimated size of the bands of protein was 120 kDa which corresponded with the 
molecular weight of APP770. Since the four selected clones of CHO transfected APP695 
did not secrete APP, more clones were selected from the second limited dilution 
cloning.
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Figure 3.5.4 Protein analysis of secreted APP by plREShyg2 transfected CHO cells in 
complete medium with DE2 antibody. Samples were run on 8% SDS-PAGE gel before 
protein transfer procedure. These samples were processed from medium collected 
after the second limited dilution cloning and transfected cells were allowed to grow for 
4 days, (a) Only clone H4 of CHO transfected APP751 (star) showed a protein band 
approximately 120 kDa in size which corresponded to the expected molecular weight 
of APP. (b) Only clone H6 of CHO transfected APP770 (star) showed a protein band 
approximately 120 kDa in size which corresponded to the expected molecular weight 
of secreted APP.
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The new four selected CHO clones of each isoform of APP were allowed to grow in 6- 
well plates for 96 hours before the selective culture medium was collected and 
processed by immunoprecipitation and immunoblotting. In addition, prepared samples 
from selective culture medium of each new clone were run on three identical sets of 
SDS-PAGE to allow analysis with three primary antibodies by immunoblotting; DE2, 993 
and 23/2. Figure 3.5.5, the membrane was incubated in primary antibody solution 
containing DE2 antibody and secondary antibody solution containing anti-mouse IgG 
AP-linked. Of the four new selected clones of each APP isoform, there were only two 
clones from CHO cells transfected with APP770 that secreted APP while the CHO cells 
transfected with APP695 and APP751 clones did not secrete APP. The size of purple 
band of protein produced by APP770 clones was approximately 120 kDa corresponding 
to molecular weight of APP770 and the existence of A(3 domain. Alongside the DE2 
antibody, the other two identical sets of membranes were incubated separately in 
primary antibody solution containing 993 and 23/2 antibody following by an 
incubation in secondary antibody solution containing anti-rabbit IgG AP-linked before 
purple band of protein was detected using the colorimetric detection method as 
shown in Figures 3.5.6 and 3.5.7, respectively. Figure 3.5.6, as the result of bovine 
APP770 in culture medium, all the clones produced purple band of protein 
(approximately 120 kDa). However, the aggregation of bovine APP and secreted APP 
resulted in a stronger band of protein from APP770 clones. The protein band 
recognised by 993 antibody also confirmed the presence of the KPI domain. Figure 
3.5.7 showed that only APP770 clones produced a 120 kDa protein band recognised by 
23/2 antibody. This confirmed the presence of 0X2 domain that exists on APP770. The 
two APP770 clones which shown the protein band at 120 kDa against DE2 antibody 
also showed protein band of approximately 120 kDa in size recognised by 993 and 23/2 
antibodies which verified the presence of APP770 in culture medium. However, the 
new selective clones did not appear to be transfected with APP695 or APP751.
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Figure 3.5.5 Protein analysis of secreted APP by plREShyg2 transfected CHO cells in 
the complete medium with DE2 antibody. Samples were run on 6% SDS-PAGE gel 
before transfer, (a) Only clone H4 of CHO transfected APP770 (star) showed a protein 
band approximately 120 kDa in size which corresponded to the expected molecular 
weight of APP770. (b) Only clone H5 of CHO transfected APP770 (star) showed a 
protein band of approximately 120 kDa which corresponded to the expected molecular 
weight of APP770.
Key: CM; complete medium, NTFX; non-transfected.
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Figure 3.5.6. Protein analysis of secreted APP by plREShyg2 transfected CHO cells in 
the complete medium with 993 antibody. Samples were run on 6% SDS-PAGE gel 
before transfer. Only clone H4 of CHO transfected APP770 (arrow) showed a protein 
band approximately 120 kDa in size which corresponded to the expected molecular 
weight of APP770. (b) Only clone H5 of CHO transfected APP770 (arrow) showed a 
protein band of approximately 120 kDa which corresponded to the expected molecular 
weight of APP770.
Key: CM; complete medium, NTFX; non-transfected
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Figure 3.5.7 Protein analysis of secreted APP by plREShyg2 transfected CHO cells in 
the complete medium with 23/2 antibody. Samples were run on 6% SDS-PAGE gel 
before transfer. Only clone H4 of CHO transfected APP770 (arrow) showed a protein 
band approximately 120 kDa in size which corresponded to the expected molecular 
weight of APP770. (b) Only clone H5 of CHO transfected APP770 (arrow) showed a 
protein band of approximately 120 kDa which corresponded to the expected molecular 
weight of APP770.
Key: CM; complete medium, NTFX; non-transfected
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3.6 Quantification of APP secretion
As previously demonstrated in Section 3.5.3, there were two CHO clones which 
successfully expressed APP770: CHO770H4 and CHO770H5. The CHO770H4 was 
originally selected as a candidate to assess methods for quantification APP secretion. 
In this experiment, selective culture medium which contained 200 pg/ml of 
hygromycin B was collected from CHO770H4 and prepared by immunoprecipitation 
and reduction and alkylation of disulphide bonds. Figure 3.6.1 (a) shows samples 
diluted in a series: 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100%, before separation by 
6% SDS-PAGE gel. Proteins were transferred onto nitrocellulose membrane followed 
by immunoblotting. The 1151 antibody was used as primary antibody in 
immunoblotting for the first time in this project because the 1151 antibody not only 
recognised a domain at the N-terminal of all three human APP isoforms but also the 
1151 antibody does not recognise bovine APP present in the culture medium which 
made this antibody a suitable antibody in human APP quantification.
So far in this project, the colorimetric detection method was used to estimate the size 
and approximate amount of protein of interest on the nitrocellulose membrane. The 
fluorescence detection method (referred to as LI-COR system) is a well-established 
method for protein quantification as it allows the protein of interest to be precisely 
quantified using the excitable fluorescence emission. Moreover, the fluorescence 
intensity corresponds to the amount of protein therefore it was used as a detection 
method to quantify the protein band in the immunoblotting procedure. The dilutions 
of APP were measured using U-COR system where the fluorescence intensity at 700 
nm from the binding of fluorescence labelled anti-rabbit secondary antibody to the 
APP-1151 protein primary antibody complex. The protein quantification numbers 
gained from LI-COR system were plotted on a graph of fluorescence intensity detection 
and the relative amount of APP. As it is shown in Figure 3.6.1 (b), the graph generated 
a standard curve of the APP concentrations against fluorescence intensity.
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Figure 3.6.1 Quantification of secreted APP using conditioned culture medium of 
CHO770H4. Conditioned culture medium from CHO770H4 was prepared by 
immunoprecipitation, reduction and alkylation of disulphide bonds, (a) Sample was 
diluted into a series of concentrations: from 0% to 100% before running on 6% SDS- 
PAGE gel following by protein transferred and immunoblotting using 1151 primary 
antibody and anti-rabbit IRDye 700 as a secondary antibody, (b) The amount of 
APP770 were measured by the fluorescence intensity reads of the fluorescence 
labelled secondary antibody which were then plotted on a graph against the 
concentration of APP770 which generated standard curve for APP quantification 
method.
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3.7 Discussion
The first objective of the project was to obtain expression vectors containing three 
different isoforms of human APP; APP695, APP751 and APP770. At the beginning of 
the project, an expression vector containing human APP770 was provided by Professor 
Nigel Hooper as E.coli stab culture. The vector was sequenced in order to confirm the 
presence of APP770 and its location within the multiple cloning sites of the vector. The 
first step in the validation process was designing a pair of primers which bound just 
outside the restriction sites where APP770 cDNA was inserted. At the same time, an 
expression vector was prepared by bacterial culture and minipreparation procedures. 
The expression vector was amplified using a pair of customised primers and the PCR 
product was purified using a gel extraction procedure before sending o ff for 
sequencing along with primers. Due to the sequencing limitations (the number of base 
pairs returned per read) a pair of internal primers was designed for sequencing 
purposes. In order to confirm that the complete sequence was obtained, the sequence 
was aligned against human APP770 reference sequence from EMBL online database. It 
was confirmed that the expression vector provided by Professor Hooper contained 
human APP770 cDNA as shown in Figure 3.2.4 and the vector subsequently expressed 
human APP770 as a consequence. At this point it was safe to continue to the next step 
to achieve the first objective of the project.
The complete sequence of human APP770 was used as a basis to generate both human 
APP751 and APP695 cDNA, as all three isoforms shared similarity in most parts of the 
structure.
In order to generate human APP751 expression vector, a pair of primers was designed 
to delete the 0X2 domain. A pair of internal primers was designed to amplify outward 
from the deleted region of the APP770 sequence. The two DNA fragments of APP751 
were generated using TD-PCR and were then assembled using OE-PCR, before gel 
extraction and sequencing procedures. The complete sequence of APP751 was aligned 
against the reference human APP751 sequence obtained from EMBL online database. 
As it is shown in Figure 3.3.3, the complete sequence of APP751 was confirmed and it 
was ligated into empty plREShyg2 in order to generate the complete human APP751 
expression vector.
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Similarly to APP751 expression vector generation, a new pair of primers was designed 
due to the need to delete both the KPI and 0X2 domains to generate APP695. These 
primers were designed to amplify outward from the deletion region of APP770 
sequence following by TD-PCR and OE-PCR. The complete sequence of APP695 was 
aligned against a reference human APP695 sequence obtained from EMBL online 
database and it showed that both sequences had 100% positive match as shown in 
Figure 3.4.3 hence the fragment was ligated to empty plREShyg2 vector to generate 
human APP695 expression vector.
To summarise, at this stage, all three isoforms of APP were obtained as expression 
vectors and the first objective of this project was achieved.
Figure 3.7.1 The confirmation of APP 695, APP751 and APP770 cDNA visualised on 
1% agarose gel. Lanes 1 and 5, 1Kb DNA ladder. Lane2, human APP695 cDNA. Lane3, 
human APP751 cDNA and Lane4, human APP770 cDNA.
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The second objective of the project was to generate stably expressing CHO cells using 
in-house expression vectors containing three different human APP isoforms: APP695, 
APP751 and APP770.
In eukaryotes, the translation of mRNAs is initiated by the binding of the initiation 
complex to the 5'-untranslated region (5'-UTR) which contains an attached cap- 
methylated guanosine. Not only is the cap-methylated guanosine recognised by the 
ribosome translation initiation complex but also ensures the stability of mRNA (Richter 
and Sonenberg 2005). The initiation complex consists of a small ribosomal subunit 
and the initiator Met-tRNAi. Once the initiation complex binds to the cap, it initiates 
the reading at 5'-UTR to the first starting codon resulting in the complete assembly of 
ribosomal units and the nascent polypeptide synthesis initiation. This manner of 
translation is called cap-dependent (Mokrejs et al. 2006; Roux et al. 2007; Sachs 2000).
Some viruses do not contain the cap at the 5'-UTR and consequently have to employ 
the alternative strategy in protein synthesis initiation which is called cap-independent 
manner. These viruses contain a long and strongly conserved structure of 5'-UTR 
mediating the binding of initiation complex and the formation of the ribosome. This 5'- 
UTR region is called internal ribosome binding site (IRES) (Li and Wang 2012; Mokrejs 
et al. 2006). The expression of IRES elements varies in size and specificity. For 
examples, the internal ribosome entry site (IRES) obtained from encephalomyocarditis 
virus (EMCV) is the most active in the transiently transfected cell lines and less stable 
in the stably transfected cell (Pierandrei-Amaldi et al. 1999). The size o f EMCV IRES 
ranges from 500-588 (Mokrejs and Pospisek 2015).
The utilisation of IRES elements as IRES-dependent expression vector in bicistronic 
expression system has been repeatedly reported in the past few decades (Li and Wang 
2012). Bicistonic expression vectors allow the protein of interest and selection marker 
gene to express using a single transcription unit (Hennecke et al. 2001; Ho et al. 2013).
plREShyg2 used in this Chapter is a bicistronic expression vector and is composed of 
first cistron located after a promoter, intervening sequence (IVS), an 
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) elements and a 
second cistron which is the hygromycin resistance gene. The hygromycin resistance 
gene is used as a selectable marker in antibiotic selection of transfection (Shikama et
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al. 2010) and EMCV IRES is one of the commonly used IRES elements in constructing 
the bicistronic expression system (Hennecke et al. 2001). As a result of the IRES 
inclusion in the vector, the first cistron is translated in a cap-dependent manner while 
the second cistron is translated in cap-independent manner (Ho et al. 2013; Shikama et 
al. 2010). It was suggested that cap-dependent translation is partially influenced by the 
IRES elements and the first cistron dictates the strength of the second cistron 
translation. A different position in which the first and second cistron are assembled in 
the bicistronic expression vector can also affect the strength of translation (Hennecke 
et al. 2001). Besides the translation in cap-independent manner has lower efficiency in 
comparison to cap-dependent manner leading to the lower expression of the second 
cistron (Ho et al. 2013; Kozak 2005). In addition, the EMCV IRES is a non-coding RNA 
enabling cap-independent protein synthesis (Bochkov and Palmenberg 2006) and 
belongs to the type 2 family of the IRES (Lindeberg and Ebendal 1999). The type 2 IRES 
has been suggested to function more efficiently than type 1 and it has been shown to 
be more sensitive to changes of the sequences (Lindeberg and Ebendal 1999). 
Therefore the expression vectors plREShyg2 containing human APP751 and APP695, 
which were constructed from plREShyg2 containing human APP770, might be affected. 
Hence this may explain the failure to stably express APP751 and APP695 with 
plREShyg2.
It has been reported that the translational efficiency of IRES elements is not only 
controlled by several cellular factors but also depends on cell type and the composition 
of IRES binding factors within the cell (Hennecke et al. 2001). For example, the proteins 
synthesised from reticulocyte ribosome tend to come from the translation initiation of 
IRES or the second cistron rather than first cistron (Bochkov and Palmenberg 2006). It 
has been shown that there are other parameters related to the construct of the vector 
which greatly influence the translation efficiency of IRES elements. This implies that 
the protein expression from the bicistronic expression vector is not stable and cannot 
be predicted (Hennecke et al. 2001). The provided expression vector plREShyg2 
containing human APP770 was originally stably transfected to HEK293 cells (Belyaev et 
al. 2010). However, when both provided (APP770) and in-house constructed (APP751 
and APP695) expression vectors were used to establish the clonal stably transfected 
CHO cells, it has shown to be more problematic and only transiently transfected CHO
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cells were achieved using APP751 and APP695. The expression of APP770 in CHO cells 
was possible however difficult as was shown in the first and the second sets of 
selected clones. There was only one out of four APP770 clones in the first set of 
selected clones which secreted APP770 and there were only two out of another four 
APP770 clones which secreted APP770 in the second set of selected clones.
Although the bicistronic expression systems have become an important tool in 
biotechnology, it does not mean the application of IRES elements is always a success 
(Kozak 2005). Although there is a total decrease in the cellular protein synthesis, the 
high translational rate of the mRNA is maintained by the internal initiation facilitated 
by the IRES elements (Kozak 2005; Sachs 2000). The 6A at the bifurcation loop of 
plREShyg2 facilitates the strong expression of the second cistron and the translation of 
the second cistron locating after EMCV IRES was shown to be independent from the 
translation of the first cistron (Bochkov and Palmenberg 2006). This might explain the 
survival of the transfected CHO cells under the pressure of hygromycin B in the culture 
media w ithout secretion of APP located in the first cistron. Also, it was reported that 
plREShyg2 affected the stability of the mRNA obtained from the cistrons within the 
expression vector which led to the poor expression of the carried cistrons (Shikama et 
al. 2010).
Finally, several successful experiments using bicistronic expression system have been 
clearly noted whereas the failed applications of bicistronic expression system were 
usually not reported (Hennecke et al. 2001; Mokrejs and Pospisek 2015)., and as a 
consequence of the challenges associated with creating stably expressing CHO cells 
using the plREShyg2 vector, alternative approaches were explored.
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Chapter 4: Generation of CHO and 
HEK293 stably expressed APP695 
APP751 and APP770 (pcDNA3.1)
4.1 Expression of APP695, APP751 and APP770 in CHO cells using the 
pcDNA3.1 expression vector
It was demonstrated in Chapter 3 that among several transfected CHO clones which 
had been screened for APP secretion, there were only two successful clones from CHO 
cells transfected with APP770 which secreted APP. Also, many attempts were made to 
produce CHO clones which expressed APP695 and APP751 w ithout success. Therefore, 
expression vectors for APP695, APP751 and APP770 were custom synthesised by Life 
Technology in order to complete the second objective of this project: CHO cells stably 
expressing APP isoforms.
4.1.1 Introduction
The new APP695, APP751 and APP770 synthesised vectors were provided in pcDNA3.1 
(Figure 4.1.1). It is a general practice that an antibiotic kill curve is carried out when 
introducing the new expression vector, there is a change in antibiotic batches or when 
the expression vector is introduced to the new cell line. The pcDNA3.1 expression 
vector contains neomycin resistance gene which is a different antibiotic resistance 
gene from the one carried on plREShyg2. Therefore it was necessary to carry out a new 
antibiotic kill curve with G418, which neomycin resistance gene protects against.
The antibiotic kill curve procedure is used to determine the optimal concentration of a 
selective antibiotic of choice in a particular cell line. The optimal concentration of a 
selective antibiotic is just enough to kill the host cells over 4-7 days period and it is 
used in transfected colony selection post transfection. The general idea of antibiotic 
selection is that the host cells taking up the expression vector benefit from an 
antibiotic resistance gene during expression of the vector by the host cells which are 
able to survive in the presence of an antibiotic.
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4.1.2 Geneticin kill curve for CHO
The synthesized expression vector containing APP695, APP751 and APP770 cDNA were 
obtained from Life Technologies, UK. Each APP isoform was cloned into the chosen 
vector; pcDNA 3.1. The pcDNA 3.1 contains two antibiotic resistance genes, it has 
neomycin gene as shown in Figure 4.1.1 which encodes aminoglycoside 3' 
phosphotransferase (APH). APH is able to deactivate neomycin, kanamycin and 
geneticin. However, neomycin and kanamycin are normally used in prokaryotic 
selection while geneticin is used in eukaryotic selection. The geneticin which is often 
referred to as G418 was used as a selectable marker in mammalian cell culture due to 
its specificity to mammalian ribosomes. G418 is classified as an aminoglycoside 
antibiotic and is produced by Micromonospora rhodorongea. The well-understood 
mechanism of action of G418 is inhibition of protein synthesis through inhibition of 
peptide elongation (Eustice and Wilhelm 1984).
Methods in brief
The recommended concentration of G418 in CHO cell culture selection is 200-400 
pg/ml (Section 2.13). The kill curve experiment was carried out in a 6-well plate over 7- 
days period. Cells were allowed to adhere for at least six hours before the addition of 
various concentrations of G418.
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Figure 4.1.1 The vector map of pcDNA3.1 with restriction sites. The pcDNA3.1 is 5.4 
kb vector which contains two antibiotic resistance genes; ampicillin and neomycin. 
Ampicillin is used as a selectable marker in transformation whereas geneticin is used in 
transfection.
Results
Cells grew but with an inverse relationship between cell growth and concentration of 
antibiotic: the growth rate decreased as G418 concentration increased. At high 
concentrations of G418, 400 and 500 pg/ml, cells were all dead on the second day 
after adding antibiotic. As shown in Figure 4.1.2 (a) on day 4, at 100 pg/ml of G418, 
cells appeared healthy but did not grow as fast as cells in the controlled well which 
contained 0 pg/ml of additional G418. Also, at 200 pg/ml of G418 a few cells began to 
die whereas there were great numbers of dead cells appeared at 300 pg/ml of G418. 
Furthermore, on day 7 at 100 pg/ml, cells became almost 100% confluence while a 
significant numbers of dead cells appeared at 200 pg/ml and cells were all dead at 300 
pg/ml, as shown in Figure 4.1.2 (b). As a result of this experiment, the optimal 
concentration determined from the geneticin kill curve experiment was 200 pg/ml and 
this concentration was used during the limited dilution cloning procedure. Also, in 
order to retain the expression vector within CHO cells, the presence of G418 in culture 
medium was required however the concentration of G418 was reduced to 100 pg/ml.
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Figure 4.1.2 CHO cells viability during geneticin kill curve. CHO cells were plated at 
2.5 x 105 cells/well in 6-well plates and allowed to adhere overnight before adding 
geneticin at various concentrations, (a) Day 4 of geneticin kill curve experiment. At 100 
and 200 pg/ml, cells were growing but quite slowly, in comparison to control (0 pg/ml) 
whereas cells started to die (detach from culture plate) at 300pg/ml. (b) Day 7 of 
geneticin kill curve experiment. At 100 pg/ml, cells became 80% confluence while at 
200pg/ml showed significant numbers of dead cell and at 300 pg/ml all cells were 
dead. It appeared that the optimal concentration of geneticin for CHO cell culture 
selection was 200 pg/ml. (magnification 200x)
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4.1.3 Generation of CHO cells stably expressing APP695 and APP751 using 
pcDNA 3.1 expression vector
Methods in brief
CHO cells were plated at 4 x 104 cells per well of a 24-well plate and cells were allowed 
to adhere overnight or allowed to grow up to 80% confluence before beginning 
transfection. Transfection was carried out according to the procedure described in 
Section 2.14. After transfection, cells were then separated in order to obtain colonies 
which originated from single cells by limited dilution cloning procedure described in 
Section 2.15. During limited dilution cloning, cells were incubated as well as being 
selected in selective culture medium which contained 200 pg/ml of G418. Later, the 
selected 10 wells of a 96-well plate were chosen from the second limited dilution 
cloning, trypsinised and transferred to a 12 well-plate and a 6-well plate, respectively. 
In the 12 well-plate, cells were allowed to grow until at least 50% confluence before 
transferring to a 6-well plate and then cells were allowed to grown up until 80% 
confluence in 2 ml selective culture medium containing 100 pg/ml G418 in 6-well plate 
before medium was collected and processed for APP secretion analysis.
In order to analyse the level of APP secretion, selective culture medium was collected 
from the 6-well plate and prepared by immunoprecipitation, reduction and alkylation 
of disulphide bonds (Sections 2.16 and 2.17, respectively) before separation on 6% 
SDS-PAGE gel following by protein transfer and immunoblotting (Sections 2.18 and 
2.19, respectively). Four primary antibodies were used during immunoblotting: DE2, 
993, 23/2 and 1151. Each primary antibody binds to a different epitope on the APP 
sequence: DE2 binds to A(3 domain present in all three isoforms, 993 binds to KPI 
domain existing on APP751 and APP770, 23/2 binds to OX2 domain which is only exists 
on APP770 and 1151 binds to the N-terminal of all three APP isoforms. The SDS-PAGE 
gels were produced in a set of four identical gels per a set of samples, and all four gels 
were run at the same time. Also the protein transfer and immunoblotting procedure of 
four gels were carried out alongside each other.
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4.1.3.1 APP695 secretion
Figure 4.1.3, all ten selected clones showed results with all four primary antibodies as 
expected. The serum free medium and selective culture medium from CHO770H4 were 
used as negative and positive controls, respectively. In comparison to both controls, 
CHO overexpressed APP695 clones showed a strong band of protein recognised by DE2 
and 1151 primary antibodies and the molecular weight of the protein band was 
approximately 115 kDa, which is expected molecular weight of APP695. None of the 
clones produced any band recognised 23/2 antibody. Also, there were only faint bands 
of protein appeared at approximately 120 kDa in size against 993 antibody.
4.1.3.2 APP751 secretion
Similarly to Figure 4.1.3, the result of selective culture medium from CHO 
overexpressed APP751 clones are shown in Figure 4.1.4 with serum free medium and 
selective culture medium from CH0770H4 were used as controls. All ten clones of CHO 
overexpressed APP751 produced a strong protein band recognised by the DE2, 1151 
and 993 antibodies and the molecular weight of the protein band was approximately 
118 kDa which is expected molecular weight of APP751. None of the clones produced a 
protein band recognised by the 23/2 antibody.
4.1.3.3 APP770 secretion
The result of selective culture medium from CHO overexpressed APP770 clones are 
shown in Figure 4.1.4 with serum free medium and selective culture medium from 
CHO770H4 were used as controls. All ten clones produced a protein band 
approximately 120 kDa in size recognised by all four antibodies.
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Figure 4.1.3 Protein expression analysis of secreted APP by APP695 pcDNA3.1 
transfected CHO cells in the culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before protein transfer. Lane 1, 
serum free medium (negative control). Lane 2, CHO770H4 clone (positive control) from 
APP770 plREShyg2 expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clone 1 to 
10 of APP695 pcDNA3.1 transfected CHO. Primary antibodies: (a) DE2, (b) 1151, (c) 993 
and (d) 23/2. All ten selected clones produced protein band recognised by DE2 and 
1151 antibodies located just below 116 kDa which correlated to the molecular weight 
of APP695; 115 kDa.
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Figure 4.1.4 Protein expression analysis of secreted APP by APP751 pcDNA3.1 
transfected CHO cells in the culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before protein transfer. Lane 1, 
serum free medium (negative control). Lane 2, CHO770H4 clone (positive control) from 
APP770 plREShyg2 expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clones 1 
to 10 of APP751 pcDNA3.1 transfected CHO. Primary antibodies: (a) DE2, (b) 1151, (c) 
993 and (d) 23/2. All ten selected clones produced a protein band recognised by DE2, 
1151 and 993 antibodies and approximately 118 kDa in size which correlated to the 
molecular weight of APP751.
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Figure 4.1.5 Protein expression analysis of secreted APP by APP770 pcDNA3.1 
transfected CHO cells in the culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before protein transfer. Lane 1, 
serum free medium (negative control). Lane 2, CHO770H4 clone (positive control) from 
APP770 plREShyg2 expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clones 1 
to 10 of APP770 pcDNA3.1 transfected CHO. Primary antibodies: (a) DE2, (b) 1151, (c) 
993 and (d) 23/2. All ten selected clones produced protein band recognised by all four 
antibodies and approximately 120 kDa in size which correlated to the molecular weight 
of APP770.
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4.2 Expression of APP695, APP751 and APP770 by HEK293 cells using 
pcDNA3.1 expression vector
It was demonstrated earlier in this Chapter that CHO cells stably expressing three APP 
isoforms could be generated using the pcDNA3.1 synthesised expression vector 
containing APP695, APP751 and APP770 cDNA. However, in order to closely reflect the 
situation of Alzheimer's disease, the Human Embryonic Kidney 293 cell line (referred to 
as HEK293) was selected as a host cell to stably express all three isoforms of APP. 
Hence the third objective of this project was to stably express APP695, APP751 and 
APP770 in HEK293 cells.
4.2.1 Introduction
In 1977, a group of scientists; Graham, Smiley, Russell and Nairn carried out a 
transformation of human embryonic kidney cells by exposure to human adenovirus, 
which later produced HEK cells and became HEK 293 that are commonly used as a tool 
in protein expression systems (Graham et al. 1977). There are several reasons 
suggesting that HEK293 is an ideal candidate as a host cell for studies of APP 
expression and processing that are related to Alzheimer's disease;
•  HEK293 cells allow expression vectors containing the CMV promoter to control 
protein synthesis and allow genes of interest in expression vectors to integrate 
into the HEK genome.
• HEK293 cells express several signalling pathways which are similar to neurons.
• HEK293 is a common and useful tool in reproduction various kind of neuronal 
protein due to its simple structure; both physically and biochemically.
• HEK293, similar to neurons, expresses four neurofilament subunits.
• Specific neuronal mRNAs can be found in HEK293.
Furthermore, HEK293 cells have a higher protein synthesis rate in comparison to  CHO 
cells. For example, HEK293 cells are able to produce 10 mg of protein in few weeks 
while CHO cells take months (Thomas and Smart 2005).
It is an important prerequisite to determine the optimal concentration o f selective 
antibiotic by determining kill curves (Section 2.13) to be used in transfection. The
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optimal concentration of selective antibiotic obtained from the antibiotic kill curve 
procedure should be just enough to kill non-transfected host cells over a period of 4-7 
days. This optimal concentration which is later used in the limited dilution cloning to 
select the host cells which have been transfected and kill the non-transfected host 
cells. The use o f antibiotic in colony selection permits the host cells that take up the 
expression vector to benefit from an antibiotic resistance gene encoded by the vector 
hence the host cells are able to survive. The pcDNA3.1 expression vector contains 
neomycin resistance gene for mammalian cell culture selection, thus providing 
resistance to geniticin (G418).
4.2.2 Geneticin kill curve for HEK293
The expression vectors containing APP695, APP751 and APP770 cDNA were obtained 
from Life Technologies, UK. Each APP isoform was cloned into vector pcDNA 3.1. The 
pcDNA 3.1 contains two antibiotic resistance genes; ampicillin and neomycin shown in 
Figure 4.1.1.
Since neomycin is not toxic to mammalian cells, geneticin (G418) was used as a 
selectable marker in mammalian cell culture due to its specificity for the mammalian 
ribosome. G418 is classified as an aminoglycoside antibiotic and is produced by 
Micromonospora rhodorangea. G418 kills mammalian cells through the inhibition of 
protein synthesis by restricting peptide elongation (Eustice and Wilhelm 1984).
Methods in brief
The recommended concentration range of G418 in HEK293 cell culture selection is 
400-1000 pg/ml (Section 2.13). The chosen concentrations were 0, 200, 400, 600, 800 
and 1000 pg/ml, where 0 pg/ml were used as a controlled concentration. The kill curve 
experiment was carried out in 6-well plates over a 7-day period. The HEK293 cells were 
allowed to adhere for at least six hours before the addition of various concentrations 
of G418.
Results
Cells grew normally with an inverse trend between cell growth and concentration of 
antibiotic. At concentrations of G418 above 600 pg/ml cells were all dead by the
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second day after adding antibiotic. As shown in Figure 4.2.1 (a) on day 4, at 200 pg/ml 
of G418, cells appeared healthy but did not grow as fast as cells in the control well 
which contained no G418. Also, at 400 pg/ml of G418 few cells began to die whereas 
there were great numbers of dead cells at 600 pg/ml of G418. Furthermore, on day 7 
at 200 pg/ml, cells became 80% confluence while there were significant numbers of 
dead cells at 400 pg/ml and cells were all dead at 600 pg/ml, as shown in Figure 4.2.1 
(b). Therefore, the optimal concentration determined from G418 kill curve experiment 
was 400 pg/ml and this concentration was used during limited the dilution cloning 
procedure. Also, in order to retain expression vector within HEK293 cells, the presence 
of G418 in culture medium was required but was reduced to 200 pg/ml.
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Figure 4.2.1 HEK293 cells viability during geneticin kill curve. HEK293 cells were 
plated at 2.5 x 105 cells/well in 6-well plates and allowed to adhere over night before 
adding geneticin at various concentrations, (a) Day 4 of geneticin kill curve 
experiment. At 200 and 400 pg/ml, cells were growing but quite slowly, in comparison 
to control whereas cells started to die (detach from culture plate) at 600 pg/ml. (b) 
Day 7 of geneticin kill curve experiment. At 200 pg/ml, cells became 80% confluence 
while at 400 pg/ml showed significant numbers of dead and at 600 pg/ml all cells were 
dead. It appeared that the optimal concentration of geneticin for HEK293 cell culture 
selection was 400 pg/ml. (magnification 200x)
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4.2.3 Generation of HEK293 stably expressed APP695, APP751 and APP770 
using pcDNA3.1 expression vector
Methods in brief
HEK293 cells were plated at 1.25 x 105 cells per well of a 24-well plate and cells were 
allowed to adhere overnight or allowed to grow up to 80% confluence before 
beginning transfection. Transfection was carried out according to the procedure 
described in Section 2.14. After transfection, cells were then separated in order to 
obtain colonies which originated from single cells by limited dilution cloning procedure 
described in Section 2.15. During limited dilution cloning, cells were incubated as well 
as being selected in selective culture medium which contained 400 pg/ml of G418. 
Later, the selected 10 wells of a 96-well plate were chosen from the second limited 
dilution cloning, trypsinised and transferred to a 12 well-plate and a 6-well plate, 
respectively. In the 12 well-plate, cells were allowed to grow until at least 50% 
confluence before transferring to a 6-well plate and then cells were allowed to  grown 
up until 80% confluence in 2 ml selective culture medium containing 200 pg/ml G418 
in 6-well plate before medium was collected and processed for APP secretion analysis.
In order to analyse the level of APP secretion, selective culture medium was collected 
from the 6-well plate and prepared by immunoprecipitation, reduction and alkylation 
of disulphide bonds (Sections 2.16 and 2.17, respectively) before separation on 6% 
SDS-PAGE gel following by protein transfer and immunoblotting (Sections 2.18 and 
2.19, respectively). Four primary antibodies were used during immunoblotting: DE2, 
993, 23/2 and 1151. Each primary antibody binds to a different epitope on the APP 
sequence: DE2 binds to A(3 domain present in all three isoforms, 993 binds to KPI 
domain existing on APP751 and APP770, 23/2 binds to OX2 domain which is only exists 
on APP770 and 1151 binds to the N-terminal of all three APP isoforms. The SDS-PAGE 
gels were produced in a set of four identical gels per a set of samples, and all four gels 
were run at the same time. Also the protein transfer and immunoblotting procedure of 
four gels were carried out alongside each other.
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4.2.3.1 APP695 secre tion
The first set of protein expression results is shown in Figure 4.2.2. Selective culture 
medium from CH0770H4 was used as the positive control and serum free culture 
medium were used as negative controls on each immunoblot. All ten clones of APP695 
produced strong bands of protein recognised by DE2 and 1151 antibodies and the 
molecular weight of protein band was approximately 115 kDa which is expected 
molecular weight of APP695. None of the clones produced any protein band 
recognised by 23/2 antibody. Also, only faint protein band recognised by 993 antibody 
being 120 kDa in size.
4.2.3.2 APP751 secretion
The second set of protein expression results is shown in Figure 4.2.3, similar to Figure 
4.2.2. Selective culture medium of CHO770H4 was used as the positive control and 
serum free culture medium was used as negative controls on each immunoblot. All 
ten clones of APP751 produced strong bands of protein recognised by DE2, 1151 and 
993 antibodies and the molecular weight of the protein band was approximately 118 
kDa which is expected molecular weight of APP751. In addition, none of the ten 
selective clones produced any bands recognised by 23/2 primary antibody.
4.2.3.3 APP770 secretion
Figure 4.2.4 showed the final set of protein expression results obtaining from selected 
clones of HEK293 transfected APP770. The selective culture medium from CH0770H4 
and serum free medium was used as positive and negative controls, respectively. All 
clones showed appropriate protein band recognised by all four primary antibodies and 
the protein bands was approximately 120 kDa in size which is expected molecular 
weight of APP770.
4.2.3.4 HEK293 stably expressing APPs selection
The results in Figures 4.2.2 to Figures 4.2.4 showed that each selected clone obtained 
from each transfection of the different isoforms of APP secreting different amounts of 
APP in the culture medium. Therefore it was crucial to  select a clone from HEK293 
transfected with each isoform of APP, which produced the similar amount of APP
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before proceeding with further experiments in order to reduce variable results 
attributable to varying levels of expression.
After several attempts a set of clones consisting of three isoforms of APP, which 
secrete comparable amounts of APP into culture medium, was established. Figure 
4.2.5, each immunoblot consisted of complete medium which was used as the 
negative control, collected culture medium from clone number 5 of HEK293 
overexpressing APP695 (HEK695.C5), collected culture medium from clone number 1 
of HEK293 overexpressing APP751 (HEK751.C1) and collected culture medium from 
clone number 6 of HEK293 overexpressing APP770 (HEK770.C6). All three samples and 
a negative control produce an appropriate positive result against all four primary 
antibodies used during the immunoblotting procedure.
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Figure 4.2.2 Protein expression analysis of secreted APP by APP695 pcDNA3.1 
transfected HEK293 cells in culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before the protein transfer 
procedure. From left to right of each membrane: Lane 1, serum free medium (negative 
control). Lane 2, CHO770H4 clone (positive control) from APP770 plREShyg2 
expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clones 1 to 10 of APP695 
pcDNA3.1 transfected HEK293. Primary antibodies: (a) DE2, (b) 1151, (c) 993 and (d) 
23/2. All ten selected clones produced a protein band recognised by DE2 and 1151 
antibodies located just below 116 kDa which correlated to the molecular weight of 
APP695.
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Figure 4.2.3 Protein expression analysis of secreted APP by APP751 pcDNA3.1 
transfected HEK293 cells in culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before the protein transfer 
procedure. From left to right of each membrane: Lane 1, serum free medium (negative 
control). Lane 2, CH0770H4 clone (positive control) from APP770 plREShyg2 
expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clones 1 to 10 of APP751 
pcDNA3.1 transfected HEK293. Primary antibodies: (a) DE2, (b) 1151, (c) 993 and (d) 
23/2. All ten selected clones produced a protein band recognised by DE2, 1151 and 
993 antibodies and approximately 118 kDa in size which correlated to the molecular 
weight of APP751.
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Figure 4.2.4 Protein expression analysis of secreted APP by APP770 pcDNA3.1 
transfected HEK293 cells in culture medium with four primary antibodies; DE2,1151, 
993 and 23/2. Samples were run on 6% SDS-PAGE gel before protein transferred 
procedure. From left to right of each membrane: Lane 1, serum free medium (negative 
control). Lane 2, CHO770H4 clone (positive control) from APP770 plREShyg2 
expression vector. Lanes 3 and 14, SDS7B2. Lanes 4 to 13, clones 1 to 10 of APP770 
pcDNA3.1 transfected HEK293. Primary antibodies: (a) DE2, (b) 1151, (c) 993 and (d) 
23/2. All ten selected clones produced a protein band recognised by all four antibodies 
and approximately 120 kDa in size which correlated to the molecular weight of 
APP770.
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Figure 4.2.5 Protein analysis of secreted APP by HEK293 transfected pcDNA3.1 
expression vector containing APP695, APP751 and APP770 cDNA, in selective culture 
medium over a 24-hour period with four primary antibodies; DE2, 1151, 993 and 
23/2. After culture medium was prepared by immunoprecipitation, reduction and 
alkylation of disulphide bonds, samples were run on 6% SDS-PAGE gel before protein 
transfer and immunoblotting procedure. Primary antibodies: (a) DE2, (b) 1151, (c) 993 
and (d) 23/2. As all three isoforms of APP produced by each clone are slightly different 
in molecular weight, each isoform produce the protein band at slightly different 
position. It was expected that APP695 was recognized by 1151 and DE2 primary 
antibodies and the protein band was just below 116 kDa: 115 kDa, APP751 was 
recognized by 1151, 993 and DE2 primary antibodies and the protein band was just 
above 116 kDa: 118 kDa, and APP770 was recognized by all four primary antibodies 
and the protein band was clearly above 116 kDa: 120 kDa.
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4.3 Discussion
After many attempts of trying to  establish CHO stably expressed APP695 and APP751 
using an in-house constructed expression vector (plREShyg2 expressing human APP695 
and APP751), no success was achieved. The new synthetic expression vector; 
pcDNA3.1 expressing three isoforms of APP were obtained. Instead of a hygromycin B 
resistance gene, pcDNA3.1 contains a neomycin resistance gene which was used as a 
selectable marker in mammalian cell culture selection. The optimal concentration of 
G418 to be used in limited dilution cloning was 200 pg/ml and the concentration of 
G418 was reduced to 100 pg/ml to maintain the expression vector within the CHO 
cells. The DE2, 1151, 993 and 23/2 antibodies were used in immunoblotting because 
each antibody recognises a different epitope on APP. The DE2 and 1151 antibodies 
recognise Ap domain and the N-terminal of all three isoforms of APP, respectively. The 
993 antibody recognises the KPI domain on APP751 and APP770 whereas the 23/2 
antibody recognises the 0X2 domain on APP770. Also, 1151 and 23/2 antibodies do 
not recognise bovine APP which was present in the culture medium.
The ten selected clones from each isoform of APP produced the expected result 
towards the four primary antibodies.
Clones 1 to 10 of CH0695 produced a protein band which was approximately 115 kDa 
in size and recognised by DE2 and 1151 antibodies which corresponded to the 
molecular weight of human APP695. Also, the protein band of APP which was 
approximately 120 kDa in size also appeared on the membrane incubated in 993 
antibody due to the existence of bovine APP in the medium and no protein band 
appeared on the membranes incubated in 23/2 antibody. Moreover, these results 
were supported by the fact that APP695 does not contain additional domains: either 
the KPI or the OX2 domain therefore the 115 kDa protein band was expected to only 
appear recognised by DE2 and 1151 antibodies.
The APP751 contain an additional domain; the KPI domain and the molecular weight of 
human APP751 is approximately 118 kDa. Clones 1 to 10 of CH0751 produced a 
protein band which was approximately 118 kDa in size and recognised by DE2, 1151 
and 993 antibodies while there was no protein band recognised by 23/3 antibody.
These results corresponded with APP751 composition and molecular weight.
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Clones 1-10 of CH0770 produced a 120 kDa protein band recognised by all antibodies 
because the estimated molecular weight of APP770 is 120 kDa and APP770 contains 
two additional domains: the KPI and the 0X2 domains hence the protein bands were 
recognised by all four primary antibodies.
Once the CHO clones stably expressing all three isoforms of APP were established, it 
was crucial to determine the shortest period of time that APP was secreted into 
culture medium and could be detected by immunoblotting (data not show). There 
were four selected time points in which selective culture medium was collected: at 0, 
24, 48 and 72 hours and samples were stored at -20 °C until the culture medium was 
collected at the final time point. Then all collected culture medium was processed at 
the same time by immunoprecipitation and reduction and alkylation of disulphide 
bonds before separation on SDS-PAGE and immunoblotting. The secreted APP can be 
detected as early as 24 hours after cells were plated out. The level of secreted APP in 
culture medium increased according to the proliferation time. In other words, the 
longer the cells were allowed to proliferate the more APP they secreted into culture 
medium.
In order to closely reflect the situation of Alzheimer's disease, HEK293 cells were 
selected as a host cell to stably express all three isoforms of APP. Therefore the third 
objective of this project was to establish HEK293 cells stably express APP695, APP751 
and APP770 in HEK293. The optimal concentration of G418 to  be used in limited 
dilution cloning was 400 pg/ml and the concentration of G418 was reduced to  200 
pg/ml to maintain the expression vector within the HEK293 cells.
Clones 1 to 10 of HEK695 produced a protein band which were approximately 115 kDa 
in size recognised by DE2 and 1151 antibodies which correlated to the molecular 
weight of human APP695. Also, the protein band of APP which was approximately 120 
kDa in size also appeared on the membrane incubated in 993 antibody due to the 
existence of bovine APP and no protein band appeared on the membrane incubated 
against 23/2 antibody. Moreover, these results were supported by the fact that 
APP695 does not contain additional domains: either the KPI or the OX2 domain 
therefore the 115 kDa protein band was expected to be recognised by DE2 and 1151 
antibodies.
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Clones 1 to 10 of HEK751 produced a protein band which were approximately 118 kDa 
in size and recognised by DE2, 1151 and 993 antibodies while there was no protein 
band recognised by 23/3 antibody. These results corresponded with APP751 
composition and molecular weight that the APP751 contain an additional domain; the 
KPI domain and the molecular weight of human APP751 is approximately 118 kDa.
Clones 1 to 10 of HEK293 transfected with APP770, as expected, each clone produced 
the 120 kDa protein band recognised by all four antibodies because the estimate 
molecular weight of APP770 is 120 kDa and APP770 contains two additional domains: 
the KPI and the 0X2 domains.
Having established a number of clones of HEK293 transfected with each isoform of 
APP, each clone appeared to produce different amounts of APP into culture medium 
(Figures 4.2.2 to 4.2.4).
As one clone of each isoform of APP was to be used as a cellular model in further 
experiments, it was necessary to select the clone from each isoform of APP which 
secreted relatively similar amounts of APP into culture medium as a way to standardise 
APP secretion. A set of clones which produced similar amounts of APP into culture 
medium was found; clone number 5 of HEK293 overexpressing APP695 (HEK695.C5), 
clone number 1 of HEK293 overexpressing APP751 (HEK751.C1) and clone number 6 of 
HEK293 overexpressing APP770 (HEK770.C6). The samples were prepared from 
selective culture medium containing 200 pg/ml of G418 from these clones were 
resolved on gels following by immunoblotting procedure using all four primary 
antibodies as shown in Figure 4.2.5. As expected, HEK695.C5 produced a protein band 
at approximately 115 kDa and was recognised by DE2 and 1151 antibodies because 
APP695 does not contain either the KPI or the OX2 additional domains. HEK751.C1 
produced a protein band at approximately 118 kDa and was recognised by DE2, 1151 
and 993 antibodies because APP751 contains a KPI additional domain and finally 
HEK770.C6 produce a protein band at approximately 120 kDa which was recognised by 
all four antibodies as APP770 contains both the KPI and the OX2 domains. Also, it 
appeared that all clones showed anticipated responses against all primary antibodies 
as well as producing similar amounts of APP.
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To conclude, the work in this Chapter showed that it was possible to stably express the 
three isoforms of APP in HEK293 cells and also to select clones of HEK293 
overexpressing each isoform of APP which secreted the comparable amounts of APP 
into the culture medium. These clones could now be used as a cellular model of APP 
for further experiments to investigate factors that modulate APP cleavage and 
secretion.
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Chapter 5: Effects of foetal bovine 
serum on HEK293 cells transfected 
with APP isoforms
5.1 Introduction
As described in Chapter 4, not only were HEK293 cells stably expressing APP695, 
APP751 and APP770 established but also an individual clone that expressed each 
isoform of APP at comparable levels were selected; HEK695.C5, HEK751.C1 and 
HEK770.C6. These clones could now be used as cellular models in an investigation on 
the effects of foetal calf serum (FCS) in culture medium on APP production which was 
the fourth objective of this project.
Foetal bovine serum (FBS) is typically derived from foetal calf blood which is harvested 
under aseptic conditions to minimize the possibility of contamination. The harvested 
blood is later centrifuged to separate blood cells (both red and white), platelets and 
coagulating factors from serum which generally contains basic essential nutrients 
required for cell metabolism, proliferation and growth; e.g. hormones and growth 
factors. FBS is a common supplement in cell culture procedures. The FBS plays four 
principal roles in cell culture medium; (1) provides hormonal factors which induce cell 
growth, proliferation and differentiation, (2) supplies culture medium with transporter 
proteins such as transferrin for transporting iron or lipoprotein for transporting lipid, 
(3) facilitates cell adherence by providing extracellular matrix molecules and (4) helps 
maintain pH of the culture medium by buffering and neutralising toxic substances both 
directly and indirectly. Nevertheless, the presence of FBS in culture medium also has 
disadvantages including; (1) may contain hidden substances or growth inhibitors as it is 
poorly defined material, (2) compositions are inconsistent due to batch-to-batch 
variation, (3) could be a source of endotoxins and microbial organisms and therefore it 
increases the risk of infection. Also, the presence of FBS might interfere w ith the 
experimental results; especially with protein purification or isolation studies (Brunner 
et al. 2010; Gstraunthaler 2003).
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Serum deprivation and serum restriction are two of several terms used to describe cell 
culture procedures involving an alteration in the concentration of FBS. For example, 
culturing cells in serum-free or reduced serum culture medium and culturing cells in 
basal medium without bovine serum albumin. To date, there have been numbers of 
researchers who used FBS concentration alteration as a tool in their studies including 
protein degradation studies (Epstein, Elias-Bishko and Flershko 1975), cellular stress 
response studies (Levin et al. 2010), apoptosis studies (Terra et al. 2011) and imitation 
of pathological condition. For example, the clinical model of the pathological 
conditions of myocardial infarction and stroke were imitated by low glucose 
concentration together with FBS restricted condition and hypoxia (Flamabe, Fujita and 
Ueda 2005; Yu et al. 2008). As components in FBS have not been completely identified, 
the removal of FBS from culture medium also removes the unknown residues which 
might cause unknown interferences in the experiment. It was strongly supported by an 
experiment on skeletal muscle cells where the molecular mechanism of action of 
insulin was demolished by the presence of FBS in culture medium whereas in the 
absence of FBS, skeletal muscle cells seemed to have normal responses to insulin 
(Ching et al. 2010). Furthermore, restriction of FBS in culture medium can also cause 
the reduction in basal activity which makes cells enter quiescent G0/G i phase. As a 
result, the population of proliferating cells are more homogenous and this aspect is 
commonly used in cell cycle or circadian rhythm research (Pirkmajer and Chibalin 
2011). Serum deprivation is also commonly used as an apoptotic trigger in 
neurodegenerative diseases studies as it allows the researchers to study the 
morphology of the cells under stress or in malnutritious conditions as well as study 
newly discovered anti-apoptotic agents (Fiorelli, Kirouac and Padmanabhan 2013; Xie 
eta l. 2013).
Although, the alteration of FBS concentrations in culture medium has been a 
commonly performed procedure, various experimental designs have been adopted. 
Therefore it was necessary to determine the effect of FBS on APP production prior to 
further experimentation. The objectives of this investigation were; (1) to determine if 
the FBS affects the cell number, APP secretion and APP mRNA level at various 
concentrations, and (2) to determine if the FBS affects each isoform of APP differently 
at various concentrations. In addition, the investigation of the effects of FBS in culture
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medium on APP was carried out in three main parts; cell number, APP secretion into 
culture medium and APP mRNA level. Also, prior to the cell counting procedure, cells 
were observed for morphological changes due to the effect of FBS in culture medium.
5.2 Effects of FBS in cell culture medium on cell number
The first part of the investigation of the effects of FBS in culture medium on APP 
production was to examine the effect of FBS on cell number.
Methods in brief
In general, all three selected clones of HEK293 transfected APP isoforms and non­
transfected HEK293 were cultured and maintained according to the cell culture 
procedures in Section 2.11. The experiments were carried out in 6-well plates and 
performed independently in triplicate. Also, there were four chosen concentrations of 
FBS including control: 0%, 1%, 5% and 10%. Each well contained the same original 
number of live cells: 5 x 105 cells in 2 ml of appropriate medium. Cells were allowed to 
settle and adhere for at least 6 hours before culture medium was discarded and fresh 
medium which contained various concentrations of FBS was added. Twenty-four hours 
after cells were grown in an incubator at 37°C and 5% CO2 in 2 ml o f medium 
containing different amount of FBS, cells were photographed using XLI cap program 
and culture medium was collected for APP secretion analysis followed by cell counting 
and cell pellet harvesting.
The cell counting procedure was carried out three times per concentration of FBS for 
each transfected HEK293 clone and non-transfected HEK293. Briefly, 10 pi of cell 
suspension and 10 pi of 0.4 % Trypan blue were combined thoroughly before pipetting 
10 pi of the mixture into Countess® Cell Counting Chamber Slides and counting by 
using the Countess® Automated Cell Counter. Each reading obtained from the cell 
counting machine measured total cell number, live cell number, dead cell number per 
ml of cell suspension and percentage of cell viability.
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Results
The cell count data are shown in Figure 5.2.1 as mean ± SEM. The two-way ANOVA 
with 95% confidence interval was coupled with Bonferroni's multiple comparisons test 
to evaluate any possible effects of the FBS concentration on cell number. These data 
were analysed based on the two independent factors; (1) the concentration of the FBS 
in culture medium and (2) the differences in the isoform of APP. The data regarding 
the effect of FBS concentrations in culture medium on cell number are shown in Figure
5.2.1 (a) and the effect of isoforms of APP on cell number are shown in Figure 5.2.1 (b). 
Moreover, the statistical analysis revealed that the different concentration of FBS and 
the isoforms of APP had significant effects on cell number (p=0.0347 and p=0.0237). 
However, both independent factors did not have significant statistical interaction on 
cell number (p>0.05) therefore the data gained from the different concentrations of 
FBS and the different isoforms of APP were interpreted separately.
Firstly, the cell count data was analysed using the same cell type cultured in complete 
medium (containing 10% FBS) as a control, as shown in Figure 5.2.1 (a). It was shown 
that the differences in the concentration of FCS did not have a significant effect on the 
cell number of each transfected clone. However, the non-transfected HEK293 which 
was cultured in culture medium containing 0% FBS showed significant reduction of cell 
numbers in comparison to the control (p<0.05).
When using non-transfected HEK293 cells cultured in culture medium containing 0%, 
1%, 5% and 10% of FBS as controls, as shown in Figure 5.2.1 (b), It was shown that only 
the HEK751.C1, which was cultured in culture medium containing 1% FCS, showed a 
significant reduction of cell number in comparison to the control (p<0.05).
Each cell type in each culture medium containing varying amounts of FBS was 
photographed after the 24-hour period ended. The photographs of the cells are shown 
in Figures 5.2.2 to 5.2.5.
Figure 5.2.2 shows the photographs of non-transfected HEK293 cells which were 
cultured in culture medium containing various concentration of FBS. It can be seen 
that the cells started to form clumps more clearly as the concentration o f FBS in 
culture medium reduced. The cells which were cultured in culture medium containing
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0% FBS clearly formed clumps linking to each other and tended to have minimal 
attachment to the bottom of the well.
Figure 5.2.3 shows the photographs of FIEK695.C5 which was cultured in culture 
medium containing various concentrations of FBS. Similarly to non-transfected HEK293 
cells, the cells started to form clusters of cells as the concentration of FBS in culture 
medium reduced. As the cells appeared to grow more slowly in the culture medium 
containing lesser amount of FBS therefore clusters of cells were clearly visible.
Figure 5.2.4 shows the photographs of HEK751.C1 which was cultured in culture 
medium containing various amounts of FBS. The cells appeared to grow normally in 
culture medium containing 1% and 5% FBS while cells grew significantly slower in 
culture medium containing 0% FBS when comparing to culture medium containing 10% 
FBS (control). Also, clusters of cells started to appear in culture medium contain FBS 
lesser than 5%. In the 0% FBS containing medium, cells appeared thinner and 
elongated as well as forming networks between clumps.
Figure 5.2.5 shows the photographs of FIEK770.C6 which was cultured in culture 
medium containing various amounts of FBS. The cells appeared to grow slowly where 
there was an alteration in concentration of FBS in culture medium; for example in 
culture medium containing 0%, 1% and 5%. In the culture medium containing 5% FBS, 
cells developed a round shape and began to elongate. The elongation of the cytoplasm 
became clearer and cells appeared thinner as the concentration of FBS in culture 
medium reduced to 0%.
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Figure 5.2.1 Overview of cell count data as mean ± SEM which were sub-grouped 
according to variable factors; cell types and concentration of FBS in culture medium.
Both variable factors had a statistically significant effect on cell number independently 
(p<0.05). (a) Cell count data was sub-grouped by cell type and culture medium
containing 10% FBS was used as control. There was a significant reduction o f cell
number of non-transfected JHEK293 culturing in the absence of FBS in culture medium 
in comparison to control (p<0.05). (b) Cell count data was sub-grouped by
concentration of FBS in culture medium and non-transfected HEK293 was used as a 
control. There was a significant reduction of cell number of HEK751.C1 in culture 
medium containing 1% FBS in comparison to control (p<0.05).
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(b)
(c) (d)
Figure 5.2.2 Non-transfected 293 cells cultured in medium containing various 
concentrations of FBS: (a) 0%, (b) 1%, (c) 5% and (d) 10%. There were approximately 5 
x 105 live cells per well at the beginning of the experiment. Cells were allowed to 
adhere for at least 6 hours before culture medium was discarded and fresh medium 
containing different concentration of FCS was added. Cells were incubated in 
conditioned medium for 24 hours before the photographs were taken. The cells start 
to form clusters more clearly as the concentration of FBS in culture medium decreased. 
Also, the clusters of cells in culture medium containing 0% of FBS linked to each other 
and appeared to have minimal attachment to the well, (magnification 200x)
150
(a) (b)
Figure 5.2.3 HEK695.C5 cultured in medium containing various concentrations of FBS:
(a) 0%, (b) 1%, (c) 5% and (d) 10%. There were approximately 5 x 105 live cells per well 
at the beginning of the experiment. Cells were allowed to adhere for at least 6 hours 
before culture medium was discarded and fresh medium containing different 
concentration of FBS was added. Cells were incubated in conditioned medium for 24 
hours before the photographs were taken. The cells start to form clusters more clearly 
as the concentration of FBS in culture medium decreased. As the cells appeared to 
grow slower in the culture medium containing lesser amounts of FBS therefore the 
clusters of cells were clearly seen, (magnification 200x)
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Figure 5.2.4 HEK751.C1 cultured in medium containing various concentrations of FBS:
(a) 0%, (b) 1%, (c) 5% and (d) 10%. There were approximately 5 x 105 live cells per well 
at the beginning of the experiment. Cells were allowed to adhere for at least 6 hours 
before culture medium was discarded and fresh medium containing different 
concentration of FBS was added. Cells were incubated in conditioned medium for 24 
hours before the photographs were taken. The cells appeared to grow normally in 
culture medium containing 1% and 5% FBS while cells grew significantly slower in 
culture medium containing 0% FBS when comparing to culture medium containing 10% 
FBS (control). Also, the clusters of cell started to appear in culture medium contain FBS 
less than 5%. In the 0% FBS containing medium, cells appeared thinner and elongated 
as well as forming networks between clumps, (magnification 200x)
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(C)
Figure 5.2.5 HEK770.C6 cultured in medium containing various concentrations of FBS:
(a) 0%, (b) 1%, (c) 5% and (d) 10%. There were approximately 5 x 105 cells per well at 
the beginning of the experiment. Cells were allowed to adhere for at least 6  hours 
before culture medium was discarded and fresh medium containing different 
concentration of FBS was added. Cells were incubated in conditioned medium for 24 
hours before the photographs of cells were taken. The cells appeared to grow slowly 
where there was an alteration in concentration of FBS in culture medium; for example 
in culture medium containing 0%, 1% and 5%. In the culture medium containing 5% 
FBS, cells developed the round shape and started to elongate. The elongation o f the 
cytoplasm became clearer and cells appeared thinner as the concentration of FBS in 
culture medium reduced to 0 %. (magnification 2 0 0 x)
153
5.3 Effects of FBS in cell culture medium on APP secretion
The second part of the investigation of the effect of FBS in culture medium on APP 
production was to determine the amount of APP secreted into culture medium. In 
brief, APP located either at the cell membrane or trans-Golgi network (TGN) is cleaved 
by one or more of a group of secretases before being released to the extracellular 
space i.e. culture medium in cell culture.
Methods in brief
The culture medium was collected prior to cell counting and was then 
immunoprecipitated using DE2 antibody following by reduction and alkylation of 
disulphide bonds. These samples prepared from collected culture medium were run on 
6% SDS-PAGE gel before proceeding with protein expression analysis by 
immunoblotting (complete procedures see Section 2.16-2.19). Four primary antibodies 
used during the immunoblotting procedure: DE2, 993, 23/2 and 1151. Each o f the 
primary antibodies recognizes a different epitope on the APP sequence; DE2 
recognizes Ap domain (amino acid 1-14) which is found in all three isoforms of APP 
after cleavage by a-secretase, 993 recognizes the KPI domain which is found in APP751 
and 770, 23/2 recognizes 0X2 domain which is only found on APP770 and 1151 
recognizes amino acid at the N-terminal of all three APP isoforms. DE2 and 993 
primary antibodies also recognize bovine APP presented in culture medium while 1151 
and 23/2 primary antibodies do not. Moreover, the fluorescence labelled secondary 
antibodies: IRDye 680RD Goat anti-Mouse IgG or IRDye 680RD Goat anti-Rabbit were 
used to detect proteins which were bound to nitrocellulose membrane.
Results
Figure 5.3.1 shows the immunoblotting results obtained from immunoprecipitated 
culture medium containing various concentrations of FBS collected from non- 
transfected HEK293. None of the samples produced the protein band recognised by 
1151, 993 and 23/2 antibodies however all four samples produced faint protein band 
against the DE2 antibody. The protein band recognised by DE2 antibody was 
approximately 120 kDa in size.
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The immunoblotting results obtained from immunoprecipitated culture medium 
containing various concentrations of FBS collected from HEK695.C5 are shown in 
Figure 5.3.2. All four samples produced protein bands recognised by 1151 and DE2 
antibodies and the approximate size of the protein band was 115 kDa. Also, none of 
the samples produced the protein band against 993 and 23/2 antibodies.
The immunoblotting results obtained from immunoprecipitated culture medium 
containing various concentrations of FBS collected from HEK751.C1 are shown in 
Figure 5.3.3. These samples produced clear protein bands recognised by 1151, 993 and 
DE2 antibodies which was approximately 118 kDa in size. Also, none of the samples 
produced a protein band against 23/2 antibody.
The final set of immunoblotting results obtained from immunoprecipitated culture 
medium containing various concentrations of FBS collected from HEK770.C6 was 
shown in Figure 5.3.4. All four samples produced protein bands against all antibodies 
and the protein band was approximately 120 kDa in size.
The protein band of APP obtained from each set of immunoblotting was quantified 
using fluorescence intensity. Figure 5.3.5 (a) shows that the clones shared the same 
APP secretion trend in each concentration of FBS: APP751 produced more APP than 
APP695 and APP770. After the number of live cells was taken into account in the 
determination of the amount of APP secretion per cell, the same trend of APP 
secretion was also found as shown in Figure 5.3.5 (b). The mean ± S.E.M. of results of 
APP secretion (a.u.) per cell are expressed as follows:
• 0% FBS: APP751 (61.29±20.08 a.u./cell)> APP695 (60.59±24.34
a.u./cell)> APP770 (46.79±4.49 a.u./cell).
• 1% FBS: APP751 (80.68±18.23 a.u./cell)> APP695 (53.10±22.37
a.u./cell)> APP770 (47.28±8.15 a.u./cell).
• 5% FBS: APP751 (97.83±43.89 a.u./cell)> APP695 (65.21±22.11
a.u./cell)> APP770 (52.54±3.07 a.u./cell).
• 10% FBS: APP751 (63.88±13.51 a.u./cell)> APP695 (54.48±12.54
a.u./cell)> APP770 (49.93±13.28 a.u./cell).
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The level of secreted APP per cell was calculated using the following formula: 
APP secretion level (a.u.) per cell = (fluorescence intensity x 106)/ cell number; where 
a.u. stands for Arbitrary unit.
In order to determine any possible effects of FBS on APP secretion, the amount of 
secreted APP was statistically analysed using two-way ANOVA with 95% confidence 
interval and Bonferroni's multiple comparison test. Also, these data were analysed 
based on two independent factors; (1) the concentrations of FBS in culture medium 
and (2) the differences in the isoform of APP. The statistical analysis revealed that both 
factors affected the APP secretion independently (p>0.05) but significantly; the type of 
cell [p<0.0001) and the different concentration of FBS (p=0.0423). The changes in the 
APP secretion were presented as mean of fold change ± S.E.M. to the control.
Figure 5.3.6 shows the of APP secretion level (mean of fold change ± S.E.M.) of each 
cell type compared to the same cells growing in the culture medium containing 1 0 % 
FBS, in order to compare the APP secretion of each cell type under different 
concentration of FBS. Each graph in Figure 5.3.6 represents each cell type; non- 
transfected HEK293 cells, HEK695.C5, HEK751.C1 and HEK770.C6 and consists of four 
concentrations of FBS; 0%, 1%, 5% and 10%. All cell types, including non-transfected 
HEK293 cells, shared the same trend of increased APP secretion under various FBS 
concentrations; APP secretion decreased as the concentration of FBS decreased. The 
average fold change of APP secretion is as follows:
• Non-transfected HEK293: 5% FBS (0.95±0.02)> 1% FBS (0.93±0.02)> 0% 
FBS (0.79±0.09).
• APP695.C5: 5% FBS (0.98±0.07)> 1% FBS (0.82±0.13) = 0% FBS 
(0.82±0.14).
• APP751.C1: 5% FBS (1.02±0.08)> 1% FBS (0.95±0.11)> 0% FBS 
(0 .86± 0 .11).
• APP770.C6: 5% FBS (1.02±0.14)> 1% FBS (0.99±0.21)> 0% FBS 
(0.79±0.13).
There were no significant differences in the level of APP secretion within each cell type 
of non-transfected HEK293 cells, HEK695.C5, HEK751.C1 and HEK770.C6.
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Figure 5.3.7 shows the APP secretion level (mean of fold change ± S.E.M) of each clone 
after subtraction of endogenous APP from non-transfected HEK293 in order to 
compare the APP secretion between isoform of APP. Each graph in Figure 5.3.7 
represents each concentration of FBS; 0%, 1%, 5% and 10% and consists of four cell 
types; non-transfected HEK293 cells, HEK695.C5, HEK751.C1 and HEK770.C6. In the 
absence of FBS and the culture medium containing 1% FBS, an increase of APP 
secretion level from APP695 and APP751 were comparable and lower than APP770. 
Also, all three isoforms of APP share the same trend of the increased APP secretion 
level in the culture medium containing 5% and 10% FBS; APP751 had larger increases 
than APP695 and APP770. The differences in the increase of the APP secretion level 
between isoforms of APP were not statistically significant. The average results of the 
increase in APP secretion level are as follows:
•  0% FBS: APP770 (5.67±0.38)> APP695 (5.04±1.72)> APP751 (5.03±1.21).
•  1% FBS: APP770 (5.19±0.23)> APP751 (4.55±0.81)> APP695 (4.06±1.26).
• 5% FBS: APP751 (4.75±0.66)> APP695 (4.57±1.1) > APP770 (3.67±0.43).
• 10% FBS: APP751 (4.37±0.32)> APP695 (4.32±0.82)> APP770
(3.47±0.12).
The APP secretion of FIEK695.C5 increased significantly at all concentrations of FBS 
(0%: p<0.01; 1%, 5% and 10%: p<0.05). Also, the APP secretion of FIEK751.C1 increased 
at all concentrations of FBS (0% and 5%: p<0.01; 1%, and 10%: p<0.05). The APP 
secretion of FIEK770.C6 only showed a significant increase in 0% and 1% FBS (p<0.001). 
Flowever, there were no significant changes in APP secretion between the cell types 
under the same condition.
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Figure 5.3.1 Protein analysis of APP secretion by non-transfected HEK293 cells which 
were cultured in medium containing varying concentrations of FBS: 0%, 1%, 5% and 
10% over 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and 
(d) DE2. None of the samples produced a protein band recognised by 1151, 993 and 
23/2 primary antibodies. However, the protein band recognised by DE2 primary 
antibody was due to bovine APP in FBS and this was confirmed by the sample obtained 
from collected culture medium which contained 0% FBS.
Figure 5.3.2 Protein analysis of APP secretion by HEK695.C5 cells which were 
cultured in medium containing varying concentrations of FBS: 0%, 1%, 5% and 10% 
over a 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) 
DE2. All culture media containing different amounts of FBS produced positive protein 
bands recognised by 1151 and DE2 primary antibodies and the approximate size of the 
protein band was 115 kDa which corresponds to the molecular weight of APP695. The 
protein band recognised by DE2 antibody was stronger than 1151 antibody possibly 
due to an additional bovine APP in FBS. Also, none of the samples produced protein 
bands against 993 and 23/2 antibodies.
Figure 5.3.3 Protein analysis of APP secretion by HEK751.C1 cells which were cultured 
in medium containing varying concentrations of FBS: 0%, 1%, 5% and 10% over a 24- 
hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) DE2. All
culture medium contained different amounts of FBS produced clear protein bands 
which were recognised by 1151, 993 and DE2 antibodies and was approximately 118 
kDa in size corresponding to the molecular weight of APP751. Also, none of the 
samples produced a protein band recognised by 23/2 antibody.
Figure 5.3.4 Protein analysis of APP secretion by HEK770.C6 cells which were 
cultured in medium containing varying concentrations of FBS: 0%, 1%, 5% and 10% 
over 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) 
DE2. All culture medium contained different amount of FBS produced protein bands 
recognised by all four antibodies and the protein bands were approximately 120 kDa 
which corresponds to the molecular weight of APP770.
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Figure 5.3.5 The APP secretion level as mean ± SEM. (a) the APP secretion (a.u.) of 
each cell type. All three clones shared the same pattern of APP secretion under the 
same FBS concentration: APP751> APP695> APP770. (b) the APP secretion (a.u.) per 
cell of each cell type. After the cell number was taken into account to calculate the 
APP secretion per cell, the same trend of APP secretion under the same FBS 
concentration was found: APP751> APP695> APP770.
162
Figure 5.3.6 The APP secretion level as mean ± SEM: cell types. Each graph 
represents each cell type; (a) non-transfected HEK293 cells, (b) HEK695.C5, (c) 
HEK751.C1 and (d) HEK770.C6 and consisted of four concentrations of FBS; 0%, 1%, 5% 
and 10%. The APP secretion of each cell type growing in culture medium containing 
10% of FBS was as used as control. There were no significant changes in APP secretion 
within each cell type of non-transfected HEK293 cells, HEK695.C5, HEK751.C1 and 
HEK770.C6. Flowever, the APP secretion trend was similar in each cell line; the APP 
secretion decreased as the FBS concentration decreased.
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Figure 5.3.7 The APP secretion level as mean ± SEM: concentration of FBS. Each graph 
represents each concentration of FCS; (a) 0%, (b) 1%, (c) 5% and (d) 10% and consisted 
of four cell types; non-transfected HEK293 cells, HEK695.C5, HEK751.C1 and 
HEK770.C6. The APP secretion of non-transfected HEK293 cells was used as a control. 
The APP secretion of HEK695.C5 increased significantly at all concentrations of FBS 
(0%: p<0.01; 1%, 5% and 10%: p<0.05) in comparison to the control. Also, the APP 
secretion of HEK751.C1 increased at all concentrations of FBS (0% and 5%: p<0.01; 1%, 
and 10%: p<0.05) in comparison to the control. The APP secretion of HEK770.C6 only 
showed significant increase in 0% and 1% FCS (p<0.001 for both concentrations of FBS) 
in comparison to the control. Moreover, there were no significant differences in APP 
secretion between cell types under the same conditions.
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5.4 Effects of FBS in cell culture medium on APP mRNA level
The final part of the investigation of FBS concentration in culture medium on APP 
production was to measure APP mRNA levels. Cells were plated out at 5 x 105 cells per 
well of 6 -well plates and were cultured in culture medium containing various 
concentrations of FBS for 24 hours before cells were photographed and counted, and 
culture medium and cell pellets were collected.
5.4.1 Reference gene stability assessment
Before the determination of the mRNA level could be carried out, it is a common rule 
that one or more reference genes are selected to be used as normalizers.
The human geNorm™ Reference Gene Selection kit (PrimerDesign), which is a set of 
primers for 12 candidate reference genes was purchased. The 12 reference genes: 
ERCC6 , UBE2D2, UBE4A, ENOX2, PRDM4, SCLY, TYW1, RNF20, CH0140RF, ACTB, 
GAPDH and 18S were tested for their expression stability between non-transfected 
HEK293 and selected clones of HEK293 transfected with APP isoforms, also the stability 
of reference genes in all experimental conditions; variation in FBS concentrations and 
the addition of 2-Deoxy-D-glucose. Therefore, the obtained reference genes are 
suitable for normalization of the mRNA level in real-time RT-PCR. As mentioned in 
Section 2.25, the expression stability values were obtained using GeNorm software 
based on reference gene removal according to calculations of pair-wise correlation, 
which results in the M-value and the ideal reference genes should have an M-value 
less than 1.5.
The three separate sets of cell pellets were collected from; (1) untreated non- 
transfected HEK293, APP695.C5, APP751.C1 and APP770.C6: (2) non-transfected 
HEK293, APP695.C5, APP751.C1 and APP770.C6 which were cultured in culture 
medium contained various concentrations of FCS (0%, 1%, 5% and 10%) for 24 hours 
and (3) non-transfected HEK293, APP695.C5, APP751.C1 and APP770.C6 which were 
cultured in culture medium contained various amount of 2-Deoxy-D-glucose (5, 25 and 
50 mM). Cell pellets were prepared according to  the procedure stated in Sections 2.20 
to 2.22 before proceeding with real-time RT-PCR (see Section 2.23). In short, total RNA 
from cell pellets were obtained using RNeasy Mini Kit following by RNA quantification
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using NanoDrop ND-1000 UV-VIS spectrophotometer before conversion to cDNA using 
RT-PCR. Then the cDNA from each cell pellet sample was plated out in triplicate before 
adding master mix and subjected to the real-time RT-PCR procedure. Also, the gene 
stability assessment was carried out in triplicate. The obtained ACt value from each 
sample in each experiment was subjected to analysis by GeNorm software and the 
results are shown in Figures 5.4.1 (a) and (b).
Figure 5.4.1 (a) shows the M-value of all 12 reference genes; the least stable reference 
gene located at the left of the graph, the average stability of genes were positioned 
due to an increase in stability and the most stable reference gene located on the right 
o f the graph. The GeNorm software not only generated a graph representing the 
stability of reference genes but it also generated a pair-wise variation value (V). The V- 
value was used as a guideline to determine the minimum number of reference genes 
required for normalization in each of the determination of mRNA level experiment and 
the V-value at 0.15 was use as a cut-off point. Figure 5.4.1 (b) showed the V-value as 
Vn/n+i and on V2/ 3 column had a V-value of less than 0.15 which means the 
determination of mRNA level experiment required a minimum of two reference genes. 
Therefore SCLY and TYW1 were the two reference genes which were selected using M- 
value and V-value parameters.
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Figure 5.4.1 The reference genes transcript stability assessments, (a) Average 
expression stability: M-value of 12 reference genes. The least stable reference gene 
was located on the left side of the graph and the most stable reference gene was 
located on the right side of the graph, (b) Determination of the optimal number of 
reference genes required in the mRNA level determination experiments: V-value which 
is displayed as Vn/n+1. If Vn has a V-value less than 0.15, there was no need to 
introduce an additional reference gene. Therefore, the minimum number of reference 
genes required for each of the determination of mRNA level experiment was two 
reference genes; SCLY and TWY1.
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5.4.2 P rim e r e ffic iency
As previously mentioned in Section 2.27, there are two models frequently used to 
determine relative quantification; one model takes the efficiency of the primers into 
account during the calculation while the other one does not. Also, the latter model is 
only used when primer efficiency is within an acceptable range due to a presumption 
made on primer efficiency during the calculation; E sa m p ie  =  E re fe re n c e  = 2 . Therefore, it is 
crucial to determine primer efficiency before proceeding to the determination of 
mRNA level experiments. Once reference genes were selected, there were three pairs 
of primers which were assessed for efficiency; primers for APPs, primers for SCLY and 
TYW1. The primer efficiency assessment was carried out by diluting cDNA converted 
from the extracted total RNA of cell pellets obtained from non-transfected HEK293, 
APP695.C5, APP751.C1 and APP770.C6 into four dilutions: 1:5, 1:10, 1:50 and 1:100. 
The cDNA was diluted by adding an appropriate volume of RNAse/ DNAse-free water 
before 1 pi of each diluted cDNA was added into MicroAmp® Optical 96-Well Reaction 
Plate in triplicate. Then, 9 pi of master mix of each set of primers was added and the 
reaction plate was sealed before placing in the StepOnePlus™ Real-Time PCR System. 
The amplification conditions were carried out according to the standard procedure in 
Section 2.24.
The Ct values gained during the amplification stages were plotted on a semi-log graph 
between Ct value and log dilution of cDNA and a linear trend line was added later. 
According to Section 2.26, the percentage of primer efficiency and primer efficiency 
were obtained using the formulas below:
% Efficiency = [(10 ” (1/slope))- l]  x 100
Efficiency (E) = 10'(1/slope)
Slope is acquired from the plotted graph using data obtained from cDNA dilutions.
Figure 5.4.2 shows the semi-log graphs between Ct value and log dilution of cDNA 
obtained from non-transfected HEK293. The slopes obtained from the trend lines were 
-3.302 and R2 value of 0.999 for APP primers, -3.224 and R2 value of 0.9924 for SCLY, 
and -3.156 and R2 value of 0.9999 for TYW1. As a consequence, the percentage of
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primer efficiency or E value of APP, SCLY and TYW1 were 101%, 104% and 107% or 
2.00, 2.04 and 2.07, respectively.
The Ct value obtained from APP695.C5 cDNA was plotted against log dilution of cDNA 
and the semi-log graphs are shown in Figure 5.4.3. According to the trend lines of the 
graphs, the slopes and R2 value of APP primers, SCLY primers and TYW1 primers were 
-3.306 and 0.9984, -3.109 and 0.9976 and -2.988 and 0.9964, respectively. The 
percentage of primer efficiency for APP, SCLY and TYW1 primers were 100%, 110% and 
116%, respectively, followed by efficiency of three primers; 2 .0 1 , 2 .1 0  and 2.16, 
accordingly.
Figure 5.4.4 shows semi-log graphs between log dilution of cDNA on X-axis and Ct 
values gained from APP751.C1 cDNA on Y-axis. The slopes and R2 values obtained from 
the graphs were as followed -3.324 and 0.9979 for APP primers, -3.062 and 0.9978 for 
SCLY and -3.103 and 0.9996 for TYW1. Subsequently, the slopes were applied to 
formulas mentioned above to generate the percentage of primer efficiency and E; APP 
(100% and 2.00), SCLY (112% and 2.12) and TWY1 (110% and 2.10).
As the Ct values gained using cDNA from APP770.C6 were plotted against log dilution 
of cDNA and shown as semi-log graphs in Figure 5.4.5, the slopes and R2 values of APP, 
SCLY and TYW1 primers were generated as a result; -3.342 and 0.9992, -2.975 and 
0.9976, and -3.292 and 0.9992, respectively. By applying the slopes to the formulas 
mentioned above, the percentage of primer efficiency and efficiency of primers were 
obtained; APP (100% and 2.00), SCLY (117% and 2.17) and TYW1 (101% and 2.01).
In order to make the results obtained from primer efficiency assessments easier to 
understand, these values and numbers of each primers and semi-log graphs are 
summarized in Figure 5.4.6.
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Figure 5.4.2 Standard curves of primer efficiency using diluted cDNA obtained from 
non-transfected HEK293. There were four dilutions: 1:5, 1:10, 1:50 and 1:100 which 
are plotted on semi-log graph against average Ct values gained from real-time RT-PCR 
by three different sets of primers; (a) APP, (b) SCLY and (c) TYW1. The slope of each 
graph was used in the primer efficiency calculation and the R2 value which indicated 
correlation between data points. The percentage of primer efficiency and R2 values 
were (a) 101% and 0.9999, (b) 104% and 0.9924 and (c) 107% and 0.9999.
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Figure 5.4.3 Standard curves of primer efficiency using diluted cDNA obtained from 
HEK695.C5. There were four dilutions: 1:5, 1:10, 1:50 and 1:100 which are plotted on 
semi-log graph against average Ct values gained from real-time RT-PCR by three 
different sets of primers; (a) APP, (b) SCLY and (c) TYW1. The slope of each graph was 
used in the primer efficiency calculation and the R2 value which indicated correlation 
between data points. The percentage of primer efficiency and R2 values were (a) 100% 
and 0.9984, (b) 110% and 0.9976 and (c) 116% and 0.9964.
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Figure 5.4.4 Standard curves of primer efficiency using diluted cDNA obtained from 
HEK751.C1. There were four dilutions: 1:5, 1:10,1:50 and 1:100 which are plotted on 
semi-log graph against average Ct values gained from real-time RT-PCR by three 
different sets of primers; (a) APP, (b) SCLY and (c) TYW1. The slope of each graph was 
used in the primer efficiency calculation and the R2 value which indicated correlation 
between data points. The percentage of primer efficiency and R2 values were (a) 100% 
and 0.979, (b) 112% and 0.9978 and (c) 110% and 0.9996.
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Figure 5.4.5 Standard curves of primer efficiency using diluted cDNA obtained from 
HEK770.C6. There were four dilutions: 1:5, 1:10, 1:50 and 1:100 which are plotted on 
semi-log graph against average Ct values gained from real-time RT-PCR by three 
different sets of primers; (a) APP, (b) SCLY and (c) TYW1. The slope of each graph was 
used in the primer efficiency calculation and the R2 value which indicated correlation 
between data points. The percentage of primer efficiency and R2 values were (a) 100% 
and 0.9992, (b) 117% and 0.9976 and (c) 101% and 0.9992.
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5.4.3 Effects o f FBS on APP mRNA leve l
After obtaining appropriate reference genes (SCLY and TYW1) and having determined 
the efficiency of each pair of primers, assessing the effects of FBS on APP mRNA level 
was then undertaken.
Methods in brief
The experiment began with plating 5 x 105 cells per well of 6-well plates. Cells were 
allowed to settle and adhere for at least 6 hours before the culture medium was 
discarded and 2 ml of fresh medium which contained varying concentrations of FBS 
was added. Twenty-four hours later cells were photographed using the XLI cap 
program and culture medium was collected for APP secretion analysis followed by cell 
counting and cell pellet harvesting. The cell count data was analysed and the results 
are shown in Section 5.2 while the culture medium was immunoprecipitated and 
analysed as the results showed in Section 5.3 along with photographs of the cells. The 
cell pellet was processed last. Total RNA was extracted from cell pellets (Section 2.20) 
using RNeasy Mini Kit before quantification using NanoDrop ND-1000 UV-VIS 
Spectrophotometer (Section 2.21). The RNA was converted into cDNA using 
QuantiTect Reverse Transcription Kit according to the procedure stated in Section 2.22 
which at this point the cDNA of each sample was ready to be amplified by the 
described real-time RT-PCR technique. A complete list of real-time PCR component and 
procedure were mention in Section 2.24.
The real-time RT-PCR reactions were set up in MicroAmp® Optical 96-Well Reaction 
Plates and each reaction consisted of 1 pi of cDNA, 0.5 pi of TaqMan® assay probe, 5 pi 
o f TaqMan® Fast Universal Master Mix and 3.5 pi of RNAse/DNAse free water. Also, 1 
pi of cDNA sample obtained from the reverse transcriptase reaction containing no 
reverse transcriptase, 1 pi reaction w ithout RNA and 1 pi RNAse/DNAse free water 
were used as negative controls. The MicroAmp® Optical 96-Well Reaction Plate was set 
up and each sample was loaded in triplicate before the reaction plate was sealed then 
placed in the StepOnePlus™ Real-Time PCR Systems and the amplification conditions 
were started.
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The data from each amplification condition of each sample was gained as Ct value and 
as each sample was carried out in triplicate per reaction, therefore the mean of 
triplicate Ct values was use in the relative quantification of the mRNA level. The chosen 
relative quantification model was the one that takes the slope of primer efficiency into 
account. The model is shown as followed:
Fold difference = Esarnple4Q samp7  Ereferenceict re,erence
Where E sam p ie  is the primer efficiency of the gene of interest; E re fe re n c e  is the primer 
efficiency of a reference gene; ACt sample is the difference of the means of Ct between 
the control and the gene of interest; ACt reference is the difference of mean of Ct between 
the reference gene of control and reference gene of sample.
The two-way ANOVA with 95% confidence interval was coupled with Bonferroni's
multiple comparison test to evaluate any possible effects of the concentration of FBS 
in culture medium on APP mRNA level in non-transfected HEK293 and clones of APP 
transfected HEK293. The data are presented as graphs between independent factors 
(X-axis) and fold differences of mRNA level (Y-axis). The data were also analysed based 
on the two independent factors; (1) the concentration of FBS in culture medium and
(2) the differences in the isoform of APP.
Results
The APP mRNA level of the cells incubated in culture medium which contained varying 
concentrations of FBS was shown in Figure 5.4.7: the effects of the FBS concentration 
in culture medium on APP mRNA level and Figure 5.4.8: the effect of the isoforms of 
APP on APP mRNA level in each concentration of FBS. The statistical analysis revealed 
that cell types and concentrations of FBS affected APP mRNA levels significantly 
(p=0.0120 and 0.0095, respectively) but both factors were independent from each 
other (p>0.05).
Figure 5.4.7 shows the graph of the mRNA level which the same cells growing in 
culture medium containing 10% FCS was used as controls. The statistical analysis 
revealed that the APP mRNA level of non-transfected HEK293 cells and HEK751.C1 
were reduced in culture medium containing 0%, 1% and 5% of FBS but the reductions 
were not statistically significant. The APP mRNA level of HEK695.C5 was reduced in
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culture medium containing 0% and 5% of FCS while it was slightly increased in the 
culture medium containing 1% of FCS. However, the changes occurred with APP mRNA 
level of HEK695.C5 were not significant. In contrast, the level of APP mRNA of 
HEK770.C6 was elevated in culture medium containing 0%, 1% and 5% of FCS but only 
the elevation of APP mRNA level in culture medium containing 0% FCS was statistically 
significant (p<0.05).
Figure 5.4.8 shows the graphs of the mRNA level data which contained all four cell 
types and each graph represented each concentration of FBS in culture medium: 0%, 
1%, 5% and 10%. The non-transfected HEK293 cells growing in each concentration of 
FBS were used as controls. The statistical analysis revealed that there were changes 
due to the differences in cell type which significantly affected the APP mRNA level 
(p<0.05). In the culture medium containing 0% FBS, the APP mRNA level of HEK695.C5 
and HEK770.C6 were reduced significantly in comparison to non-transfected HEK293 
cells (p<0.05), whereas the APP mRNA level of HEK751.C1 appeared to be slightly 
increased though it was not statistically significant. In addition, all cell types which 
were cultured in culture medium containing 1% and 5% FBS shared the same pattern 
of APP mRNA level in comparison to non-transfected HEK293; the APP mRNA level of 
HEK695.C5 and HEK770.C6 were reduced significantly (p<0.05), and APP mRNA level of 
HEK751.C1 was reduced slightly. All cell types which were cultured in medium 
containing 10% FBS showed a similar pattern of the APP mRNA level to the culture 
medium containing 1% and 5% FBS: the level of APP mRNA of HEK695.C5, HEK751.C1 
and HEK770.C6 were reduced though only APP mRNA level of HEK695.C5 was 
significantly reduced (p<0.05).
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Figure 5.4.7 The APP mRNA level results as mean ± S.E.M.: cell types. The X-axis: 
concentration of FBS and Y-axis: fold difference of APP mRNA level. The same cell 
type incubated in complete culture medium containing 10% FBS were used as 
controls. There were four cell types; (a) non-transfected HEK293, (b) APP695.C5, (c) 
APP751.C2 and (d) APP770.C6. The APP mRNA level of non-transfected HEK293 cells 
and HEK751.C1 were reduced in culture medium containing 0%, 1% and 5% of FBS but 
the reductions were not statistically significant. The APP mRNA level of HEK695.C5 was 
reduced in culture medium containing 0% and 5% of FCS while it was slightly increased 
in the culture medium containing 1% of FCS. However, the changes which occurred to 
levels of APP mRNA of HEK695.C5 were not significant. In contrast, the level of APP 
mRNA of HEK770.C6 was elevated in culture medium containing 0%, 1% and 5% of FCS 
but only the elevation of APP mRNA level in culture medium containing 0% FCS was 
statistically significant (p<0.05).
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Figure 5.4.8 The APP mRNA level results as mean ± S.E.M.: concentrations of FBS. The 
X-axis: isoforms of APP and Y-axis: fold difference of APP mRNA level. The non- 
transfected HEK293 cells growing in each concentration of FBS were used as controls.
There were four concentrations of FBS; (a) 0%, (b) 1%, (c) 5% and (d) 10%. In 
comparison to non-transfected HEK293 cells the APP mRNA level of HEK695.C5 was 
reduced significantly in all four concentrations of FBS (p<0.05), HEK751.C1 was slightly 
reduced in culture medium containing 1%, 5% and 10% FBS but the level of APP mRNA 
was slightly elevated in the absence of FBS in the culture medium, and HEK770.C6 was 
significantly reduced in culture medium containing 0%, 1% and 5% FBS (p<0.05).
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5.5 mRNA: protein ratio
It was reported that there was a strong correlation between secreted APP and the APP 
mRNA level in the brains of patients with AD (Matsui et al. 2007). The translational 
efficiency is the rate of conversion from mRNA into proteins which could be 
determined using measured protein and mRNA level, as follows:
mRNA: Protein = [mRNA/cell] /  [Protein/cell]
The statistics revealed that the HEK751.C1 is the least efficient in translating APP 
mRNA into APP while HEK695.C5 and HEK770.C6 are the most efficient. The lower the 
ratio the higher the translation and efficiency. The complete analysis of mRNA:Protein 
ratio is as follows:
• HEK695.C5: 0% FBS (0.04±0.04)> 1% FBS (0.03±0.02)= 5% FBS (0.03±0.02)
•  HEK751.C1: 0% FBS (0.26±0.13)> 5% FBS (0.18±0.09)> 1% FBS (0.15±0.09)
•  HEK770.C6: 5% FBS (0.04±0.02)> 1% FBS (0.03±0.02)= 0% FBS (0.03±0.01)
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5.6 Discussion
The three clones that stably expressed isoforms of APP at comparable levels; 
HEK695.C5, HEK751.C1 and HEK770.C6 were used as cellular models in an investigation 
into the effects of FBS in culture medium which was the fourth objective of this 
project.
It was hypothesised that selected clones secreting similar amounts of APP695, APP751 
and APP770 into culture media under normal cultured conditions (culture medium 
containing 10% FBS and 25 mM glucose) would be the consequence of production of 
equal amounts of mRNA for each isoform. However, the mRNA level of each isoform of 
APP appeared to be different: APP751> APP770> APP695. On average, the mRNA level 
between APP751 was 4 fold higher than APP695. The differences in mRNA levels 
between isoforms of APP could have significant effects on APP secretion and, 
ultimately, A(3 peptide secretion.
FBS in culture medium presents advantages and disadvantages. The advantages of FBS 
include providing hormonal factors, transporter proteins, facilitating cellular 
adherence and maintaining the pH of culture medium. The disadvantages include 
composition inconsistency, batch-to-batch variation and increased risk of infection. 
Also, the presence of FBS might interfere with the experimental results; especially with 
protein purification or isolation studies (Brunner et al. 2010). Therefore the objectives 
of this investigation were; (1) to determine whether FBS concentration affects the cell 
number, APP secretion and APP mRNA level at various concentrations, and (2) to find 
out if the alteration of FBS affects each isoform of APP differently.
The investigation of the effects of FBS in the culture medium was carried out in three 
separate parts: cell number, APP secretion and APP mRNA level. The data gained from 
each part of an investigation was subjected to statistical analysis based on two 
independent factors; (1) the concentrations of FCS in culture medium (using culture 
medium containing 10% FCS as control) and (2) the differences in isoforms of APP 
(using non-transfected HEK293 cells as control). Also, prior to the cell counting 
procedure, cells were photographed in order to observe morphological changes.
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Serum deprivation and serum restriction are two of several interchangeable terms 
used to describe cell culture procedures involving an alteration in the concentration of 
FBS (Pirkmajer and Chibalin 2011). To date, there have been numbers of researchers 
who have used FBS concentration alteration as a tool in their studies including protein 
degradation studies (Epstein, Elias-Bishko and Hershko 1975), cellular stress response 
studies (Levin et al. 2010), apoptosis studies (Terra et al. 2011) and im itation of 
pathological conditions (Hamabe, Fujita and Ueda 2005; Pirkmajer and Chibalin 2011; 
Yu et al. 2008). As components in FBS have not been completely identified, the 
removal of FBS from culture medium also removes the both known and unknown 
residues which might cause interferences in the experiment (Pirkmajer and Chibalin
2011). Nevertheless, serum deprivation is commonly used as an apoptotic trigger in 
neurodegenerative disease studies as it allows the researchers to study the 
morphology of the cells under stress or in malnutritional conditions as well as studying 
newly discovered anti-apoptotic agents (Fiorelli, Kirouac and Padmanabhan 2013; Xie 
e ta l. 2013).
A tk l, also known as protein kinase Ba (PKBa), is a serine/ threonine protein kinase 
(Filippa et al. 1999; Nicholson and Anderson 2002) and it has been suggested to play 
role as a regulator of apoptosis, cell growth and proliferation, cell differentiation and 
cell metabolism (Mulukutla et al. 2010; Nicholson and Anderson 2002). A tk l is 
activated by an activation of phosphoinositide 3-kinase (PI3K) initiating a synthesis of 
phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) which facilitates the localization, 
phosphorylation and activation of A tk l. One of several ways which PI3K can be 
activated is autophosphorylation of kinase by ligands including growth factors and 
amino acids (Fayard et al. 2005; Filippa et al. 1999; Nicholson and Anderson 2002; 
Scheid and Woodgett 2003). Once the A tk l is activated, it subsequently initiates 
protein translation/synthesis and cell growth via the mammalian target of rapamycin 
complex 1 (mTORCl).
Under growth factor and amino acid insufficiency mimicked by FBS concentration 
alteration, it was hypothesised that the cell number would decrease along with a 
decreased concentration of FBS as a result of an A tk l inactivation. However, the cell 
count data presented in this Chapter (Figure 5.2.1) revealed that there is no significant 
reduction of cell number between concentrations of FBS in culture medium. Previous
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studies have reported that the earliest which the changes in cell population culturing 
under serum deprived condition could be detected is 48 hours (Deorosan and Nauman 
2011; Fiorelli, Kirouac and Padmanabhan 2013). The role of A tk l in apoptosis 
regulation has been supported by a study demonstrating an inhibition of apoptosis 
signalling-regulating kinase-1 (ASK1) by activated A tk l (Milosch et al. 2014). The 
activated A tk l has been proposed to inhibit apoptosis by regulating the expression or 
phosphorylation of a series of pro-apoptotic proteins leading to inactivation of these 
proteins (Mulukutla et al. 2010; Scheid and Woodgett 2003). However the morphology 
of the cells as shown in Figure 5.2.2-5.2.5, which were cultured in culture medium 
containing various amounts of FBS, have shown the resemblance to cells undergoing 
apoptosis. These characters included cluster formation, shrinkage, blebbling and 
echinoid spike, all of which have been observed by several studies (Bottone et al. 2013; 
Fiorelli, Kirouac and Padmanabhan 2013; LeBlanc 1995; Steiger-Barraissoul and Rami 
2009; Xie e ta l. 2013).
Not only does mTORCl function, downstream of A k tl, as a regulator of cell growth but 
is also responsible for an increase of protein and ribosomal synthesis once activated 
(Kim et al. 2011; Li et al. 2014). Therefore it could be assumed that an inactivation of 
A k tl by reducing growth factors and amino acids, provided by FBS in culture medium, 
ultimately inactivates mTORCl thereby reducing protein synthesis (Mulukutla et al. 
2010; Ueki et al. 1998). Hence it was hypothesised that culturing the cells with reduced 
FBS would essentially reduce APP synthesis thereby reducing APP secretion (only 
sAPPa has been measured in this experiment). Indeed, the APP secretion data (Figure 
5.3.5-5.3.7) has revealed that the APP secretion has decreased with the concentration 
of FBS in culture medium, apart from cells which were cultured in complete culture 
medium containing 10% FBS. This could be the result of cell-cell contact inhibition 
which occurs in confluent culture and fast growing cell lines (Levine et al. 1965; Wieser 
and Oesch 1986; Puliafito et al. 2010).
As there was a decrease of the APP secretion level, it was hypothesised that the APP 
mRNA level should have decreased as well. Once the protein synthesis process is 
inhibited it would consequently inactivate the ribosomal synthesis (Kim et al. 2011; 
Ladevaia et al. 2012). However, the APP mRNA data (Figure 5.4.7-5.4.8 ) has revealed 
that the APP mRNA level remains at the similar level between concentrations of FBS
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instead of reflecting the level of APP secretion. Since the secreted APP and the APP 
mRNA level were found to be correlated in human brains, the ratio between these two 
parameters was used to determine the efficiency of protein translation (Matsui et al. 
2007). The efficiency of protein translation (shown as mRNA:protein ratio ± S.E.M.) 
revealed that HEK695.C5 and HEK770.C6 are the most efficient in APP secretion with 
the average ratio of 0.03±0.03 and 0.03±0.02 while the HEK751.C1 is the least efficient 
in APP secretion with the average ratio of 0.20±0.12.
In conclusion, the different isoforms of APP and the different concentration of FBS in 
culture medium did not affect the cell number, APP secretion and the APP mRNA level. 
This meant the FBS could be used in further experiments.
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Chapter 6: Effects of 2-Deoxy-D- 
glucose on APP secretion in HEK293 
cells transfected with APP isoforms
6.1 Introduction
The effect of FBS in culture medium on APP production was established in Chapter 5 
on cellular models of APP; APP695.C5, APP751.C1 and APP770.C6. There were four 
experimental aspects which were taken into consideration; cell morphology, cell 
number, amount of secreted APP in culture medium and APP mRNA level. These 
aspects were also used to assess the effect of 2-deoxy-D-glucose (2DG) on APP 
transfected HEK293. This was the fifth and final objective of this project.
Glucose is a vital and main source of energy for living organisms, including humans. 
Although the brain only accounts for 2% of the body weight, it requires nearly 20% of 
all energy derived from glucose. Also, neuronal cells in the adult human brain have the 
highest demand for energy and require a constant supply of glucose from blood. The 
physiological functions of the brain are maintained through an ability to generate 
adenosine triphosphate (ATP), facilitate cellular maintenance and produce 
neurotransmitters from glucose, (Mergenthaler et al. 2013). Studies have shown that 
the functions and survival of neurons depended on the efficiency o f energy 
metabolism from the main source of energy in the brain; glucose (Demitrius and Driver 
2013). For example, when the blood glucose level is below 2-3 mM (blood glucose at 
normal fasting level), the brain shows certain cognitive impairments. Also, cells which 
use glucose as their primary source (such as neurons) are unlikely to be affected by 
stress in comparison to the cells that use other energy sources and undergo glycolysis 
as a consequence (Dwyer 2002).
In order to maintain the structure of the brain and its optimal function, the brain relies 
crucially on oxidative metabolism. ATP is one of many end-products obtained from the 
tricarboxylic acid cycle during oxidative metabolism of glucose. ATP is essential for 
cellular and molecular functions such as protein synthesis, ion homeostasis and
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maintaining suitable pH conditions for the endoplasmic reticulum (ER) and Golgi 
apparatus. As ATP is mainly gained from glucose, then any impairment occurring in 
neuronal glucose oxidative metabolism results in glycation and accumulation of its 
product within neurons which made the neurons susceptible to degeneration (Hoyer 
2004).
It was reported that the cellular and molecular functions in the brain of AD patients 
were disrupted due to abnormal activities during glucose metabolism. For example, 
A P1-40 and AP1-42 are believed to be the cause of a reduction in glucose metabolism by 
not only decreasing insulin binding to its receptor but also reducing insulin receptor 
autophosphorylation. If the shortage of neuronal glucose only occurs partly and 
temporarily, the brain is able to compensate for the loss of ATP from glucose by 
utilizing other available substrates in the brain such as amino acids and fatty acids. The 
glucoplastic amino acids are the amino acids that could be converted into glucose 
through the gluconeogenesis process and are commonly utilized; especially glutamate 
to make up for the lost ATP. As a result of the utilization of glutamate, neurotoxic 
ammonia is produced which later inhibits mitochondria dehydrogenases. In late onset 
or sporadic AD, the severe disruption of glucose metabolism occurs at early stages of 
the disease and worsens as clinical manifestations progress. As a consequence, the 
ATP production from glucose reduces by 50% (de la Monte 2012; Hoyer 2004). 
Moreover, several studies showed that early stages of AD are characterised by a 
shortage of glucose in the brain due to disruption of glucose metabolism especially in 
the temporal, parietal and frontal lobes of AD patients (Furst et al. 2012; Gasparini et 
al. 1997; Solano et al. 2000; Vassar et al. 2009). Also, the progression of the clinical 
manifestations of AD corresponded to worsen shortages of brain glucose (de la Monte
2012). Not only was cognitive decline linked to the reduction in glucose metabolism in 
the frontal and temporo-parietal lobes of the brain (Furst et al. 2012) but also a 
reduction in brain glucose metabolism was found in patients with mild cognitive 
impairment (Valliquette, O'Conner and Vassar 2005).
In vitro, the shortage of glucose can be mimicked by using a glucose antagonist such as 
2-deoxy-D-glucose (2DG). 2DG shares the same structure with glucose apart from the 
replacement of a hydroxyl group with hydrogen at the second carbon atom (Aft, Zhang 
and Gius 2002) which means 2DG is transported into cells by glucose transporters.
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Under normal conditions glucose is transported into the cell and phosphorylated by 
hexokinase to produce glucose-6 -phosphate (G6 P), before being subjected to 
conversion by phosphoglucose isomerase and entry into the glycolytic pathway; or 
being metabolized by glucose-6 -phosphate dehydrogenase prior to entry into the 
pentose phosphate pathway (PPP), as shown in Figure 6.1.1. Regardless, the end 
product gained from both pathways is the same; pyruvate (Mergenthaler et al. 2013). 
So far, there are three proposed mechanisms of action of 2DG; (1) the 2DG inside the 
cell binds to hexokinase but cannot be phosphorylated (Yao et al. 2011), (2) 2DG is 
phosphorylated by hexokinase but due to hydrogen replacement at the 2 -hydroxy 
group, is inhibited from further glucose metabolic processes (Aft, Zhang and Gius 
2002), and (3) 2DG inhibits hexokinase and phosphoglucose-isomerase activities 
(Raiser et al. 2008). The consequences of these mechanisms of action are interference 
in glucose metabolism and sudden inhibition of cell growth.
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Figure 6.1.1 A simplified overview of glucose metabolism pathways. Glucose is 
transported into the cell and phosphorylated by hexokinase; obtaining glucose-6- 
phosphate (Glc-6-P). The phosphorylation process is not reversible. Glc-6-P could 
either continue along the glycolytic pathway or enter the pentose phosphate pathway 
(PPP). In the glycolytic pathway, Glc-6-P is converted by a series of enzymes; glucose-6- 
phosphate dehydrogenase, phosphofrucktokinase and glyceraldehye-3-phosphate 
dehydrogenase before yielding pyruvate as the end product of this pathway. While, 
glucose entering the PPP generates NADPH (used in oxidative stress management) 
before re-entering glycolytic pathway in the manner mentioned above (Adapted from 
Mergenthaler et al. 2013).
The objectives of this investigation were; (1) to find out how each isoform of APP 
responded to different levels of stress caused by various concentrations of 2DG and (2) 
to compare the responses between different isoforms of APP under the same stress 
level caused by the same concentration of 2DG. In addition, the investigation of the 
effect of 2DG in culture medium on APP was carried out by measuring these 
parameters; cell number, APP secretion into culture medium and APP mRNA level. 
Also, prior to cell counting, cells were photographed in order to observe the 
morphological changes due to the effect of 2DG in the culture medium.
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6.2 E ffec ts  o f  2DG in  c e ll c u ltu re  m e d iu m  o n  c e ll n u m b e r
In a similar manner to the investigation of the effects of FBS on HEK293 stably 
transfected APP cells, the first part of an investigation of the effect of 2-deoxy-D- 
glucose (2DG) on APP production was to examine the effect of 2DG on cell number. All 
three selected clones of HEK293 transfected APP isoforms; APP695.C5, APP751.C1 and 
APP770.C6 and non-transfected HEK293 were cultured according to the cell culture 
procedures described in Section 2.11.
Methods in brief
The experiments were carried out in 6-well plates and performed independently in 
triplicate. Also, there were three chosen concentrations of 2DG: 5 mM, 25 mM and 50 
mM which were prepared with complete medium. The concentrations of 2DG were 
chosen on the basis on the range of the amount of glucose in culture medium (5mM- 
55mM or 1 g/L-10 g/L) and available publications (Aft, Zhang and Gius 2002; Chang et 
al. 2011; Domingues et al. 2007; Kaplan et al. 1990; Keenan, Liang and Clynes 2004; 
Mattson, Guo and Geiger 1999; Raiser et al. 2008; Shi, Xiang and Simpkins 1997; 
Solano et al. 2000). Each well contained approximately the same starting number of 
live cells: 5 x 105 cells in 2 ml of complete culture medium. Cells were allowed to settle 
and adhere for at least 6 hours before the culture medium was discarded and fresh 
medium which contained the appropriate concentration of 2DG was added. Twenty- 
four hours later, cells were photographed using the XLI cap program and culture 
medium was collected for APP secretion analysis followed by cell counting and cell 
pellet harvesting.
Cell counting was carried out three times per concentration of 2DG for each cell type. 
Briefly, 10 pi of cells suspension and 10 pi of 0.4% Trypan blue were combined 
thoroughly before 10 pi of the mixture was pipetted into the Countess® Cell Counting 
Chamber Slides and counted by using Countess® Automated Cell Counter. Each reading 
obtained from the cell counter machine measured total cell number, live cell number, 
dead cell number per ml of cell suspension and percentage of cell viability.
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Results
The cell count data are shown as mean ± SEM. The two-way ANOVA with 95% 
confidence interval was coupled with Bonferroni's multiple comparisons test to 
evaluate any possible effect of 2DG on cell number. The data were analysed based on 
two independent factors; (1) the concentration of 2DG in culture medium on cell 
number, and (2) the differences in the isoform of APP. Moreover, the statistical 
analysis revealed that both the different concentrations of 2DG and the isoforms of 
APP had significant effects on cell number (p<0.0001 and p<0.0001, respectively). 
However, the interaction between both independent factors showed statistical 
significance (p<0.01) therefore the data gained from both independent factors were 
interpreted simultaneously, meaning that both factors have a dependable effect on 
cell number.
The cell count data were analysed using the same cells cultured in standard complete 
medium containing 25 mM glucose as the control. The data are sub-grouped according 
to cell type; non-transfected HEK293, HEK695.C5, HEK751.C1 and HEK770.C6 and there 
are three concentrations of 2DG (5 mM, 25 mM and 50 mM) in the culture medium 
and one control which contained 25 mM of glucose. Figure 6.2.1 shows that in the 
culture medium containing 5 mM 2DG the cell number of all three APP transfected 
HEK293 clones decreased significantly (p<0.01, p<0.0001 and p<0.05, respectively) 
while there was a significant increase in cell number of non-transfected HEK293 
[p<0.05). The reduction in cell number occurred in all four cell types grown in culture 
medium containing 25 mM 2DG, however only the reductions in cell number of 
HEK695.C5, HEK751.C1 and HEK770.C6 were statistically significant (p<0.0001, 
p<0.0001 and p<0.005, respectively). In addition, the cell number of all cell types 
appeared to decrease significantly (p<0.005) in the culture medium containing 50 mM 
of 2DG.
The other way to analyse the cell count data was to use non-transfected HEK293 cells 
cultured in culture medium containing the same concentration of 2DG; 5 mM, 25 mM 
and 50 mM as controls. The data are sub-grouped according to the concentration of 
2DG in the culture medium. In Figure 6.2.2, all three APP transfected HEK293 clones 
shared the same pattern of the cell number in all concentrations of 2DG; cell number
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of HEK695.C5, HEK751.C1 and HEK770.C6 significantly decreased when cells were 
cultured in culture medium containing all three different concentrations of 2DG 
(p<0.0001). However, there was no significant reduction of cell number between 
different isoforms of APP.
Each cell type in culture medium containing various concentrations of 2DG was 
photographed at the end of 24-hour incubation period. The photographs of the cells 
are shown in Figure 6.2.3 to Figure 6.2.6
Figure 6.2.3 shows the photographs of the non-transfected HEK293 cells which were 
cultured in medium containing various concentrations of 2DG. It showed that cells 
grew at the minimal rate and majority of the cells adhered to the bottom of the well. 
The number of dead cells increased with an increase in concentration of 2DG; the cells 
started to detach themselves and died when they were cultured in the culture medium 
which contained 25 mM 2DG. Also, the majority of the cells showed the round and 
pebble-like morphology.
Figure 6.2.4 shows the photographs of HEK695.C5 cells which were cultured in culture 
medium containing various concentrations of 2DG. It appeared that not only did the 
cells grow extremely slowly, or did not grow at all, but also the live cells which were 
plated out originally appeared unhealthy i.e. as they showed round morphology and 
became detached from the wells.
Figure 6.2.5 shows the photographs of HEK751.C1 cells which were cultured in the 
culture medium containing various concentrations of 2DG. The majority of the cells 
adhered to the bottom of the well and they showed differentiation in character in the 
culture medium containing 25 mM and 50 mM 2DG whereas in the culture medium 
containing 5 mM 2DG the cells appeared flat and full. There were only a few cells 
which showed the round morphology indicating lesser numbers of dead.
Figure 6.2.6 shows the photographs of HEK770.C6 cells which were cultured in the 
culture medium containing various concentrations of 2DG. The cells did not appear to 
grow in any of the concentrations of 2DG. Many live cells, which were plated out 
originally, died as they detached from the wells when they were cultured in culture 
medium containing 25 mM and 50 mM 2DG. Also, in the culture medium containing 50
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mM 2DG some cells were in a state of vacuolation. Moreover, there were only a small 
number of dead cells in 5 mM concentration of 2DG and the live cells showed 
pronounced apoptotic morphology, including elongation.
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Figure 6.2.1 Cell count data as mean ± SEM. Each graph illustrated each concentration 
of 2DG in culture medium; (a) 5 mM, (b) 25 mM and (c) 50 mM. Also, cell count data 
were sub-grouped according to cell type and statistical analysis was carried out using 
the same cell type growing in complete culture medium as the control. Statistical 
significance description: *p-value<0.05, **p-value<0.01, ***p-value<0.005 and * * * *p -  
value<0.0001
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Figure 6.2.2 Cell count data as mean ± SEM. Each graph illustrated each concentration 
of 2DG in culture medium; (a) 5 mM, (b) 25 mM and (c) 50 mM. Also, cell count data 
were sub-grouped according to concentration of 2DG and statistical analysis was 
carried out using non-transfected HEK293 cells grown at same concentration of 2DG as 
control. It was clearly showed that there was significant reduction in all HEK293 
transfected APP isoforms in every concentration of 2DG. Statistical significance 
description: ****p-value<0.0001.
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Figure 6.2.3 Photographs of non-transfected HEK293 cells which were cultured in 
culture medium containing various concentrations of 2DG; (a) control, (b) 5 mM, (c)
25 mM and (d) 50 mM. Cells grew at the minimal rate and majority of the cells 
adhered to the bottom of the well. The number of dead cells increased with an 
increase in concentration of 2DG; the cells started to detach themselves and died 
when they were cultured in the culture medium contain 25 mM 2DG. Also, the 
majority of the cells showed the round, pebble-like morphology, (magnification 200x)
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Figure 6.2.4 Photographs of HEK695.C5 cells which were cultured in culture medium 
containing various concentrations of 2DG; (a) control, (b) 5 mM, (c) 25 mM and (d) 50
mM. It appeared that not only did cells grow extremely slowly or did not grow at all 
but also 50% of the live cells which were plated out originally appeared unhealthy and 
dead; as shown by the round shape and detachment from the wells. The number of 
unhealthy and dead cells increased as the concentration of 2DG increased in culture 
medium, (magnification 200x)
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Figure 6.2.5 Photographs of HEK751.C1 cells which were cultured in the culture 
medium containing various concentrations of 2DG; (a) control, (b) 5 mM, (c) 25 mM
and (d) 50 mM. The majority of the cells adhered to the bottom of the well and they 
showed a differentiated character in culture medium containing 25 mM and 50 mM 
2DG whereas in the culture medium containing 5 mM 2DG the cells appeared flat and 
full. There were only a few cells which showed round morphology indicating lesser 
numbers of dead cells in each concentration, (magnification 200x)
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Figure 6.2.6 Photographs of HEK770.C6 cells which were cultured in the culture 
medium containing various concentrations of 2DG; (a) control, (b) 5 mM, (c) 25 mM
and (d) 50 mM. The cells did not appear to grow in any of the concentrations of 2DG. 
Many live cells which were plated out originally died as they detached from the wells 
when they were cultured in culture medium containing 25 mM and 50 mM 2DG. Also, 
in the culture medium containing 50 mM 2DG some cells were in a state of 
vacuolation. Moreover, there were only a small number of dead cells in 5 mM of 2DG 
and the live cells showed pronounced a differentiated morphology as the cells started 
to elongate, (magnification 200x)
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6.3 E ffec ts  o f  2DG in  c e ll c u ltu re  m e d iu m  o n  APP s e c re t io n
The second part of the investigation of the effect of 2DG in culture medium on APP 
production was to determine the amount of APP which was secreted into culture 
medium. It was previously mentioned that the majority of APP is processed through 
the secretory pathway. In brief, APP located either at the cell membrane or trans-Golgi 
network (TGN) is cleaved by a series of secretases before being transported to the 
extracellular space.
Methods in brief
The culture medium was collected prior to cell counting and then immunoprecipitated 
using DE2 antibody followed by reduction and alkylation of disulphide bonds. These 
samples prepared from collected culture medium were run on 6% SDS-PAGE gels 
before proceeding to protein expression analysis by immunoblotting (complete 
procedure: see Sections 2.16-2.19). Four primary antibodies and two secondary 
antibodies used during immunoblotting procedure were listed in Chapter 2 (Figure 
2.19.1).
Results
Figure 6.3.1 shows the immunoblotting results obtained from immunoprecipitated 
culture medium containing various concentrations of 2DG collected from non- 
transfected HEK293. None of the samples produced the protein band against 1151, 
993, 23/2 and DE2 antibodies however the control (non-transfected HEK293 cells 
grown in complete culture medium) produced a faint protein band against 993, 23/2 
and DE2 antibody. The protein bands were approximately 120 kDa in size and most 
likely to be the result from bovine APP in the culture medium.
The immunoblotting results obtained from immunoprecipitated culture medium 
containing various concentrations of 2DG collected from HEK695.C5 is shown in Figure 
6.3.2. All culture medium contained different amounts of 2DG produced protein bands 
against 1151 and DE2 primary antibodies and the approximate size of the protein band 
was 115 kDa which correspondened to the molecular weight of APP695. The protein 
bands produced against DE2 antibody were stronger than 1151 antibody possibly due
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to bovine APP in the culture medium. Also, none of the samples produced protein 
bands against 993 and 23/2 antibodies.
The immunoblotting results obtained from immunoprecipitated culture medium 
containing various concentrations of 2DG collected from HEK751.C1 are displayed in 
Figure 6.3.3. All culture medium contained different amounts of 2DG produced clear 
protein bands against 1151, 993 and DE2 antibodies which was approximately 118 kDa 
in size corresponding to the molecular weight of APP751. Also, none of the samples 
produced a protein band against 23/2 antibody.
The final set of immunoblotting results obtained from immunoprecipitated culture 
medium containing various concentrations of 2DG collected from HEK770.C6 is shown 
in Figure 6.3.4. All culture medium contained different amounts of 2DG produced 
protein bands against all four antibodies and the protein band was approximately 120 
kDa which corresponded to the molecular weight of APP770.
The APP obtained from cells grown in complete medium (CM) containing 10% FBS and 
25 mM D-glucose was referred back to data collected in Chapter 5. Figure 6.3.5 (a) 
shows that the clones shared the same APP secretion trend in each concentration of 
2DG; APP751 produced more APP than APP695 and APP770. After the number of live 
cells was taken into account in the determination of the amount of APP secretion per 
cell, the same trend of APP secretion was also found as shown in Figure 6.3.5 (b). The 
mean ± S.E.M. of the results of APP secretion (a.u.) per cell are as follows:
• CM: APP751 (34.69±7.13 a.u./cell)> APP695 (27.37±3.09 a.u./cell)> 
APP770 (16.04±9.26 a.u./cell).
•  5 mM: APP751 (76.58±0.3 a.u./cell)> APP695 (42.61±2.12 a.u./cell)> 
APP770 (32.48±9.51 a.u./cell).
•  25 mM: APP751 (85.41±3.07 a.u./cell)> APP695 (62.10±7.35 a.u./cell)> 
APP770 (42.71±14.08 a.u./cell).
• 50 mM: APP751 (149.5±7.93 a.u./cell)> APP695 (83.66±0.92 a.u./cell)> 
APP770 (74.99±18.67 a.u./cell).
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The level of secreted APP per cell was calculated using the following formula: 
APP secretion level (a.u.) per cell = (fluorescence intensity x 106)/ cell number; where 
a.u. stands for Arbitrary unit.
The amount of secreted APP was statistically analysed using two-way ANOVA with 95% 
confidence interval and Bonferroni's multiple comparison test. Also, these data were 
analysed based on two independent factors; the concentrations of 2DG in culture 
medium and the differences in the isoform of APP. The statistical analysis revealed that 
each factor affected the APP secretion independently (p>0.05) and significantly; the 
type of cell (p=0.0182) and the different concentration of 2DG (p=0.0019). The changes 
in the APP secretion were presented as mean of fold change ± S.E.M. to the control.
Figure 6.3.6 shows the APP secretion level (mean of fold change ± S.E.M.) of each cell 
type compared with the same cells growing in the complete medium containing 25 
mM of D-glucose, in order to compare the APP secretion of each cell type under 
different concentration of 2DG. The fold of APP secretion of non-transfected HEK293 
were lower than the control at all concentrations of 2DG. The fold increase of APP695 
and APP751 were similar to the control while the fold increases of APP770 were higher 
than control. The average changes in APP secretion are as follows:
• Non-transfected HEK293: 5 mM (0.85±0.08)> 25 mM (0.83±0.09)> 50
mM (0.80±0.1).
•  APP695: 25 mM (1.09±0.15)> 50 mM (1.07±0.12)> 5 mM (1.03±0.09).
• APP751: 25 mM (1.07±0.05)> 50 mM (1.05±0.06)> 5 mM (1.01±0.04).
• APP770: 50 mM (2.25±0.89)> 5 mM (1.94±0.63)> 25 mM (1.9±0.63).
Each graph in Figure 6.3.6 represents each cell type; (a) non-transfected HEK293 cells, 
(b) FIEK695.C5, (c) HEK751.C1 and (d) FIEK770.C6 consisting of data from three 
concentrations of 2DG; 5 mM, 25 mM, 50 mM and control. There were no significant 
changes in APP secretion within each cell type of non-transfected HEK293 cells, 
HEK695.C5 and FIEK751.C1, where the cells were cultured in the culture medium 
containing various concentrations of 2DG. Flowever, the APP secretion of FIEK770.C6 in 
culture medium containing 50 mM 2DG showed a significant increase in comparison to 
control (p<0.05).
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Figure 6.3.7 shows the APP secretion level (mean of fold change ± S.E.M.) of each clone 
after subtraction of endogenous APP from non-transfected HEK293 in order to 
compare the APP secretion between isoforms of APP. All three isoforms of APP share 
the same trend of increases of APP secretion in the presence of 2DG; APP751 had 
higher fold increase than APP695 and APP770. The average results of fold of APP 
secretion are as follows:
• CM: APP751 (4.73±0.82)> APP695 (4.33±0.97)> APP770 (1.7±0.48).
• 5 mM: APP751 (5.47±0.40)> APP695 (4.99±0.52)> APP770 (3.32±0.53).
• 25 mM: APP751 (5.94±0.29)> APP695 (5.37±0.06)> APP770 (3.510.95).
• 50 mM: APP751 (6.11±0.63)> APP695 (5.53±0.37)> APP770 (4.01±0.83).
Each graph in Figure 6.3.7 represents each concentration of 2DG; (a) 5 mM, (b) 25 mM 
and (c) 50 mM and consists of four cell types; non-transfected HEK293 cells,
HEK695.C5, HEK751.C1 and HEK770.C6. The APP secretion of HEK695.C5 and 
FIEK751.C1 increased significantly at all concentrations (p<0.001 and p<0.001,
respectively). Also, the APP secretion of HEK770.C6 increased greatly at all 
concentrations (5 mM: p<0.05; 25 mM: p<0.05 and 50 mM: p<0.05). Moreover, the 
APP secretion of FIEK751.C1 was significantly greater than FIEK770.C6 at the same 
concentration of 2DG (5 mM: p<0.05; 25 mM: p<0.05 and 50 mM: p<0.05).
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Figure 6.3.1 Protein analysis of secreted APP by non-transfected HEK293 cells which 
were cultured in culture medium containing various concentrations of 2DG; 5 mM, 
25 mM and 50 mM over 24-hour period with four primary antibodies; (a) 1151, (b) 
993, (c) 23/2 and (d) DE2. None of the samples produced a protein band recognised by 
any primary antibodies. However, the control sample (non-transfected HEK293 cells) 
produced a faint protein band recognised by all four primary antibodies which could be 
the result of bovine APP as the band was approximately 120 kDa in size.
Figure 6.3.2 Protein analysis of secreted APP by HEK695.C5 which were cultured in 
culture medium containing various concentration of 2DG; 5 mM, 25 mM and 50 mM 
over 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) 
DE2. Culture media contained different amounts of 2DG produced a protein band 
recognised by 1151 and DE2 primary antibodies and the approximate size of the 
protein band was 115 kDa which corresponded to the molecular weight of APP695. 
The produced protein band was recognised by DE2 antibody and was stained more 
strongly than 1151 antibody possibly due to bovine APP in culture medium. Also, none 
of the samples produced protein band recognised by 993 and 23/2 antibodies.
Figure 6.3.3 Protein analysis of secreted APP by HEK751.C1 which was cultured in 
culture medium containing various concentrations of 2DG; 5 mM, 25 mM and 50 mM 
over 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) 
DE2. Culture media contained different amounts of 2DG produced clear protein band 
recognised by 1151, 993 and DE2 antibodies which was approximately 118 kDa in size 
which corresponded to the molecular weight of APP751. Also, none of the samples 
produced protein band against 23/2 antibody.
Figure 6.3.4 Protein analysis of secreted APP by HEK770.C6 which was cultured in 
culture medium containing various concentrations of 2DG; 5 mM, 25 mM and 50 mM 
over 24-hour period with four primary antibodies; (a) 1151, (b) 993, (c) 23/2 and (d) 
DE2. Culture medium contained different amounts of 2DG produced protein band 
recognised by all four antibodies and the protein band was approximately 120 kDa 
which corresponded to the molecular weight of APP770.
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Figure 6.3.5 The APP secretion level as mean ± SEM. (a) the APP secretion (a.u.) of 
each cell type. All three clones shared the same pattern of APP secretion under the 
same concentration of 2DG: APP751> APP695> APP770. (b) the APP secretion (a.u.) 
per cell of each cell type. After the cell number was taken into account to calculate the 
APP secretion per cell, the same trend of APP secretion under the same concentration 
of 2DG was found: APP751> APP695> APP770.
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Figure 6.3.6 The APP secretion level as mean ± S.E.M.: cell type. Each graph
represents each cell type; non-transfected HEK293 cells, HEK695.C5, HEK751.C1 and 
HEK770.C6 and consists of three concentrations of 2DG; 5mM, 25 mM and 50 mM. The 
APP secretion of each cell type grown in culture medium containing 25 mM glucose 
was as used as a control. There were no significant changes in APP secretion within 
each cell type of non-transfected HEK293 cells, HEK695.C5 and HEK751.C1, where the 
cells were cultured in the culture medium containing various concentrations of 2DG. 
However, the APP secretion of HEK770.C6 in culture medium containing 50 mM 2DG 
showed a significant increase in comparison to the control (p<0.05).
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Figure 6.3.7 The APP secretion level as mean ± S.E.M.: concentrations of 2DG. Each 
graph represents different concentration of 2DG; (a) 5 mM, (b) 25 mM and (c) 50 mM 
and consists of four cell types; non-transfected HEK293 cells, HEK695.C5, HEK751.C1 
and HEK770.C6. The APP secretion of non-transfected HEK293 cells was used as the 
control. The APP secretion of HEK695.C5 and HEK751.C1 increased significantly at all 
concentrations (p<0.001 and p<0.001, respectively). Also, the APP secretion of 
HEK770.C6 increased greatly at all concentrations (5 mM: p<0.05; 25 mM: p<0.05 and 
50 mM: p<0.01). Moreover, the APP secretion of HEK751.C1 was significantly greater 
than HEK770.C6 at the same concentration of 2DG (5 mM: p<0.05; 25 mM: p<0.05 and 
50 mM: p<0.05).
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6.4  E ffec ts  o f  2DG in  c e ll c u ltu re  m e d iu m  on  APP m R N A  le v e l
The last part of the investigation of the effects of 2DG on HEK293 transfected APP 
isoforms was to evaluate the levels of APP mRNA.
It is obligatory that appropriate reference genes are selected before the beginning of 
the determination of mRNA level experiments. As reference genes are to be used as a 
normaliser during the determination of mRNA level experiments, the most stable 
reference genes across the different experimental conditions were selected. The 
reference gene stability assessment was demonstrated in Chapter 5. In short, the 12 
reference genes were tested for their expression stability between non-transfected 
HEK293 cells and selected clones of each HEK293 transfected APP isoforms under 
untreated and all experimental conditions; including the variation of 2DG 
concentrations in complete culture medium. The reference gene expression stability 
values (M-value) and the minimum number of reference genes required for 
normalisation (V-value) in the experiments were obtained using GeNorm software. As 
a result of the GeNorm software analysis, at least two reference genes were required 
in the determination of mRNA level analysis and SCLY and TYW1 were selected.
Methods in brief
After obtaining appropriate reference genes (SCLY and TYW1) and the efficiency of
each pair of primers, measuring the determination of the effects of 2DG on APP mRNA
levels was then carried out. The experiment began by plating approximately 5 x 105 of
live cells per well in 6-well plates. Cells were allowed to settle and adhere for at least 6
hours before culture medium was discarded and fresh complete medium which
contained varying concentrations of 2DG was added. Twenty-four hours later, cells
were photographed using the XLI cap program and culture medium was collected for
APP secretion analysis followed by cell counting and cell pellet harvesting. The cell
count data was analysed as described in Section 6.2 including photographs of the cells.
The culture medium was analysed and the results described in Section 6.3. Finally, the
total RNA was extracted from the cell pellets according to the procedure described in
Section 2.20 using RNeasy Mini Kit before quantification using NanoDrop ND-1000 UV-
VIS Spectrophotometer (Section 2.21). The RNA was converted into cDNA using
QuantiTect Reverse Transcription Kit as described in Section 2.23. At this point the
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cDNA of each sample was ready to be amplified under real-time RT-PCR conditions. A 
complete list of real-time PCR components and procedures are described in Section 
2.28.
The data from each amplification condition of each sample was obtained as the Ct 
value. Each sample was carried out in triplicate per reaction, therefore the mean of 
triplicate Ct values was used in relative quantification of the mRNA level. The chosen 
relative quantification model was the one that takes the slope of primer efficiency into 
account. The model is as followed:
Fold difference = Esamp,eac,sampl7  Ere,erence" :treference
Where Esampie is primer efficiency of gene of interest; Ereference is primer efficiency of a 
reference gene; ACt sample is the difference of mean of Ct between control and gene of 
interest; ACt reference is the difference of the mean of Ct between the reference gene of 
control and the reference gene of sample.
The two-way ANOVA with 95% confidence interval was coupled with Bonferroni's 
multiple comparison test to evaluate any possible effect of 2DG at various 
concentrations in culture medium on APP mRNA level of non-transfected HEK293 cells 
and clones of APP transfected HEK293: HEk695.C5, HEK751.C1 and HEK770.C6. The 
APP mRNA level data are presented as graphs between independent factors on the X- 
axis and the fold difference of mRNA level on the Y-axis. Also, the data were analysed 
based on two independent factors; the concentration of 2DG and the differences in 
the isoform of APP.
Results
The statistical analysis showed that both isoforms of APP and the concentration of 2DG 
had significant effects on APP mRNA level (p=0.0003  and p<0.0001, respectively) but 
both dependent factors were independent from each other (p>0.05).
Figure 6.4.1 shows the graph of the APP mRNA level which contained all three 
concentrations of 2DG in culture medium and each graph represented each of the cell 
types: (a) non-transfected HEK293, (b) HEK695.C5, (c) HEK751.C1 and (d) HEK770.C6.
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The same cells growing complete culture medium containing 25 mM of glucose were 
used as the controls. Overall, the APP mRNA level of all four cell types increased in 
comparison to controls but there were only a few changes which were significant. The 
statistical analysis revealed that the APP mRNA level of non-transfected HEK293 at 50 
mM 2DG increased significantly in comparison to control (p<0.05). The APP mRNA level 
of HEK695.C5 increased significantly at all concentrations of 2DG (5 mM: p<0.05; 25 
mM: p<0.001 and 50 mM: p<0.001) and there was a significant decrease in APP mRNA 
level at 5 mM 2DG in comparison to 50 mM 2DG (p<0.001). The APP mRNA level of 
HEK751.C1 at 25 mM and 50 mM 2DG increased significantly in comparison to controls
(,p<0.01).
Figure 6.4.2 shows the graph of APP mRNA level which contained four cell types and 
each graph represented each concentration of 2DG in culture medium: (a) 5 mM, (b) 
25 mM and (c) 50 mM. The non-transfected HEK293 growing in each concentration of 
2DG was used as controls. There was an increase in the APP mRNA level of four cell 
types and the changes between each concentration shared the same pattern: the 
mRNA of APP695 has the highest increase and the increase of mRNA of APP770 is 
greater than APP751. The APP mRNA level of HEK695.C5 increased significantly at all 
concentrations of 2DG (5 mM: p<0.05; 25 mM: p<0.001 and 50 mM: p<0.001). Also, 
the APP mRNA level of HEK751.C1 and HEK770.C6 significantly decreased in 
comparison to HEK695.C5 at all concentrations (at least p<0.05).
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Figure 6.4.1 The APP mRNA level as mean ± S.E.M.: cell types. The X-axis: the 
concentrations of 2DG and the Y-axis: fold difference of APP mRNA level. The same 
cell type cultured in complete culture medium was used as a control. Each graph 
represents each cell type; (a) non-transfected HEK293 cell, (b) HEK695.C5, (c) 
HEK751.C1 and (c) HEK770.C6 treated with three 2DG concentrations; 5 mM, 25 mM 
and 50 mM. Each cell type cultured in culture medium containing 25 mM glucose was 
used as the control. The APP mRNA level of non-transfected HEK293 at 50 mM 2DG 
increased significantly in comparison to the control (p<0.05). The APP mRNA level of 
HEK695.C5 increased significantly at all concentrations of 2DG (5 mM: p<0.05; 25 mM: 
p<0.001 and 50 mM: p<0.001) and there was a significant decrease in APP mRNA level 
at 5 mM 2DG in comparison to 50 mM 2DG (p<0.001). The APP mRNA level of 
HEK751.C1 at 25 mM and 50 mM 2DG increased significantly in comparison to controls 
(p<0.01).
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Figure 6.4.2 The APP mRNA level as mean ± S.E.M.: concentrations of 2DG. The X- 
axis: cell types and the Y-axis: fold difference of APP mRNA level. The non- 
transfected HEK293 was used as a control. Each graph represents each concentration 
of 2DG; (a) 5 mM, (b) 25 mM and (c) 50 mM consisted of four cell types; non- 
transfected HEK293 cell, HEK695.C5, HEK751.C1 and HEK770.C6. The APP mRNA level 
of HEK695.C5 increased significantly at all concentrations of 2DG (5 mM: p<0.01; 25 
mM: p<0.001 and 50 mM: p<0.001). Also, the APP mRNA level of HEK751.C1 and 
HEK770.C6 significantly decreased in comparison to HEK695.C5 at all concentrations 
( t; p< 0.05, t t ;  p<0.01, t t t ;  p<0.001).
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770
6.5 mRNA: protein ratio
It was reported that there was a strong correlation between secreted APP and the APP 
mRNA level in the brains of patients with AD (Matsui et al. 2007). The translational 
efficiency is the rate of conversion from mRNA into proteins which could be 
determined using measured protein and mRNA level, as follows:
mRNA: Protein = [mRNA/cell] /  [Protein/cell]
The statistics revealed that the HEK751.C1 is the most efficient in translating APP 
mRNA into APP following by HEK770.C6 and HEK695.C5. The complete analysis of 
mRNA:Protein ratio is as follows:
• HEK695.C5: 50 mM (18.17±4.65)> 25 mM (14.55±3.16)> 5mM (9.37±1.93)
•  HEK751.C1: 50 mM (0.65±0.09)> 25 mM (0.54±0.09)> 5mM (0.48±0.04)
•  HEK770.C6: 50 mM (6.09±3.01)> 25 mM (5.78±3.48)> 5mM (4.97±2.27)
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6.6  D is c u s s io n
The objectives of this investigation were; (1) to find out how each isoform of APP 
responded to different levels of stress caused by various concentrations of 2DG and (2) 
to compare the response between different isoforms of APP under the same stress 
level caused by the same concentration of 2DG. In addition, the investigation of the 
effect of 2DG in culture medium on APP was carried out in three main parts; cell 
number, APP secretion into culture medium and APP mRNA level. Also, prior to the cell 
counting procedure, cells were photographed in order to observe morphological 
changes due to  the effects of 2DG in culture medium.
Impaired cerebral glucose metabolism has become a consistent pathophysiological 
feature of Alzheimer's disease (Chen and Zhong 2013). Since the brain has high energy 
consumption rate and the brain's energy is predominantly gained from glucose 
metabolism, the brain is susceptible to impaired glucose metabolism; both 
hypoglycaemia and hyperglycaemia (Hoyer 2004; Mergenthaler et al. 2013). Not only 
could cerebral glucose impairment enhance amyloid plaque deposition and tau 
phosphorylation but also affect the downstream pathological pathways including 
oxidative stress, mitochondrial dysfunction, inflammation and apoptosis (Chen and 
Zhong 2013).
The glucose antagonist, 2-deoxy-D-glucose (2DG) was used to initiate the glucose 
impairment in vitro by mimicking glucose shortage. The 2DG inhibits glycolysis at the 
same equimolar concentration as glucose by inhibiting hexokinase and the inhibition 
can be reversed by further addition of glucose (Barban and Schulze 1961; Mulukutla et 
al. 2010). Since 2DG shares a similar structure to glucose, it could be transported into 
the cell by glucose transporters and it can be phosphorylated by hexokinase at the first 
step of glycolysis. However, it cannot be processed further due to the substitution of 
the hydrogen at the second carbon atom. As a result, phosphorylated 2DG is trapped 
within the cell leading to intracellular phosphate depletion and an increase of the 
AMP: ATP ratio (Aft, Zhang and Gius 2002).
The increase of AMP: ATP ratio during cellular phosphate depletion activates the AMP-
activated protein kinase (AMPK) which is one of the metabolic regulators (Laderoute et
al. 2006; Mulukutla et al. 2010). The activated AMPK inactivates mammalian target of
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rapamycin complex 1 (mTORCl) which essentially inhibits cell growth (Li et al. 2014; 
Mulukutla et al. 2010).
Previous studies have demonstrated that culturing cells in glucose deprived culture 
medium, with or without the presence of 2DG, has led to cell cycle and cell 
proliferation arrest whereas the viability of the cells was not affected (Aft, Zhang and 
Gius 2002; Jelluma et al. 2006; Webster et al. 1998). The cell count data presented in 
this Chapter have confirmed that while the cell viability remains constant at all 
concentrations of 2DG, the proliferation of the cell has slowed down at the lowest 
concentration of 2DG and stopped or decreased at the highest concentration of 2DG 
(Figure 6.2.1-Figure 6.2.2). The cell cycle arrest under glucose deprivation condition 
could be a result of phosphorylation of p53 by AMPK (Mulukutla et al. 2010).
Also, glucose metabolism has been strongly linked to apoptosis (Caro-Maldonado et al. 
2010; King and Gottlieb 2009). One of several roles of glucose metabolism is to 
minimise cellular reactive oxygen species (ROS) levels by promoting glucose-6- 
phosphate (G6P) to the pentose phosphate pathway (PPP) which ultimately generates 
the reduced form of glutathione (GSH) as a consequence (King and Gottlieb 2009). It 
was suggested that 2DG is more likely to cause apoptotic cell death via the activation 
of caspase 3 and poly ADP ribose polymerase (PARP) (Aft, Zhang and Gius 2002). Cells 
undergoing apoptosis could be morphologically characterised by nuclear condensation, 
DNA fragmentation, membrane budding, cytoplasm elongation, shrinkage and forming 
clusters (Bottone et al. 2013; Fiorelli, Kirouac and Padmanabhan 2013; King and 
Gottlieb 2009; LeBlanc 1995; Steiger-Barraissoul and Rami 2009; Xie et al. 2013). The 
morphological changes of the cells cultured in culture medium containing 2DG 
resemble apoptosis. It has been proposed that under glucose deprivation conditions, 
the apoptotic process is initiated via stress-response pathways such as mitogen- 
activated protein kinases (MAPK) (Mulukutla et al. 2010).
The AMPK activation enhances the energy-generating processes, including glucose 
metabolism, to generate more ATP and suppresses several anabolic processes, 
including protein synthesis, to conserve ATP (Laderoute et al. 2006; Li et al. 2014; 
Mulukutla et al. 2010). The suppression of anabolic processes occurs via the 
inactivation of mTORCl which is responsible for synthesising macromolecules such as
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protein under normal nutrient and ATP-level conditions (Dibble and Manning 2013). 
Hence it was hypothesised that culturing the cells with 2DG would reduce APP 
synthesis thereby reducing the APP secretion (only sAPPa has been measured in this 
experiment). However, the APP secretion data has revealed that the APP secretion has 
increased as the concentration of 2DG increased in culture medium (Figure 6.3.5 -  
Figure 6.3.7). This could be because of a protective property of sAPPa which has been 
demonstrated by several studies (Corrigan et al. 2011; Corrigan et al. 2014; Milosch et 
al. 2014; Smith-Swintosky et al. 1994; Steinbach et al. 1998; Young-Pearse et al. 2008).
As there is an increase of the APP secretion level, it was hypothesised that the APP 
mRNA level should increase as well. Once the protein synthesis process is activated, it 
would promptly activate the translation-associated components which increase the 
translation of the existing mRNA (translational efficiency) as a consequence (Ladevaia 
et al. 2012). As expected, the level of APP mRNA reflects the level of secreted APP: 
there is an increase of APP mRNA level with the concentration of 2DG in the culture 
medium. Since the secreted APP and the APP mRNA level were found to be correlated 
in human brain, the ratio between these two parameters was used to determine the 
efficiency of protein translation (Matsui et al. 2007). The efficiency of protein 
translation (shown as mRNA:protein ratiotS.E.M.) revealed that HEK751.C1 is the most 
efficient in APP secretion with the average ratio of 0.56±0.07 following by HEK770.C6 
with the average ratio of 5.61±0.47. Although, protein production efficiency decreased 
as the concentration of 2DG increased, the mRNA:protein ratio of these two clones did 
not vary significantly. The HEK695.C5 appeared to be the most efficient in producing 
protein (ratio of 9.37) in the medium containing 5 mM 2DG and the least efficient in 
the medium containing 50 mM 2DG with the ratio of 18.17.
In conclusion, the different isoforms of APP showed the ability to tolerate the stress 
equally which is indicated by the similarity of cell number under the stressed 
condition. Under the same level of stress APP751 appeared to secrete APP the most 
and have the most efficient in producing APP whereas APP695 appeared to have the 
highest APP mRNA level and the least efficient in producing APP. This could suggest 
that under glucose deprivation condition APP751 might be responsible for an increase 
of APP and its metabolites, such as Ap peptide.
226
Chapter 7: General discussion
The aim of this project was to investigate the hypothesis that one of the APP isoforms 
(APP695, APP751 and APP770) is more likely to be the source of A(3 in Alzheimer's 
disease under stress-induced conditions.
7.1 To provide an appropriate model of APP processing for 
pathological study of Alzheimer's disease.
Despite the commonly used animal model in pathological studies of Alzheimer's 
disease, the animal models have several drawbacks. For example, there are 17 amino 
acid differences between rodent APP and human APP, and three of them are located in 
the A{3 domain: rodent -> human (Gly601-> Arg, Phe606-> Tyr and Arg609-> His) (De 
Strooper et al. 1995). These three amino acids were responsible for the small amount 
of Ap peptide produced in rodent model experiments and the low susceptibility of 
amyloid aggregation (Fraser et al. 1992). Hence it would be appropriate to  select an 
alternative model; a human cellular model for pathological studies of the disease.
Prior to testing the proposed hypothesis, the cellular models overexpressing APP695,
APP751 and APP770 were established. Firstly, the expression vector plREShyg2
containing human APP770 cDNA was provided by Professor Nigel Hooper. It was used
to generate the expression vector plREShyg2 containing human APP751 and human
APP695 using molecular biology techniques consisting of conventional PCR, touchdown
PCR and Overlap extension PCR. These expression vectors were then transfected into
Chinese Hamster Ovary (CHO) cells in order to generate stably expressing clones which
expressed APP at a similar level. After several unsuccessful attempts o f trying to stably
express the isoforms of APP in CHO, only the original expression vector plREShyg2
containing human APP770, was successful, albeit with difficulty. The sequencing
results of the expression vector plREShyg2 containing APP751 and APP695 confirmed
that the sequence of both APP isoforms were intact yet failed to express in CHO. It has
been suggested that the plREShy2 vector has an effect on the mRNA of the inserted
DNA, resulting in suppression of the protein of interest expression in mammalian cells
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(Shikama et al. 2010). Also, the mammalian cells were able to selectively silence the 
gene of interest which resulted in no or low expression of the protein of interest yet 
the cells still are able to survive the antibiotic selection. The in-house construct 
expression vectors could be more sensitive to post-translational modification as CHO 
cells are glycosylation abundant (Stanley 1988).
In order to carry on further with the project, three synthetic expression vectors, 
pcDNA3.1 containing human APP695, APP751 and APP770, were obtained and 
expressed in CHO cells to generate stably expressing clones which expressed APP at 
similar levels. As the new synthetic expression vectors were shown to be successful in 
CHO cells, these vectors were expressed in Human Embryonic Kidney 293 (HEK293) 
cells in order to more closely reflect the situation of Alzheimer's disease. Also, HEK293 
is an ideal candidate as a host cell for studies of APP expression and processing 
because it allows the gene of interest in the expression vector to integrate into the 
host cell genome. HEK293 expresses signalling pathways, four neurofilament subunits 
and it has high rate of protein synthesis in comparison to CHO (Thomas and Smart 
2005). One out o fte n  clones stably expressed each APP isoform at comparable levels 
and was selected as the cellular models overexpressing human APP695, APP751 and 
APP770.
7.2 To confirm the use of novel antibodies for the detection of 
secreted human APP expression.
The media of HEK293 cells expressing human APP695, APP751 and APP770 were
subjected to antibodies testing to determine the utility of these antibodies. Four
antibodies were used; 1151, 993, 23/2 and DE2. Each antibody recognises a different
epitope of the APP sequence. The 1151 recognises the amino acid at the N -  terminal
of all three APP isoforms and is recognised by anti-rabbit antibody. The DE2 recognises
the Ap domain of all three APP isoforms and is recognised by anti-mouse antibody. The
993 antibody recognises the KPI domain on the APP sequence of APP751 and APP770
and is recognised by anti-rabbit antibody. The 23/2 antibody recognises the 0X2
domain on the APP sequence of APP770 and is recognised by anti-rabbit antibody.
Also, 1151 and 23/2 did not recognise bovine APP which typically exists in complete
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medium. It was demonstrated throughout the project that not only could the different 
antibodies can be used to distinguish the isoform of APP, but also could be used in APP 
quantification with fluorescence detection.
7.3 Efficiency of mRNA translation by each isoform of APP
Several isoforms of APP ranging from 365 to 770 amino acid residues resulted from the 
alternative splicing of the APP transcript, three of which are the most relevant in 
Alzheimer's disease: APP695, APP751 and APP770, as shown in Figure 1.3.1, Chapterl 
(Zheng and Koo 2011). Also, APP695 is the predominant isoform in the brain while 
APP751 and APP770 are mainly expressed in non-neuronal tissues (O'Brien and Wong 
2011).
Prior to this study, it was hypothesised that when selected clones that secreted similar 
amounts of APP695, APP751 and APP770 into culture media under normal cultured 
conditions (culture medium containing 10% FBS and 25 mM glucose) would be the 
consequence of equal amounts of mRNA for each isoform.
There is approximately 10% difference in amino acid content among these isoforms of 
APP isoforms. Since under normal culture conditions the APP secretion from each 
isoform of APP was at a comparable level, it was then hypothesised that the mRNA 
levels would also be at comparable levels. However, the mRNA level of each isoform of 
APP appeared to be at different levels: APP751> APP770> APP695 (as reported in 
Chapter 5, Section 5.4). On average, the mRNA level between APP751 was 4 fold 
higher than APP695. The differences in mRNA levels between isoforms of APP could 
have significant effects on APP secretion and, ultimately, A(3 peptide secretion. As 
APP751 has the highest average level of mRNA resulting in the lowest protein 
production efficiency, it is hypothesised that APP751 translation might be subjected to 
a cellular "brake" system on protein conversion which slowed down mRNA translation 
into protein. If true, then in AD, reduction in the "brake" may lead to over production 
of APP751, leading to the greater secretion of A{3 peptide. Nevertheless, these 
observations are based on a single clone for each isoform of APP. Therefore this 
experiment requires repeating with more clones representing each isoform of APP.
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The outcome of further experiments with more clones of each isoform of APP could 
provide the evidences for one of the following three scenarios. The first scenario (as 
shown in Figure 7.3.1) is that the new clones of each isoform of APP produce similar 
mRNA:protein ratios to the previous clone which indicates that APP751 is the least 
efficient in the mRNA-protein translation process while APP695 is the most efficient.
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Figure 7.3.1 The first possible outcome of the further experiments with new clones.
The new clones of each isoforms of APP would produce a similar outcome to the 
previous clone.
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The second scenario (as shown in Figure 7.3.2) is that the new clones of HEK695 and 
HEK770 produce similar mRNA: protein ratios to the previous clones while the new 
clones of HEK751 produce different mRNA:protein ratios to the previous clone. This 
scenario would suggest that there are other factors other than the mRNA levels which 
affect the translational and post-translational process of APP in relation to AD 
pathogenesis besides the isoform of APP.
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Figure 7.3.2 The second possible outcome of the further experiments with new 
clones. The new clones of HEK695 and HEK770 produce a similar outcome to the 
previous clones while the new clones of HEK751 produce a different outcome to the 
previous clone.
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The third and final scenario (as shown in Figure 7.3.3) is that there is considerable 
variability in mRNA:protein ratios between clones, both previous and new clones, of 
each isoform of APP. This scenario would suggest that the results are more difficult to 
interpret but which could be due to multiple factors.
0.14
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■ Old clone ■ New clone A ■ New clone B
Figure 7.3.3 The third possible outcome of the further experiment with new clones.
The outcome from all clones; both previous and new clones do not show any similarity 
between each clone of each isoform.
7.4 To investigate the hypothesis that APP secretion of one of these 
APP isoforms (APP695, APP751 and APP770) is more likely to be 
affected by stress.
One of several ways that cells respond to stress is to undergo the apoptotic pathway 
(Fulda et al. 2010). Also, it has been reported that apoptosis plays an essential role in 
neurodegenerative mechanism in AD (Alberghina and Colangelo 2006) as the Ap was 
found to have induced apoptosis in both cell culture and animal models. Flowever the 
soluble APP produced from APP processing was found to be advantageous to the
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neuron (Araki and Wurtman 1998). Therefore, it was hypothesised that APP secretion 
of one of these APP isoforms; APP695, APP751 and APP770 would be more affected 
under stress-induced conditions; alteration of FBS concentration and energy 
deprivation using 2-deoxy-D-glucose (2DG). Also, one of these APP isoforms could be 
the source of Ap in AD.
The basic survival strategy of cells is based on the regulation of extracellular nutrients 
and intracellular metabolites (Yuan, Xiong and Guan 2013). Under normal physiological 
conditions, the mammalian target of rapamycin complex 1 (mTORCl) combines the 
signals from nutrients (both growth factors and amino acids) and energy sufficiency in 
order to regulate cell growth (Roux et al. 2007) by activating anabolic processes which 
convert nutrients and energy into macromolecules such as protein and lipid (Dibble 
and Manning 2013). mTORCl is a conserved serine/threonine kinase which is known as 
a nutrient-energy responsive regulator (Mulukutla et al. 2010; Roux et al. 2007). Also, 
mTORCl plays a significant role in autophagy which is an essential housekeeping 
process in order to maintain the cellular functions and structure by balancing between 
anabolic and catabolic processes (Glick, Barth and Macleod 2010; Kim et al. 2011). 
Autophagy is activated by starvation which put cells under survival mode until the 
nutrients are available again (Glick, Barth and Macleod 2010).
It has been reported that A tk l (also known as protein kinase B a, PKBa) is responsive 
to growth factors and amino acids while AMP-kinase (AMPK) is responsive to  cellular 
energy. However, these two kinases have the same downstream target; mTORCl. The 
Figure 7.4.1 shows the relationship of A tk l, AMPK and mTORCl.
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Figure 7.4.1 The possible mechanism of effects of FBS alteration and 2DG.By reducing 
the concentration of FBS in culture medium the available growth factors and amino 
acids are effectively reduced which possibly inactivated A tk l thereby activating 
mTORCl and inhibiting cell growth and protein synthesis. 2DG inhibits glucose 
metabolism by inhibiting hexokinase leading to ATP reduction and increased AMP. The 
increased AMP activates AMPK thereby activating mTORCl and inhibiting cell growth 
and protein synthesis.
A tk l play role as a regulator of apoptosis, cell growth and proliferation, cell 
differentiation and cell metabolism (Mulukutla et al. 2010; Nicholson and Anderson 
2002) and can be activated by activation of phosphoinositide 3-kinase (PI3K) initiating 
synthesis of phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) which facilitates the 
localization, phosphorylation and activation of A tk l. One of several ways which PI3K 
can be activated is autophosphorylation of kinase by ligands including growth factors 
and amino acids (Fayard et al. 2005; Filippa et al. 1999; Nicholson and Anderson 2002; 
Scheid and Woodgett 2003). As shown in Figure 7.4.1 once the A tk l is activated, it 
subsequently initiates protein translation/synthesis and cell growth via the mammalian
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target of rapamycin complex 1 (mTORCl). In order to mimic nutrient starvation the 
concentration of FBS containing both growth factors and amino acids was altered. It 
was hypothesised that the cell number, APP secretion as a consequence of APP 
production and the APP mRNA level would decrease with the decreased concentration 
of FBS due to A tk l inactivation thereby inhibiting mTORCl. The data in this project 
have shown that there is no change in cell number, APP secretion and APP mRNA level 
which suggests that the A tk l might not be inactivated, possibly due to the short 
incubation period (Deorosan and Nauman 2011; Fiorelli, Kirouac and Padmanabhan 
2013). Also, the different isoforms of APP and the different concentrations of FBS in 
culture medium did not affect the cell number, APP secretion and the APP mRNA level. 
This mean the FBS could be used in further experiments where required w ithout 
causing statistical variation on the APP related factors.
AMPK plays role as a metabolic regulator which once activated would inactivate 
mTORCl and thereby inhibit cell growth (Laderoute et al. 2006; Li et al. 2014; 
Mulukutla et al. 2010). As shown in Figure 7.4.1, the AMPK can be activated when 
there is an increase of AMP: ATP ratio during cellular phosphate depletion (Laderoute 
et al. 2006; Mulukutla et al. 2010). The glucose antagonist, 2-deoxy-D-glucose (2DG) 
was used to initiate the glucose impairment in vitro by mimicking glucose shortage. 
The 2DG inhibits glycolysis at the same equimolar concentration as glucose and the 
inhibition can be reversed by further addition of glucose (Barban and Schulze 1961). 
Since 2DG shares the similar structure to glucose, it could be transported into the cell 
by glucose transporters and it can be phosphorylated by hexokinase at the first step of 
glycolysis. However, it cannot be processed further due to the substitution of the 
hydrogen at the second carbon atom. As a result, phosphorylated 2DG is trapped 
within the cell leading to intracellular phosphate depletion and an increase of the 
AMP: ATP ratio (Aft, Zhang and Gius 2002). Therefore it was hypothesised that the cell 
number, APP secretion as a consequence of APP production, and the APP mRNA level 
would decrease as the concentration of 2DG increased due to AMPK activation thereby 
inhibiting mTORCl. The data in this project have shown that there is a decrease in cell 
number and there is an increase in both APP secretion and mRNA level which suggest 
that the AMPK is activated but might be offset by a protective property o f sAPPa
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(Corrigan et al. 2011; Corrigan et al. 2014; Milosch et al. 2014; Smith-Swintosky et al. 
1994; Steinbach et al. 1998; Young-Pearse et al. 2008).
7.5 Future w ork
Although the morphological changes of the cells cultured in both stress-induced 
conditions: FBS alteration and 2DG, resemble apoptosis, further experiments are still 
required to confirm this observation. These experiments include measuring plasma 
membrane alteration, mitochondrial dysfunction and AMP: ATP ratio, chromatin 
condensation and DNA fragmentation.
The cellular models of APP695, APP751 and APP770 could be used in further 
experiments to determine whether a cellular "brake" system exists and how it is 
modulated in relation to AD pathogenesis. The proposed experiments would enable 
the first step towards the clarification process of the cellular "brake" system through 
measurement of heat shock protein (HSP) since HSP is not only associated with aging 
and stress conditions but also the main mitochondrial stress proteins (e.g. HSP10 or 
HSP60). Also these cellular models should be treated with other stress-inducing 
substances and conditions such as reactive oxygen species, transition metals and 
hypoxic condition. This could be carried out in serum free media to avoid the 
contamination of known and unknown substances including transition metals. Also, it 
was shown in this project that the presence or absence of FBS in culture medium did 
not affect the APP production and secretion levels. These treatments along with the 
complete profile of APP metabolites and HSP level would provide further 
understanding regarding the pathogenesis of AD which might enable the therapeutic 
discovery or prevention for AD.
Since an impaired glucose metabolism has been shown as an important feature of AD 
these cellular models could be used in testing herbal extracts such as charatin and 
allicin which have indications for lowering blood glucose and enhancing the sensitivity 
of beta cells as well as maintaining insulin production leading to  stable glucose 
metabolism. One leading hypothesis might be the stable level of Ap peptide 
production as regulated by controlled glucose metabolism as a direct consequence of
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the use of these herbal extracts. The longer term ambition for future work would be to 
compare clinical monitoring for blood and brain glucose metabolism w ith APP 
metabolites as well as cognitive function when using these herbal extracts as directed 
by completion of the cell model studies.
7.6 Final conclusion
The data described in this project has shown no significant effects of short term stress, 
in term of nutrient deprivation, on the APP mRNA level and secretion when compared 
to the three main isoforms of APP: APP695, APP751 and APP770. This suggests that 
mTORCl inhibition via A tk l might require other effectors and take longer than 24 
hours under starvation conditions. A significant finding, however, is that a difference 
between APP751 on one hand and APP695 and APP770 on the others, with the former 
consistently showing a lower efficiency of conversion of mRNA to  protein under 
normal culture condition. This may result from APP751 being subjected to a cellular 
"braking" system. Pathological changes in AD occur over numbers of year, so a small 
change in the "braking" system give the relatively high levels of APP751 mRNA which 
could result in the considerable changes in APP secretion as shown when culturing in 
2DG containing medium. Not only does this confirm the importance of glucose as a 
source of energy but also suggest the possible relationship between glucose 
metabolism and pathogenesis of AD. Ultimately, this could also be the source of A(3 
peptide and hence the pathogenesis of AD.
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